View Filing Data

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
DOCUMENT AND ENTITY INFORMATION	Jul. 31, 2012
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Entity Filer Category	Smaller Reporting Company
Document Type	S-1
Amendment Flag	false
Document Period End Date	Jul. 31, 2012

BALANCE SHEETS - USD ($)	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2007
ASSETS
Cash	$ 5,288	$ 1,096,538	$ 108,381
Other Current Asset Receivable	0	477,788	0
Grant Receivable		0	244,479
Prepaid expenses	39,926	37,474	38,511
Other Current Assets	33,182	2,221	0
Total Current Assets	78,396	1,614,021	391,371
Deferred expenses - clinical	1,014,178	1,380,103	233,322
Property, Plant & Equipment (net of accumulated depreciation)	82,660	0	28,406
Intangible Assets (net of accumulated amortization)	2,405,934	2,256,852	2,125,991
Deferred Financing Cost	68,188	65,848	0
Interest Receivable & Other Assets	473,848	323,738	96,096
TOTAL ASSETS	4,123,204	5,640,562	2,875,186
LIABILITIES AND SHAREHOLDERS? DEFICIENCY
Accounts payable and Accrued Expenses	6,053,853
Accounts payable	7,472,494	2,420,260	2,586,008
Accrued expenses		2,976,334	647,125
Deferred Investment Funds	50,000
Notes Payable - convertible promissory notes and fair value of embedded derivative	1,085,571	5,091,298	751,456
Notes payable - Officer (including interest payable)	395,566	408,069	687,034
Notes Payable - other	250,000
Interest Payable - other	140,492
Total Current Liabilities	7,837,250	10,895,961	4,671,623
Deferred Rent	19,212	62,441	0
Long-term Convertible Notes	0	570,802	0
Common Stock Warrant	1,265,985	6,391,071	13,006,194
Total Liabilities	9,122,447	17,920,275	17,677,817
Shareholder's Deficiency:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at July 31, 2012 and at October 31, 2011.
Common Stock - $0.001 par value; authorized 500,000,000 shares, issued and outstanding 375,135,008 at July 31, 2012 and 250,173,570 at October 31, 2011.	375,135	250,173	198,101	$ 9,380,902
Additional Paid-In Capital	50,235,200	33,000,064	23,074,978
Promissory Note Receivable	(9,998,210)	(9,998,210)	(10,659,710)
Deficit accumulated during the development stage	(45,611,368)	(35,531,740)	(27,416,000)
Total Shareholder's Deficiency	(4,999,243)	(12,279,713)	(14,802,631)	$ 4,267,979
TOTAL LIABILITIES AND SHAREHOLDERS? DEFICIENCY	$ 4,123,204	$ 5,640,562	$ 2,875,186

BALANCE SHEETS [Parenthetical] - $ / shares	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Preferred stock, par value (in dollars per share)	$ 0.001	$ 10,000	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	740	740	789
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, shares issued	375,135,008	250,173,570	198,100,817
Common stock, shares outstanding	375,135,008	250,173,570	198,100,817
Series Preferred Stock [Member]
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 10,000
Preferred stock, shares issued	740	740	789
Preferred stock, shares outstanding	740	740	789

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		116 Months Ended	125 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2011	Jul. 31, 2012
Revenue	$ 0	$ 0	$ 0	$ 0	$ 0	$ 508,481	$ 1,863,343	$ 1,863,343
Research & Development Expenses	1,331,415	1,958,518	5,760,158	6,392,919	8,078,901	4,904,298	23,156,740	28,916,898
General & Administrative Expenses	2,251,725	1,638,287	4,297,110	3,581,888	4,939,935	3,530,198	21,179,833	25,476,943
Total Operating expenses	3,583,140	3,596,805	10,057,268	9,974,807	13,018,836	8,434,496	44,336,573	54,393,841
Loss from Operations	3,583,140	(3,596,805)	(10,057,268)	(9,974,807)	(13,018,836)	(7,926,015)	(42,473,230)	(52,530,498)
Other Income (expense):
Interest expense	(1,045,297)	(1,769,974)	(4,241,805)	(2,721,020)	(4,698,983)	(3,814,863)	(10,449,337)	(14,691,142)
Other Income	25,375	(4,004)	25,715	53,603	(45,700)	80,161	280,918	273,422
(Loss) on note retirement	(932,421)	(115,396)	(2,173,491)	(109,492)	(461,595)	123,963	1,194,845	(978,646)
Write-off of intangible assets					(33,211)	0	(33,211)
Net changes in fair value of common stock warrant liability and embedded derivative liability	2,430,914	9,127,394	6,020,434	7,134,709	9,763,113	445,576	14,411,686	20,432,120
Net (Loss) Income before benefits for income taxes	(3,104,569)	3,641,215	(10,426,415)	(5,617,007)	(8,495,212)	(11,091,178)	(37,068,329)	(47,494,744)
Income tax benefit	0	0	346,787	379,472	379,472	278,978	1,580,473	1,927,260
Net Income (Loss)	(3,104,569)	3,641,215	(10,079,628)	(5,237,535)	(8,115,740)	(10,812,200)	(35,487,856)	(45,567,484)
Dividends attributable to preferred shares	185,000	185,000	555,000	1,353,686	1,538,686	0	1,582,570	2,137,570
Net Income (Loss) applicable to Common Stock	$ (3,289,569)	$ 3,456,215	$ (10,634,628)	$ (6,591,221)	$ (9,654,426)	$ (10,812,200)	$ (37,070,426)	$ (47,705,054)
Net Income (Loss) per share, basic (in dollars per share)	$ (0.01)	$ 0.02	$ (0.03)	$ (0.03)	$ (0.04)	$ (0.07)
Net Income (Loss) per share, diluted (in dollars per share)	$ (0.01)	$ 0.01	$ (0.03)	$ (0.03)	$ (0.04)	$ (0.07)
Weighted average number of shares outstanding, basic (in shares)	346,851,744	228,375,277	298,430,345	212,269,995	222,918,519	150,928,808
Weighted average number of shares outstanding, diluted (in shares)	346,851,744	300,847,826	298,430,345	212,388,256	222,918,519	150,928,808

STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Stock Subscription Receivable [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2002		$ 15,598		$ 229,895	$ (166,936)	$ 78,557
Balance (in shares) at Dec. 31, 2002		15,597,723
Options granted to consultants				8,484		8,484
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004	$ (15,969)			15,969
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)	(232)
Common stock issued upon partial conversion of long-term convertible promissory notes	$ 15,969					15,969
Stock Issued During Period, Shares, Conversion of Convertible Securities	232
Net Loss					(909,745)	(909,745)
Balance at Dec. 31, 2003		$ 15,598	$ (1,076,681)	254,348	(1,076,681,000)	(806,735)
Balance (in shares) at Dec. 31, 2003		15,597,723
Balance at Oct. 31, 2003		$ 15,598		254,348	(1,076,681)	(806,735)
Balance (in shares) at Oct. 31, 2003		15,597,723
Stock dividend on preferred stock	$ 43,884				(43,884)
Stock dividend on preferred stock (in shares)	638
Options granted to consultants				5,315		5,315
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004	$ (43,884)			43,884
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)	(638)
Net Loss					(538,076)	(538,076)
Balance at Oct. 31, 2004		$ 15,598		303,547	(1,658,641)	(1,339,496)
Balance (in shares) at Oct. 31, 2004		15,597,723
Debt Conversion, Converted Instrument, Amount		$ 2,136
Common Stock Issued During Period Value Payment Of Placement Agent On Re-Capitalization		$ 753		(753)
Common Stock Issued During Period Shares Payment Of Placement Agent On Re-Capitalization		752,600
Stock Issued During Period Value Payment Of Placement Agent On Effect Of Re-Capitalization		$ 753		(753)
Stock Issued During Period Shares Payment Of Placement Agent On Effect Of Re-Capitalization		752,600
Options granted to consultants				64,924		64,924
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004				(88,824)		(88,824)
Net Loss					(1,805,789)	(1,805,789)
Balance at Oct. 31, 2005		$ 37,686		5,178,319	(3,464,430)	1,751,575
Balance (in shares) at Oct. 31, 2005		37,686,428
Debt Conversion, Converted Instrument, Amount		$ 2,136,000		611,022		613,158
Debt Conversion, Converted Instrument, Shares Issued		2,136,441
Issuance of Common Stock for cash, net of shares to Placement Agent		$ 17,451,000		4,335,549		4,353,000
Issuance of Common Stock for cash, net of shares to Placement Agent (in shares)		17,450,693
Issuance of common stock to consultants		$ 587,000		166,190		166,777
Issuance of common stock to consultants (in shares)		586,970
Issuance of common stock in connection with the registration statement		$ 408,000		117,090		117,498
Issuance of common stock in connection with the registration statement (in shares)		409,401
Issuance costs				(329,673)		(329,673)
Options granted to employees and directors				71,667		71,667
Net Loss					(6,197,744)	(6,197,744)
Balance at Oct. 31, 2006		$ 40,239		5,914,793	(9,662,173)	(3,707,141)
Balance (in shares) at Oct. 31, 2006		40,238,992
Debt Conversion, Converted Instrument, Amount		$ 1,767		$ 298,233		$ 300,000
Debt Conversion, Converted Instrument, Shares Issued		1,766,902
Options granted to consultants and professionals				172,831		172,831
Stock Issued During Period Value Share Based Compensation		$ 229		$ 54,629		$ 54,858
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		229,422
Issuance of common stock to consultants		$ 557		139,114		139,674
Issuance of common stock to consultants (in shares)		556,240
Stock Issued During Period, Value, New Issues		$ 59,228		9,321,674		9,380,902
Stock Issued During Period, Shares, New Issues		59,228,334
Options granted to employees and directors				222,501		222,501
Net Loss					(2,454,453)	(2,454,453)
Balance at Oct. 31, 2007	$ 16,276,648	$ 107,957	(12,116,626)	16,276,648	(12,116,626)	4,267,979
Balance (in shares) at Oct. 31, 2007		107,957,977
Debt Conversion, Converted Instrument, Amount		$ 6,974		$ 993,026		$ 1,000,010
Debt Conversion, Converted Instrument, Shares Issued		6,974,202
Options granted to consultants and professionals				268,577		268,577
Stock Issued During Period Value Share Based Compensation		$ 416		$ 73,384		$ 73,800
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		416,448
Issuance of common stock to consultants		$ 1,100		220,678		221,778
Issuance of common stock to consultants (in shares)		1,100,001
Offering Costs				(2,243,535)		(2,243,535)
Warrants Issued				1,505,550		1,505,550
Options granted to employees and directors				257,854		257,854
Net Loss					(5,416,418)	(5,416,418)
Balance at Oct. 31, 2008	16,584,414	$ 109,319	(17,533,044)	$ 16,584,414	(17,533,044)	$ (839,311)
Balance (in shares) at Oct. 31, 2008		109,319,520
Options granted to consultants and professionals				(42,306)		(42,306)
Stock Issued During Period Value Share Based Compensation		$ 996		$ 85,005		$ 86,001
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		995,844
Issuance of common stock to consultants		$ 154		14,462		14,616
Issuance of common stock to consultants (in shares)		153,846
Offering Costs				(78,013)		(78,013)
Warrants Issued				39,198		39,198
Common Stock Penalty Shares		$ 212		31,566		31,778
Common Stock Penalty Shares (in shares)		211,853
Common Stock Issued Upon Exercise of Warrants		$ 3,300		(3,300)		0
Common Stock Issued Upon Exercise of Warrants (in shares)		3,299,999
Options granted to employees and directors		$ 0		467,304		467,304
Options granted to consultants				12,596		12,596
Net Loss					929,244	929,244
Balance at Oct. 31, 2009		$ 115,638		754,834	(16,603,800)	(15,733,328)
Balance (in shares) at Oct. 31, 2009		115,638,243
Stock Issued During Period Value Share Based Compensation		$ 423		17,757		18,180
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		422,780
Issuance of common stock to consultants		$ 2,596		49,383		51,979
Issuance of common stock to consultants (in shares)		2,595,944
Warrant's classified as a liability				(12,785,695)		(12,785,695)
Stock Issued During Period, Value, New Issues	$ 0			6,828,293
Stock Issued During Period, Shares, New Issues	789	789
Common Stock Issued Upon Exercise of Warrants		$ 62,265	(10,659,710)	18,647,522		8,050,077
Common Stock Issued Upon Exercise of Warrants (in shares)		62,265,059
Options granted to employees and directors				455,166		455,166
Common stock issued upon conversion of Bridge Notes		$ 15,414		3,306,677		3,322,091
Common stock issued upon conversion of Bridge Notes (in shares)		15,413,960
Net Loss					(10,812,200)	(10,812,200)
Balance at Oct. 31, 2010	$ 0	$ 198,101	(10,659,710)	23,074,978	(27,416,000)	(14,802,631)
Balance (in shares) at Oct. 31, 2010	789	198,100,817
Stock Issued During Period Value Share Based Compensation		$ 750		114,750		115,500
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		750,000
Common stock issued to former employees		$ 145		(145)		0
Common stock issued to former employees (in shares)		144,666
Stock Issued During Period Warrants				(7,693,230)		(7,693,230)
Common stock issued to University of Pennsylvania		$ 389		69,611		70,000
Common stock issued to University of Pennsylvania (in shares)		388,889
Common Stock issued under Numoda Stock Purchase Agreement		$ 3,500		591,500		595,000
Common Stock issued under Numoda Stock Purchase Agreement (in shares)		3,500,000
Stock Issued During Period, Value, New Issues	$ 0			1,676,554		$ 1,676,554
Stock Issued During Period, Shares, New Issues	177					40,500,000
Common Stock Issued Upon Exercise of Warrants		$ 22,986	(2,389,500)	5,782,511		$ 3,415,997
Common Stock Issued Upon Exercise of Warrants (in shares)		22,986,244				15,752,903
Common Stock Issued Upon Exchange of Warrants		$ 5,841		1,528,124		$ 1,533,965
Common Stock Issued Upon Exchange of Warrants (in shares)		5,840,748
Options granted to employees and directors				717,029		717,029
Common stock issued upon conversion of Bridge Notes		$ 9,513		1,809,204		1,818,717
Common stock issued upon conversion of Bridge Notes (in shares)		9,513,210
Common stock issued upon conversion of May 2011 Notes		$ 12,647		2,250,536		2,263,183
Common stock issued upon conversion of May 2011 Notes (in shares)		12,647,076
Net Loss					(8,115,740)	(8,115,740)
Balance at Oct. 31, 2011	$ 0	$ 250,173	(9,998,210)	33,000,064	(35,531,740)	(12,279,713)
Balance (in shares) at Oct. 31, 2011	740	250,173,570
Debt Conversion, Converted Instrument, Amount						$ 1,897,000
Debt Conversion, Converted Instrument, Shares Issued						8,652,737
Stock Issued During Period Value Share Based Compensation				28,197		$ 28,197
Issuance of common stock to consultants		$ 333		49,667		50,000
Issuance of common stock to consultants (in shares)		333,333
Common stock issued to former employees		$ 752		80,779		81,531
Common stock issued to former employees (in shares)		752,142
Stock Issued During Period Warrants				(1,228,838)
Preferred Stock redeemed	$ 0		3,051,000	(3,141,003)		(90,003)
Preferred Stock redeemed (in shares)	(226)
Reclassification of warrant liability to equity				36,982		36,982
Reclassification of Embedded Derivative Liability to Beneficial Conversion Feature				132,488		132,488
Interest on Optimus Notes Receivable				202,856		202,856
Common Stock Issued Upon Exercise of Warrants		$ 2,745		409,019		411,764
Common Stock Issued Upon Exercise of Warrants (in shares)		2,745,097
Options granted to employees and directors				289,725		289,725
Common stock issued upon conversion of Bridge Notes		$ 1,127		167,873		169,000
Common stock issued upon conversion of Bridge Notes (in shares)		1,126,667
Common stock issued upon conversion of May 2011 Notes		$ 12,827		2,332,698		2,029,936
Common stock issued upon conversion of May 2011 Notes (in shares)		12,827,060
Common stock issued upon conversion of December 2011 Notes		$ 8,183		1,636,237		1,348,784
Common stock issued upon conversion of December 2011 Notes (in shares)		8,183,333
Issuance of common stock warrants				279,807		279,807
Interest on Optimus Notes				50,402		50,402
Common stock issued upon partial conversion of long-term convertible promissory notes		$ 3,600		382,237		385,837
Stock Issued During Period, Shares, Conversion of Convertible Securities		3,600,000
Net Loss					(4,365,544)	(3,754,319)
Balance at Jan. 31, 2012	$ 0	$ 278,655	$ (9,998,210)	38,558,521	(39,897,284)	(11,058,318)
Balance (in shares) at Jan. 31, 2012	740	278,655,727	(9,998,210)
Stock Issued During Period Value Share Based Compensation				10,459		10,459
Balance at Oct. 31, 2011	$ 0	$ 250,173	$ (9,998,210)	33,000,064	(35,531,740)	$ (12,279,713)
Balance (in shares) at Oct. 31, 2011	740	250,173,570
Stock Issued During Period, Shares, New Issues		4,000,000				25,560,000
Common Stock Issued Upon Exercise of Warrants						$ 2,745,097
Net Loss						(10,079,628)
Balance at Jul. 31, 2012	$ 0	$ 375,135	(9,998,210)	50,235,200	(45,611,368)	(4,999,243)
Balance (in shares) at Jul. 31, 2012	740	375,135,008
Debt Conversion, Converted Instrument, Amount						$ 169,000
Debt Conversion, Converted Instrument, Shares Issued						1,126,667
Balance at Jan. 31, 2012	$ 0	$ 278,655	$ (9,998,210)	38,558,521	(39,897,284)	$ (11,058,318)
Balance (in shares) at Jan. 31, 2012	740	278,655,727	(9,998,210)
Common Stock Issued Upon Exchange of Warrants		$ 1,597		221,998		223,595
Common Stock Issued Upon Exchange of Warrants (in shares)		1,597,112
Options granted to employees and directors				279,045		279,045
Options granted to consultants				8,333		8,333
Common stock issued upon conversion of May 2011 Notes		$ 253		37,745		35,460
Common stock issued upon conversion of May 2011 Notes (in shares)		253,333
Common stock issued upon conversion of December 2011 Notes		$ 5,517		972,594		772,697
Common stock issued upon conversion of December 2011 Notes (in shares)		5,516,666
Interest on Optimus Notes				49,306		49,306
Exchange of Bridge Notes				260,706		260,706
Issuance of shares to directors		$ 999		31,558		32,557
Issuance of shares to directors (in shares)		999,632
Issuance of shares to employees under Employee Stock Purchase Plan		$ 16		2,146		2,146
Issuance of shares to employees under Employee Stock Purchase Plan (in shares)		15,862
Net Loss					(2,609,515)	(2,401,563)
Balance at Apr. 30, 2012	$ 0	$ 287,037	$ (9,998,210)	40,421,952	(42,506,799)	(11,796,020)
Balance (in shares) at Apr. 30, 2012	740	287,038,332
Common Stock Issued Upon Exchange of Warrants		$ 37,553		4,134,466		4,172,019
Common Stock Issued Upon Exchange of Warrants (in shares)		37,552,901
Options granted to employees and directors				293,528		293,528
Options granted to consultants				(3,839)		(3,839)
Common stock issued upon conversion of Bridge Notes		$ 584		81,208		81,792
Common stock issued upon conversion of Bridge Notes (in shares)		583,333
Common stock issued upon conversion of December 2011 Notes		$ 12,135		1,486,639		1,498,774
Common stock issued upon conversion of December 2011 Notes (in shares)		12,135,049
Common stock issued upon conversion of December 2011 Notes		$ 2,505		294,308		296,813
Common stock issued upon conversion of December 2011 Notes (in shares)		2,504,902
Interest on Optimus Notes				50,401		50,401
Issuance of shares to employees under Employee Stock Purchase Plan		$ 68		6,737		6,805
Issuance of shares to employees under Employee Stock Purchase Plan (in shares)		68,397
Net Loss					(3,104,569)	(3,104,569)
Balance at Jul. 31, 2012	$ 0	$ 375,135	$ (9,998,210)	50,235,200	$ (45,611,368)	(4,999,243)
Balance (in shares) at Jul. 31, 2012	740	375,135,008
Debt Conversion, Converted Instrument, Amount						$ 38,000
Debt Conversion, Converted Instrument, Shares Issued						253,333
Issuance of settlement shares		$ 4,000		801,000		$ 805,000
Issuance of settlement shares (in shares)		4,000,000
Common Stock issued upon conversion of long-term convertible promissory note		$ 4,726		275,478		280,204
Common Stock issued upon conversion of long-term convertible promissory note (in shares)		4,725,927
Common Stock issued to consultants		$ 416		39,442		39,858
Common Stock issued to consultants (in shares)		415,167
Common Stock issued under Numoda Stock Purchase Agreement		$ 15,000		1,365,000		1,380,000
Common Stock issued under Numoda Stock Purchase Agreement (in shares)		15,000,000
Common Stock issued to Socius		$ 11,111		$ 988,880		$ 999,991
Common Stock issued to Socius (in shares)		11,111,000

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended		116 Months Ended	125 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2011	Jul. 31, 2012
OPERATING ACTIVITIES
Net loss	$ (10,079,628)	$ (5,237,535)	$ (8,115,740)	$ (10,812,200)	$ (35,487,856)	$ (45,567,484)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	877,251	619,326	795,226	570,664	3,800,645	4,677,896
Amortization of deferred financing costs	0	0	0	0	260,000	260,000
Amortization of discount on convertible promissory notes	1,331,368	455,619	482,507	550,040	1,156,393	2,487,761
Impairment of intangible assets	0	0	0	0	26,087	26,087
Non-cash interest expense	2,885,053	2,198,214	4,106,212	3,238,054	8,570,732	11,455,784
(Gain) loss on change in value of warrants and embedded derivative	(6,020,434)	(7,134,709)	(9,763,113)	(445,576)	(14,411,686)	(20,432,120)
Warrant Expense	0	71,899	557,935	206,275	764,210	764,210
Employee Stock Purchase Plan expense	9,727	0				9,727
Value of penalty shares issued	0	0	0	0	149,276	149,276
Depreciation expense	9,184	28,406	28,406	38,528	195,672	204,858
Amortization expense of intangibles	109,859	99,274	132,288	100,420	594,640	704,499
Other Income	0	0	267	0	267	33,478
Write-off of intangible assets			33,211	0	33,211
Loss (Gain) on note retirement	2,173,491	109,492	461,595	(123,963)	(1,194,845)	978,646
Changes in operating assets and liabilities :
Decrease (increase) in prepaid expenses	(2,452)	(12,352)	1,037	(2,066)	(37,473)	(39,925)
Decrease in grant receivable	0	244,479	244,479	(244,479)	0	0
Decrease (increase) in other current assets	(30,961)	(27,221)	(2,221)	0	(2,221)	(33,182)
Increase in other assets	0	(140,222)	(38,438)	(89,956)	(132,271)	(132,271)
Decrease (increase) in deferred expenses	365,925	(43,830)	(1,146,783)	212,952	(872,375)	(506,450)
Increase in accounts payable and accrued expenses	4,445,333	1,258,911				11,370,590
(Decrease) increase in deferred rent	(43,228)	61,231	62,441	0	62,441	19,212
Increase (decrease) in interest payable	24,759	51,469	94,547	(178,700)	(65,862)	(41,104)
Increase in accounts payable			739,536	388,924	3,906,728
Increase in accrued expenses			2,383,767	167,143	3,018,528
Net cash used in operating activities	(3,944,753)	(7,397,549)	(8,942,842)	(6,423,940)	(29,665,759)	(33,610,512)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations			0	0	(44,940)
Purchase of property and equipment	(91,844)	0	0	(12,436)	(150,093)	(241,937)
Cost of intangible assets	(258,940)	(239,019)	(296,358)	(854,773)	(2,915,740)	(3,219,620)
Net cash used in Investing Activities	(350,784)	(239,019)	(296,358)	(867,209)	(3,110,773)	(3,461,557)
FINANCING ACTIVITIES
Proceeds from convertible debenture	500,000	875,000	955,000	80,000	1,995,000	2,495,000
(Increase) in deferred offering expenses	(58,500)	(23,500)	(52,000)	0	(52,000)	(110,500)
Cash paid for deferred financing costs	0	(25,000)	(25,000)	0	(584,493)	(584,493)
Principal payments on notes payable	(87,941)	(613,573)	(769,379)	(1,798,119)	(2,691,089)	(2,779,030)
Proceeds from notes payable	2,388,963	6,701,775	7,691,063	1,255,000	13,951,952	16,340,885
Deferred Investment Funds	50,000	0				50,000
Net proceeds of issuance of Preferred Stock	0	1,342,672	1,342,672	7,032,827	8,610,499	8,610,499
Cancellation of warrants	0	0	0	0	(600,000)	(600,000)
Proceeds from exercise of warrants	411,765	1,085,001	1,085,001	170,000	1,255,001	1,666,766
Net proceeds of issuance of common stock	0	0	0	0	11,988,230	11,988,230
Net cash provided by Financing Activities	3,204,287	9,342,375	10,227,357	6,739,708	33,873,070	37,077,357
Net increase (decrease) in cash	(1,091,250)	1,705,807	988,157	(551,441)	1,096,538	5,288
Cash at beginning of period	1,096,538	108,381	108,381	659,822	0	0
Cash at end of period	$ 5,288	$ 1,814,188	$ 1,096,538	$ 108,381	$ 1,096,538	$ 5,288

Supplemental Disclosures of Cash Flow Information - USD ($)	9 Months Ended		12 Months Ended		116 Months Ended	125 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2011	Jul. 31, 2012
Cash paid for Interest	$ 53,027	$ 70,372	$ 148,392	$ 311,784	$ 681,992	$ 788,017
Supplemental Schedule of Noncash Investing and Financing Activities
Equipment acquired under notes payable	0	0	0	0	45,580	45,580
Common stock issued to Founders	0	0	0	0	40	40
Notes payable and accrued interest converted to Preferred Stock	0	0	0	0	15,969	15,969
Stock dividend on Preferred Stock	0	0	0	0	43,884	43,884
Accounts Payable from vendors settled in Common Stock	3,249,990	0				3,249,990
Accounts Payable from consultants settled with Common Stock	62,275	0	0	0	51,978	114,253
Notes payable and embedded derivative liabilities converted to Common Stock	9,224,971	1,638,673	4,149,114	3,322,092	5,835,250	15,060,221
Intangible assets acquired with notes payable	0	0	0	0	360,000	360,000
Intangible assets acquired with common stock	0	0	0	70,000	70,000	70,000
Debt discount in connection with recording the original value of the embedded derivative liability	306,568	3,622,701	3,505,605	578,770	6,166,817	6,527,552
Allocation of the original secured convertible debentures to warrants	0	0	0	0	214,950	214,950
Allocation of the warrants on convertible notes as debt discount	571,207	778,052	778,052	712,036	2,431,049	3,001,806
Cancellation of Note Receivable in connection with Preferred Stock Redemption	0	(3,051,000)				(3,051,000)
Note receivable in connection with exercise of warrants	0	2,389,500	(661,500)	10,659,710	9,998,210	9,998,210
Common stock issued in exchange for warrants	134,796	0				134,796
Warrants Issued in connection with issuance of Common Stock	517,797	0	0	0	1,505,550	2,023,347
Warrants Issued in connection with issuance of Preferred Stock	$ 0	$ 0	$ 0	$ 0	$ 3,587,625	$ 3,587,625

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

9 Months Ended

Jul. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Nature of Operations

Advaxis Inc. (the “Company”) is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations.

Since the Company’s inception in 2002, it has focused its initial development efforts upon immunotherapies targeting cervical cancer, its predecessor condition, cervical intraepithelial neoplasia, head and neck cancer, breast cancer, prostate cancer, and other cancers and infectious diseases. Although no products have been commercialized to date, research and development and investment continue to be placed behind the pipeline and the advancement of this technology. Pipeline development entails risk and expense. It is anticipated that ongoing operational costs for the Company will continue to increase significantly due to several ongoing clinical trials in this fiscal year.

Basis of Presentation

The accompanying unaudited interim financial statements include all adjustments (consisting only of those of a normal recurring nature) necessary for a fair statement of the results of the interim period. The October 31, 2011 balance sheet is derived from the audited balance sheet included in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2011 (the “Form 10-K’). These interim financial statements should be read in conjunction with the Company’s financial statements and notes for the fiscal year ended October 31, 2011 included in the Form 10-K. The Company believes these financial statements reflect all adjustments and reclassifications that are necessary for a fair presentation of its financial position and results of operations for the periods presented.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Please refer to Footnote #14: Subsequent Events for the Company’s financing activities that occurred subsequent to July 31, 2012. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Results of operations for the interim periods presented are not necessarily indicative of results to be expected for the year.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Prior Period Restatements

The Company intends to restate its financial statements for the three month period ended January 31, 2012 as well as the three and six month periods ended April 30, 2012 in order to correct the losses (which were understated) recognized on conversions of its May, October and December 2011 Notes into shares of our common stock.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles required management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and the differences could be material. The most significant estimates impact the following transactions or account balances: stock compensation, liabilities (including the embedded derivative liability), warrant valuation, impairment of intangibles and projected operating results.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Intangible Assets

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses. The license and patent costs capitalized primarily represent the value assigned to the Company’s 20-year exclusive worldwide license agreement with Penn, which are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective date of Penn Agreement dated July 1, 2002. The value of the license and patents are based on management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future uses.

We review our long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets are recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, we would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued we would record an impairment of its estimated book value.

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, facilities and related overhead costs.

Accounting for Stock-Based Compensation

Stock-based compensation is estimated at the grant date based on the award’s fair value as calculated by the Black-Scholes-Merton option-pricing model (hereinafter referred to as the “BSM model”) and is recognized as expense over the requisite service period. The BSM model requires various assumptions including volatility, forfeiture rates and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense may differ materially in the future from that recorded in the current period. See Note 10 for information on stock-based compensation expense incurred in the three and nine month periods ending July 31, 2012.

Warrants/Embedded Derivatives

The Company has outstanding Warrants in conjunction with its convertible promissory notes (“Bridge Notes”) and the May 2011, October 2011 December 2011, and the May 2012 Notes). The Company has two classifications of warrants: liability or equity. The liability warrants are recorded at fair value at issuance, using the Black-Scholes valuation model (BSM Model), and will continue to be recorded at fair value each subsequent balance sheet date. Any change in value between reporting periods will be recorded on the statement of operations at each reporting date. The liability warrants will remain until such time as they are exercised or expire at which time they will be adjusted to fair value and reclassified from liabilities to equity. The equity warrants are recorded at their relative fair values at issuance, using the Relative Fair Value Method.

The Company has convertible features (embedded derivatives) in its convertible promissory notes . The embedded derivatives are recorded at fair value and classified as liabilities on the balance sheet. The embedded derivatives will continue to be recorded at fair value each subsequent balance sheet date. Any change in value between reporting periods will be recorded on the statement of operations at each reporting date. These embedded derivatives will remain until such time as they are exercised or expire at which time they will be adjusted to fair value and reclassified from liabilities to equity.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

1. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has approximately 19 (19) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute , Cancer Research – UK , the Wistar Institute , and the University of Pennsylvania.

Basis of Presentation

The preparation of financial statements in accordance with GAAP involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from estimates.

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets which raises substantial doubt about its ability to continue as a going concern. These losses are expected to continue for an extended period of time. The Company intends to continue raising funds through the sale of both debt and equity in order to continue funding ongoing clinical trials activity.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Results of operations for the interim periods presented are not necessarily indicative of results to be expected for the year.

Summary of Significant Accounting Policies

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met; persuasive evidence of an arrangement exists, services have been rendered, the contract price is fixed or determinable, and collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple grants. For the year ended October 31, 2011, the Company did not receive any revenue from grants.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (money market) that at times exceed federally insured limits.

Fixed Assets

Equipment is stated at cost. Depreciation and amortization are provided for on a straight-line basis over the estimated useful life of the asset ranging from 3 to 5 years. Expenditures for maintenance and repairs that do not materially extend the useful lives of the respective assets are charged to expense as incurred. The cost and accumulated depreciation and/or amortization of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations.

Intangible Assets

Intangible assets, which consist primarily of legal and filing costs in obtaining patents and licenses and are being amortized on a straight-line basis over 20 years.

We review our long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, we would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued we would record an impairment of its estimated book value.

Net Loss Per Share

Basic net income or basic net loss per common share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. For 2011 and 2010, approximately 49.4 million warrants and 86 million warrants, respectively (excluding approximately 25.6 million warrants and 15.8 million warrants, respectively, held by an affiliate of Optimus as defined in Note #11) include anti-dilutive provisions to adjust the number and price of the warrants based on certain types of equity transactions.

	As of October 31,
	2011		2010
Warrants		137,841,857		103,139,628
Stock Options		27,317,424		26,467,424
Convertible Debt (using the if-converted method)		61,660,382		4,358,176
Total		226,819,663		133,965,228

Income Taxes

Deferred income taxes are provided for the differences between the bases of assets and liabilities for financial reporting and income tax purposes. Future ownership changes may limit the future utilization of these net operating loss and research and development tax credit carry-forwards as defined by the Internal Revenue Code. The amount of any potential limitation is unknown. The net deferred tax asset has been fully offset by a valuation allowance due to our history of taxable losses and uncertainty regarding our ability to generate sufficient taxable income in the future to utilize these deferred tax assets.

Accounts Payable

Accounts payable consists entirely of trade accounts payable

Research and Development Expenses

Research and development expenses include, but are not limited to, payroll and personnel expenses, lab expenses, clinical trial and related clinical manufacturing costs, facilities and related overhead costs.

Accounting for Stock-Based Compensation

Stock-based compensation is estimated at the grant date based on the award’s fair value as calculated by the Black-Scholes-Merton option-pricing model (hereinafter referred to as the “BSM model”) and is recognized as expense over the requisite service period. The BSM model requires various assumptions including volatility, forfeiture rates and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense may differ materially in the future from that recorded in the current period. See Note #2 for information on stock-based compensation expense incurred (in addition to the various assumptions utilized in the BSM Model) in the years ending October 31, 2011 and 2010.

Warrant Liability/Embedded Derivative Liability

The Company has outstanding Warrants and convertible features (Embedded Derivatives) in its outstanding short-term convertible promissory notes (which include our Bridge Notes, May 2011 Notes and October 2011 Notes). . The Warrants and Embedded Derivatives are recorded at their relative fair values at issuance. Those Warrants, which are classified as liabilities, along with all Embedded Derivatives will continue to be recorded at fair value each subsequent balance sheet date. Any change in fair value between reporting periods will be reported on the statement of operations. As of October 31, 2011, the Company had approximately 101 million of its outstanding warrants classified as liabilities (liability warrants) and approximately 36.8 million of its outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at fair value in the stockholders equity section of the balance sheet. Our equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant) and approximately 49.4 million of our approximately 101 million liability warrants are subject to anti-dilution provisions.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

NET LOSS PER SHARE

9 Months Ended

Jul. 31, 2012

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

3. NET LOSS PER SHARE

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

	As of July 31 ,
	2012		2011
Warrants (includes Optimus warrant of 25,560,000 at July 31, 2012 and 2011 and exchange warrants(see Note 12) of 34,791,156 at July 31, 2012)		114,738,770		96,994
Stock Options		44,807,424		27,317,424
Convertible Debt (using as-if converted method)		11,594,873		-
Total		171,141,067		27,414,418

INTANGIBLE ASSETS

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

4. INTANGIBLE ASSETS

The following is a summary of intangible assets as of the end of the following fiscal periods:

	(Unaudited)
	July 31, 2012			October 31, 2011
License	$	651,992		$	651,992
Patents		2,376,445			2,117,505
Total intangibles		3,028,437			2,769,497
Accumulated Amortization		(622,503	)		(512,645	)
Intangible Assets	$	2,405,934		$	2,256,852

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended if market approval is granted and/or based on existing laws and regulations. Amortization expense amounted to $37,435 and $34,018 for the three months ended July 31, 2012 and July 31, 2011, respectively. Amortization expense amounted to $109,858 and $99,274 for the nine months ended July 31, 2012 and July 31, 2011, respectively.

3. INTANGIBLE ASSETS

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses. The license and patent costs capitalized primarily represent the value assigned to the Company’s 20-year exclusive worldwide license agreement with Penn which are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective date of Penn Agreement dated July 1, 2002. The value of the license and patents are based on management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future uses. This license now includes the exclusive right to exploit 39 patents issued and 37 patents pending and applied for in most of the largest markets in the world.

As of October 31, 2011, all gross capitalized costs associated with the licenses and patents filed and granted as well as costs associated with patents pending are $2,769,497 as shown under licenses and patents on the table below. The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. During the fiscal year ended October 31, 2011, the Company wrote off approximately $33,000 in capitalized patent costs related to four patent applications that had expired or were abandoned. Nopatent applications with future value were abandoned or expired and charged to expense in the prior year. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses.

Under the amended and restated agreement we are billed actual patent expenses as they are passed through from Penn and or billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31, 2011			October 31, 2010
License	$	651,992		$	651,992
Patents		2,117,505			1,854,355
Total intangibles		2,769,497			2,506,347
Accumulated Amortization		(512,645	)		(380,356	)
Intangible Assets	$	2,256,852		$	2,125,991

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2012	$	140,000
2013		140,000
2014		140,000
2015		140,000
2016		140,000

ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

The following table represents the major components of accounts payable and accrued expenses:

	(Unaudited)
	July 31, 2012		October 31, 2011
Accounts Payable	$	4,947,357	$	4,778,508
Salaries and other compensation		696,645		531,040
Clinical Trial		56,468		-
Vendors		77,512		-
Consultants		32,200		32,200
Financing Costs		140,492		-
Legal		81,231		46,346
Other		21,768		8,500
	$	6,053,853	$	5,396,594

4. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	October 31, 2011		October 31, 2010
Salaries and other compensation	$	531,041	$	500,927
Sponsored Research Agreement		-		119,698
Clinical Research Organization (CRO)		2,358,247		-
Consultants		32,200		18,000
Legal		46,346
Other		8,500		8,500
	$	2,976,334	$	647,125

DEFERRED INVESTMENT FUNDS

9 Months Ended

Jul. 31, 2012

Deferred Investment Funds [Abstract]

Deferred Investment Funds [Text Block]

6. DEFERRED INVESTMENT FUNDS

During the nine months ended July 31, 2012, the Company received funds in the aggregate amount of $290,000 from four accredited investors, including $50,000 from our chief executive officer, Thomas A. Moore. During the nine months ended July 31, 2012, $240,000 of these funds were invested into the Rodman May 2012 Convertible Debt Financing (See Footnote #7). At July 31, 2012, the Company recorded a current liability for Mr. Moore’s funds of $50,000 that had not yet been invested in the next financing.

NOTES PAYABLE - CONVERTIBLE PROMISSORY NOTES

9 Months Ended

Jul. 31, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

7. NOTES PAYABLE - CONVERTIBLE PROMISSORY NOTES

Convertible Promissory Notes

We refer to all Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in our Bridge Notes, each Investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of Warrant. As of July 31, 2012, substantially all of the Bridge Warrants have an exercise price of $0.15 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the Maturity Date. The warrants may be exercised on a cashless basis under certain circumstances.

During the three months ended July 31, 2012, the Company entered into an exchange agreement with an accredited investor in which the investor exchanged a convertible promissory note in the aggregate principal amount of $50,000 for (i) an aggregate of approximately 583,000 shares of our common stock and (ii) a warrant to purchase up to 20,834 shares of common stock at an exercise price of $0.15 per share. The warrant expires in October 2015. The Company recorded noncash expense of approximately $24,000 to the loss on note retirement account resulting from this exchange for the three months ended July 31, 2012.

During the nine months ended July 31, 2012, the Company entered into an exchange agreement with an accredited investor in which the investor exchanged a convertible promissory note in the aggregate principal amount of $300,000 for (i) a convertible promissory note in the aggregate principal amount $352,941 and in substantially the same form as the existing note except with a maturity date of June 30, 2012 and (ii) a warrant to purchase up to 2,352,940 shares of common stock at an exercise price of $0.15 per share. The warrants expire in February 2015. The Company recorded noncash expense of approximately $247,000 to the loss on note retirement account resulting from this exchange for the nine months ended July 31, 2012.

During the nine months ended July 31, 2012, the Company paid approximately $53,000 in principal on its Bridge Notes. In addition, the Company converted approximately $169,000 of principal on these Bridge Notes into 1,126,667 shares of the Company’s common stock at a conversion price of $0.15 per share. The Company recorded noncash expense of approximately $27,000 to the loss on note retirement account resulting from these conversions for the nine months ended July 31, 2012.

As of July 31, 2012, the Company had approximately $536,000 in principal outstanding on its junior subordinated convertible promissory notes with Original Issue Discount (“OID”) amounts ranging from 10% to 15% and with maturity dates ranging from October 19, 2011 to June 30, 2012.

Rodman 2011 Financings

During the months of May, October and December 2011, the Company entered into various Note Purchase agreements with accredited investors including Thomas A. Moore, our Chairman and Chief Executive Officer, and Mark J. Rosenblum, our Chief Financial Officer. Mr. Rosenblum acquired a note in the principal amount of approximately $59,000 for an aggregate purchase price of $50,000. Mr. Moore acquired his note in exchange for the cancellation of $400,000 of outstanding indebtedness owed by us to Mr. Moore. The Company issued $10.6 million of our convertible promissory notes for an aggregate purchase price of approximately $9.0 million in the private placement. In connection with these financings, the Company issued 38,784,491warrants to purchase shares of the Company’s common stock at a conversion price equal to $0.15 per share.

Effective May 14, 2012,the Company entered into exchange agreements with certain holders of an aggregate of approximately $4.5 million of the outstanding principal amount of certain convertible promissory notes of the Company, pursuant to which such holders received an aggregate of approximately 52.2 million shares of Common Stock and warrants to purchase an aggregate of approximately 5.8 million shares of Common Stock in exchange for surrendering or converting the Existing Notes and surrendering warrants to purchase an aggregate of approximately 31.3 million shares of Common Stock originally issued in the Prior Offerings.

The Exchange Agreements also provides that, for three months from the date of the Exchange Agreements, if the Company offers, issues, or agrees to issue any of its securities, other than Exempt Issuances (as defined in the Exchange Agreements), at an effective price per share less than the Base Share Price (as defined in the Exchange Agreements), then the Company shall issue additional shares of Common Stock to each Existing Investor in accordance with the formula set forth in the Exchange Agreements.

The Company accounted for the exchange as an extinguishment of a liability and recorded a noncash expense of approximately $1.5 million to the loss on note retirement account resulting from this exchange for the three months ended July 31, 2012.

The remaining holders (who did not participate in the above exchange agreements) of an aggregate of approximately $249,000 in principal related to the convertible promissory notes entered into Amendment, Consent and Waiver Agreements with our company, pursuant to which such holders agreed to amend the note purchase agreements between our company and such holders to terminate (i) such holders’ right to participate in any proposed or intended issuance or sale or exchange of our securities, and (ii) the prohibition on our ability to effect, or enter into an agreement to effect, any issuance of our securities for cash consideration involving a variable rate transaction.

In addition to the exchange discussed above, during the nine months ended July 31, 2012, the Company converted approximately $4,017,000 into 26,780,392 shares of the Company’s common stock at a conversion price of $0.15.

Rodman 2012 Financings

Effective May 14, 2012, we entered into a Note Purchase Agreement with certain accredited investors, whereby the investors acquired approximately $953,333 of our convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash which represented an original issue discount of 25%. The May 2012 Notes are convertible into shares of our common stock at $0.15 per share. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2012 Notes at an exercise price of $0.15 per share. The Notes and Warrants also provide that on December 1, 2012, solely to the extent the conversion price of the Notes or the exercise price of the Warrants, as applicable, is less than the “Market Price” (as defined in the Notes or the Warrants, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The May 2012 Notes mature on May 18, 2013. We may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances and expire on May 18, 2017.

The Company elected to apply the fair-value option to account for the May 2012 notes and have recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the notes which amounted to $18,190 for the period from the date of issuance or May, 14, 2012 through July 31, 2012 were recognized as a noncash expense.

In addition, as a result of the reset provisions discussed above, the warrants which have been recorded at a fair value of $291,400 on May 14, 2012 are being reflected as a warrant liability as of the date of issuance. As of July 31, 2012, the warrant liability amounted to $222,467 which resulted in a noncash income of approximately $69,000 for the three months ended July 31, 2012.

Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with the May 2012 offering and received compensation of a cash placement fee equal to 7% of the aggregate purchase price paid by investors (Rodman raised $400,000 of the total purchase price of $715,000) in the May 2012 offering amounting to$28,000 and warrants to purchase 355,556 shares of our common stock, which warrants are exercisable at $0.15 per share and shall expire on May 18, 2017.

July 2012 Note

On July 21, 2012, we received $250,000 from an accredited investor in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and matures on December 31, 2012. We may not redeem this Note without the written consent of the investor.

We refer to all convertible promissory notes with a maturity date less than one year collectively as “Short-term Convertible Promissory Notes.”

Short-term Convertible Promissory Notes – Principal Value – Issued	$	18,225,036
Principal payments on Bridge Notes		(2,124,851	)
Short-term Convertible Promissory Note Conversions		(9,890,228	)
May, October and December 2011 Debt for Equity Exchanges		(4,114,176	)
Bridge Note Exchanges		4,712
Original Issue Discount, net of accreted interest		(26,525	)
Fair Value of Attached Warrants at issuance		(5,805,580	)
Fair Value of Embedded Derivatives at issuance		(6,034,500	)
Accreted interest on embedded derivative and warrant liabilities		11,097,689
Adjustments to fair value – May 2012 Notes		(248,142	)

Convertible Notes- as of July 31, 2012	$	1,083,435
Embedded Derivatives Liability at July 31, 2012		2,136
Notes Payable – convertible promissory notes and fair value of embedded derivative	$	1,085,571

Long-term Convertible Promissory Notes

On April 28, 2011, Advaxis, Inc. issued and sold to an accredited investor convertible promissory notes of the Company in the aggregate principal amount of $660,000 to JMJ Financial for cash. The notes bear interest in the form of a one-time interest charge of 8%. and mature onApril 28, 2014. The notes are convertible, in whole or in part, into shares of the Company’s common stock, at a per share conversion price equal to 80% of the average of the two lowest trade prices for the Common Stock in the 20 trading days previous to the effective date of each such conversion, subject to a conversion floor of $0.15.

The Company elected to apply the fair-value option to account for these notes and have recorded the notes at a fair value of approximately $820,000 upon issuance. Unrealized gains on the mark-to-market of the notes which amounted to approximately $17,000 and $186,000 for the three and nine months ended July 31, 2012, respectively, were recognized as a noncash income.

In November and December, 2011, the Company converted $500,000 into 3,600,000 shares of common stock. As a result, the Company recorded a noncash income of approximately $36,000 related to the conversion of these notes to equity.

On May 8, 2012, the Company entered into a Settlement Agreement (the “ Settlement Agreement ”) with JMJ Financial which provides for (i) an additional borrowing by the Company of $500,000 from JMJ Financial on the principal amount outstanding under one of the notes issued by JMJ to the Company in April 2011, (ii) the cancellation of all of the outstanding notes issued by JMJ to the Company in April 2011, (iii) the cancellation of all of the outstanding notes issued by the Company to JMJ in April 2011, other than the portion of such notes for which JMJ has paid cash to the Company, (iv) a mutual release of any claims held by the Company or JMJ relating to an outstanding dispute and (v) the issuance by the Company of 4,000,000 newly issued shares of the Company’s common stock (the “ Settlement Shares ”) to JMJ as consideration for the cancellation of the notes and the release. As a result of the Settlement Agreement, no further payments will be made by either the Company or JMJ under the notes issued by each party in April 2011. The Company recorded noncash expense of approximately $805,000 for the issuance of the Settlement Shares to JMJ under the Settlement Agreement and recognition of a beneficial conversion feature, resulting from the issuance of shares.

The Company elected to apply the fair-value option to account for the note and has recorded the note at a fair value of approximately $324,000 upon issuance. Unrealized gains on the mark-to-market of the note which amounted to $75,000 for the three months ended July 31, 2012 was recognized as a noncash income.

During the three months ended July 31, 2012, the Company converted all of the notes outstanding totaling $660,000 into 4,725,927 shares of the Company’s common stock.. The Company recorded noncash income of approximately $250,000 upon conversion.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

NOTES PAYABLE - OFFICER

9 Months Ended

Jul. 31, 2012

8. NOTES PAYABLE – OFFICER

On September 22, 2008, Advaxis entered into an agreement (the “Moore Agreement”) with the Company’s Chief Executive Officer, Thomas A. Moore, pursuant to which the Company agreed to sell senior promissory notes to Mr. Moore, from time to time (“the Moore Notes”). The terms and maturity date of the Moore Notes have been amended from time to time to change maturity dates and repayment provisions. Currently, under the terms of the amended and restated Moore Notes: (i) the maturity date is the earlier of (x) the date of consummation of an equity financing by us in an amount of $6.0 million or more and (y) the occurrence of any event of default as defined in the Moore Notes, (ii) Mr. Moore may elect, at his option, to receive accumulated interest thereon on or after April 15, 2011, (iii) we will make monthly installment payments of $100,000 on the outstanding principal amount beginning on June 15, 2011, and (iv) we may retain, at the option of Mr. Moore, $200,000 of the repayment amount for investment in our next equity financing.

During the nine months ended July 31, 2012, the Company paid Mr. Moore $35,000 in principal. As of July 31, 2012, the Company was not in default under the terms of the Moore Agreement. As of July 31, 2012, the Company owed Mr. Moore approximately $396,000, inclusive of accrued interest in the amount of approximately $158,000 in the form of a Note Payable – Officer.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

DERIVATIVE INSTRUMENTS

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

9.DERIVATIVE INSTRUMENTS

The table below lists the Company’s derivative instruments as of July 31, 2012:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Total Valuation at October 31, 2011	$	8,976,071		$	1,300,347		$	6,391,071		$	946,046
Issuance of December 2011 Notes		1,232,353			258,178			-			306,568
Conversion of Bridge Notes		(169,000	)								-
Conversion of May 2011 Notes		(1,924,060	)								(341,342	)
Conversion of October 2011 Notes		(1,227,500	)								(329,433	)
Partial Note Repayments		(52,941	)
Conversion of Long-term Convertible Promissory Notes		(540,000	)
Exchange of Warrants								59,572
Accreted Interest					(532,559	)
Change in FV								(923,052	)		159,657
Total Valuation at January 31, 2012	$	6,294,923		$	1,025,966		$	5,527,591		$	741,496
Exchange of Bridge Notes		52,941						-
Conversion of May 2011 Notes		(38,000	)								(5,016	)
Conversion of December 2011 Notes		(827,500	)								(160,677	)
Exchange of Warrants								(134,796	)
Accreted Interest					(569,419	)
Change in FV								(2,302,707	)		(438,054	)
Total Valuation at April 30, 2012	$	5,482,364		$	456,547		$	3,090,088		$	137,749

Issuance of May 2012 Notes		953,333						291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673	)		(200,632	)					(115,046	)
Debt for Equity Exchange: Bridge Notes		(50,000	)					(4,750	)
July 2012Exchange of Warrants								(407,501	)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800	)
Accreted Interest					(229,392	)
Change in FV								(1,703,252	)		(20,567	)
Total Valuation at July 31, 2012	$	1,739,224			26,523			1,265,985			2,136

Warrant Liability/Embedded Derivative Liability

Warrant Liability

As of July 31, 2012, the Company had approximately 99.6 million of its total approximately 114.7 million total warrants classified as liabilities (liability warrants). Of these 99.6 million liability warrants, approximately 64.8 million warrants are outstanding and 34.8 million warrants are exchange warrants – nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 47 million of our 99.6 million liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At July 31, 2012, the fair value of the warrant liability was approximately $1,266,000. For the three months ended July 31, 2012 and July 31, 2011, the Company reported income of approximately $1.7 million and $6.9 million, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2012 and July 31, 2011, the Company reported income of approximately $4.9 million and approximately $5.8 million, respectively, due to changes in the fair value of the warrant liability.

Embedded Derivative Liability

The Company has convertible features (Embedded Derivatives) in its outstanding convertible promissory notes . The Embedded Derivatives are recorded as liabilities at issuance. These Embedded Derivatives are valued using the Black-Scholes Model (BSM Model) and are subject to revaluation at each reporting date. Any change in fair value between reporting periods will be reported on the statement of operations.

At July 31, 2012, the fair value of the Embedded Derivative Liability was approximately $2,140. For the three months ended July 31, 2012 and July 31, 2011, the Company reported income of approximately $28,000 and approximately $2.2 million, respectively, due to changes in the fair value of the Embedded Derivative Liability partially resulting from debt to equity exchanges during the period. . For the nine months ended July 31, 2012 and July 31, 2011, the Company recorded income of approximately $307,000 and approximately $1.3 million, respectively, due to changes in the fair value of the Embedded Derivative Liability.

6. DERIVATIVES

The table below lists the Company’s derivative instruments as of October 31, 2011:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Bridge Note 1-June 18, 2009	$	1,131,353		$	169,703		$	250,392		$	711,258
Bridge Note II & III-October 26 & 30, 2009		2,147,059			322,059			690,119			868,388
Optimus September 24, 2009		-			-			3,587,625			-
Other outstanding warrants		-			-			12,785,695			-
Total Valuation at Origination		3,278,412			491,762			17,313,831			1,579,646
Change in fair value		-			-			(5,352,697	)		(493,132	)
Accreted interest		-			(123,846	)		-			-
Total Valuation as of October 31, 2009	$	3,278,412		$	367,916		$	11,961,734		$	1,086,514
Bridge Notes IV-December 1, 2009 through January 31. 2010		555,882			83,382			207,617			164,400
Bridge Note I- Extension of Maturity Date		-			-			202,500			103,400
Change in fair value		-			-			1,995,372			(905,259	)
Accreted interest		-			(225,321	)		-			-
Exercise of Common Stock Warrants		-			-			(1,702,073	)		-
Total Valuation as of January 31, 2010	$	3,834,294		$	225,977		$	12,665,150		$	449,055
Bridge Note V		640,307			97,807			229,619			271,554
Change in fair value		-			-			5,363,854			421,404
Accreted interest		-			(251,188	)		-			-
Exercise of common stock warrants		-			-			(1,790,823	)		-
Note Payoffs		(1,040,177	)		(4,222	)		-			(64,354	)
Total Valuation as of April 30, 2010		3,434,424			68,374			16,467,800			1,077,659
Issuance of Optimus Warrants		-			-			6,856,946			-
Bridge Note Conversions		(2,420,373	)		-			-			(701,718	)
Change in fair value		-			-			(3,866,801	)		(260,843	)
Accreted interest		-			(50,842	)		-			-
Exercise of common stock warrants		-			-			(1,475,758	)		-
Note Payoffs		(88,236	)								(12,665	)
Total Valuation as of July 31, 2010	$	925,815		$	17,532		$	17,982,187		$	102,433
Bridge Note VI		265,457			25,457			72,300			39,416
Note Payoff		(414,118	)		-			-			(46,945	)
Issuance of Warrants		-			-			1,042,559			-
Accreted Interest		-			(21,052	)		-			-
Exercise of Warrants		-			-			(4,156,797	)		-
Change in FV		-			-			(1,934,055	)		(13,876	)
Total Valuation at October 31, 2010	$	777,154		$	21,937		$	13,006,194		$	81,028
Issuance of November 2010 Bridge Notes		931,579			96,579			391,076			150,156
Exchange of November 2010 Bridge Notes		17,175			17,175			86,963			9,389
Issuance of January 2011 Bridge Notes		452,941			57,941			173,808			41,024
Note Payoffs		(187,582	)
Issuance of Warrants								35,523
Accreted Interest					(73,363	)
Exercise of Warrants								(1,382,847	)
Change in FV								(3,789,889	)		(51,972	)
Total Valuation at January 31, 2011		1,991,267			120,269			8,520,828			229,625

Issuance of Q2 2011 Bridge Notes		473,392			43,392			121,238			71,336
Issuance of Long-term Convertible Promissory Notes		626,400									-
Note Payoffs		(159,675	)								(5,904	)
Issuance of Warrants								2,990,520
Accreted Interest					(74,422	)
Exercise of Warrants								(639,960	)
Change in FV								4,915,676			763,523
Total Valuation at April 30, 2011	$	2,931,384		$	89,239		$	15,908,302		$	1,058,580

Issuance of Q3 2011 Bridge Notes		11,765			1,765			4,968			5,051
Issuance of May 2011 Notes		7,077,936			1,553,254			-			2,719,345
Note Payoffs		(26,316	)								(8,860	)
Additional warrants issued to Bridge Note holder								36,376
Exchange of Bridge Notes		8,033			8,033						2,656
Conversion of Bridge Notes		(1,164,947	)								(381,209	)
Conversion of May 2011 Notes		(671,500	)								(166,980	)
Exchanges/Exercises of October 2007 Warrants								(1,186,959	)
Accreted Interest					(340,050	)
Change in FV								(6,826,019	)		(2,141,984	)
Total Valuation at July 31, 2011	$	8,166,355			1,312,241			7,936,668			1,086,599
Issuance of October 2011 Notes		2,326,471			459,396			-			396,818
Note Payoffs		(155,806	)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788)									(10,530	)
Conversion of May 2011 Notes		(1,225,561)									(110,494	)
Reclassification of Warrant liability to Equity								(186,908)
Exchange of Warrants								816,259
Accreted Interest					(471,290	)
Change in FV								(2,174,948 )			(416,347	)
Total Valuation at October 31, 2011	$	8,976,071			1,300,347			6,391,071			946,046

Warrants

As of October 31, 2011, there were outstanding warrants to purchase 137,841,857 shares of our common stock with exercise prices ranging from $0.15 to $0.1952 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	0.15		47,090,487	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		287,001	August 2012	August 2007 Notes
Common Stock Purchase Warrant	$	0.15		23,593,122	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		7,754,902	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15 - $0.17		22,630,101	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		7,674,512	August 2014	Executive Officer
Common Stock Purchase Warrant	$	0.15-$0.1952		446,956	February 2012	Vendor & Other
Common Stock Purchase Warrant	$	0.15		2,804,776	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
	Subtotal			112,281,857

Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Optimus Preferred Stock Agreement (4/04/2011)
	Grand Total			137,841,857

(1) For purposes of this warrant, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

Warrant Liability/Embedded Derivative Liability

The fair value of the Warrants and Embedded Derivatives are estimated using an adjusted BSM model. The Company computes multiple valuations, each quarter, using the BSM model for each derivative instrument to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the derivative at the reporting date. As of October 31, 2011, the fair value of the Warrants and Embedded Derivatives were determined to be approximately $6.4 million and $946,000, respectively. As of October 31, 2010, the fair value of the Warrants and Embedded Derivatives were determined to be approximately $13.0 million and $81,000, respectively. We increased income approximately $9.8 million for net changes in the fair value of the common stock warrant liability and embedded derivative liability for the year ending October 31, 2011. We increased income approximately $446,000 for net changes in the fair value of the common stock warrant liability and embedded derivative liability for year ending October 31, 2010.

During the year ended October 31, 2011, investors in the Company exercised 7,233,341 warrants at a price of $0.15, resulting in total proceeds to the Company of approximately $1,085,000 In addition, in an effort to reduce the number of the warrants outstanding from the October 17, 2007 private placement by Advaxis, Inc. (the “ Company”), the Company has entered into exchange agreements with certain of the holders of such warrants pursuant to which such holders received shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock”), and/or warrants to purchase shares of Common Stock in amounts that were determined in such negotiations. As of October 31, 2011, the Company has exchanged October 2007 warrants to purchase 28,511,125 shares of Common Stock, including Mr. Moore, in return for 5,840,748 shares of Common Stock and new warrants to purchase 14,651,854 shares of Common Stock (which number includes the warrants issued to Mr. Moore in exchange for his October 2007 warrants as described below). The new warrants issued pursuant to the exchanges are identical to the October 2007 warrants, except that such warrants do not contain any economic anti-dilution adjustment.

Furthermore, during the year ended October 31, 2011, Mr. Moore entered into an exchange agreement with the Company (the “ Exchange Agreement”), pursuant to which he received a new warrant to purchase 7,674,512 shares of Common Stock (which new warrant (the “ Warrant”) is identical to the October 2007 warrant except that it does not contain any economic anti-dilution adjustment rights, all as more particularly described in the Warrant attached hereto as Exhibit 4.1) in exchange for (i) surrendering an October 2007 warrant to purchase 2,666,667 shares of Common Stock and (ii) amending a Note Purchase Agreement, dated as of September 22, 2008, by and between the Company and Mr. Moore, to terminate his right to receive warrants in connection with an equity financing, including the equity financing the Company completed in May 2011, which otherwise would have permitted Mr. Moore to receive a warrant to purchase 4,118,956 shares of Common Stock.

Therefore, primarily as a result of these efforts, the Company reduced the total number of outstanding warrants, subject to anti-dilution provisions, to approximately 49.4 million warrants, as of October 31, 2011. In addition, the Company recorded a non-cash charge of approximately $458,000 to other expense (loss on retirement) and approximately $486,000 in non-cash warrant expense, for the fiscal year ended October 31, 2011, as a result of these warrant exchanges (including Mr. Moore).

The company recognized non-cash warrant expense of approximately $72,000, for the year ending October 31, 2011, related to the fair value of the additional warrants issued to bridge note holders as well as a placement agent for the sale of junior unsecured convertible promissory notes.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS

9 Months Ended

Jul. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10. ACCOUNTING FOR STOCK BASED COMPENSATION PLANS

The Company records compensation expense associated with stock options based on the estimated fair value of each option award that was granted using the Black-Scholes option valuation model.

The table below summarizes compensation expenses from share-based payment awards:

	Three Months Ended				Nine months Ended
	July 31,				July 31,
	2012		2011		2012		2011

Research & Development	$	128,011	$	95,263	$	397,231	$	265,768
General & Administrative		161,678		104,005		480,020		353,531
Total stock compensation recognized	$	289,689	$	199,268	$	877,251	$	619,299

Total unrecognized estimated compensation expense related to non-vested stock options granted and outstanding as of July 31, 2012 was approximately $2.25 million which is expected to be recognized over a weighted-average period of approximately 2.0 years.

No options were exercised over the three and nine month periods ended July 31, 2012. For the nine month period ended July 31, 2012, the Company granted 17,740,000 options at an exercise price of approximately $0.15. The Company utilized the following assumptions in the Black-Scholes valuation model to arrive at a fair value of $0.1448 per option granted during the three and nine months ended July 31, 2012:

Exercise Price:	$	0.148
Stock Price:	$	0.148
Days to Maturity:		3,650 days (10-year life for all options granted	)
Risk-free Rate:		2.10	%
Volatility:		143	%

A summary of changes in the stock option plan for nine months ended July 31, 2012 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2011:		27,317,424	$	0.16
Granted		17,740,000	$	0.15
Exercised		-		—
Expired		-
Outstanding at January 31, 2012		45,057,424	$	0.16
Cancelled		250,000		0.15
Outstanding at April 30, 2012		44,807,424		0.16
Outstanding at July 31, 2012		44,807,424		0.16
Exercisable at July 31, 2012		27,560,653	$	0.16
Not Exercisable at July 31, 2012		17,246,771	$	0.15

2011 Employee Stock Purchase Plan

Our board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which we refer to as the ESPP, on August 22, 2011, and our stockholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 5,000,000 shares of our common stock are reserved for issuance under the ESPP.

During the three months ended July 31, 2012 approximately $8,535 was withheld from employees, on an after-tax basis, in order to purchase 122,819 shares of our common stock in August 2012. During the nine months ended July 31, 2012, approximately $18,300 was withheld from employees, on an after-tax basis, in order to purchase 15,862 shares of our common stock in February 2012, another 68,397 shares of our common stock in May 2012 and another 122,819 shares of our common stock in August 2012.

Subsequent to July 31, at our annual meeting held on August 13, 2012, shareholders ratified & approved an amendment to our 2011 Omnibus Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 45,000,000 shares.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS AND CONTINGENCIES

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

11. COMMITMENTS AND CONTINGENCIES

University of Pennsylvania

On May 10, 2010, we entered into a second amendment to the Penn license agreement pursuant to which we acquired exclusive licenses for an additional 27 patent applications related to our proprietary Listeria vaccine technology. As part of this amendment we exercised our option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in our common stock (approximately 388,889 shares of our common stock based on a price of $0.18 per share) and agreed to pay historical patent costs incurred by the University of Pennsylvania.

As of July 31, 2012, the Company owed approximately $507,000 to Penn under all licensing agreements.

Numoda

On June 19, 2009 we entered into a Master Agreement and on July 8, 2009 we entered into a Project Agreement with Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda will be responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Per the agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 3,500,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded a deferred expense on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through July 31, 2012, the Company has paid Numoda approximately $7.4 million.

Numoda -Stock Purchase Agreement

On June 13, 2012, we entered into a stock purchase agreement with Numoda Corporation pursuant to which we issued to Numoda 15 million shares of our common stock, which we refer to as the AR Cancellation Shares, at a purchase price per share of $0.15, in exchange for the immediate cancellation of $2,250,000 of accounts receivables owed by us to Numoda pursuant to the Master Agreement, dated June 19, 2009, between Numoda and us.. In connection with such issuance, we have also agreed to register the resale by Numoda of the AR Cancellation Shares with the SEC . The Company recorded noncash income of approximately $869,000 as a result of this stock purchase agreement.

Numoda- Socius Stock Issuance

On July 24, 2012, the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which we refer to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which we refer to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which we refer to as the Claim. Socius purchased approximately $1.8 million of the Claim against us from Numoda Corporation.

Pursuant to the terms of the Order and the Stipulation, we issued and delivered to Socius an aggregate of 11,111,000 shares of our common stock for one-half of the Claim, which are subject to adjustment as described in the Stipulation. The Company recorded noncash income of approximately $444,000 related to the issuance of stock to Socius in settlement of one-half of the Claim.

As of July 31, 2012, the Company owed Numoda approximately $1.7 million, which is recorded in our Accounts Payable at the balance sheet date.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to a 9,143 square foot leased facility in Princeton, NJ approximately 12 miles south of its former location. The agreement is for a period of approximately twenty months at the rate of approximately $15,600 per month plus utilities. Utility costs are estimated to be $7,200 per month and are capped at approximately $10,700 per month. Under the current lease, the Company expects to spend approximately $288,000 for the fiscal year ended October 31, 2012. As an inducement to enter into the agreement, the company will receive rent abatement for a specified number of months through July 31, 2011. The agreement has a termination date of November 29, 2012 and the Company is in discussions with building owner for lease terms beyond this date.

As a result of the rent abatement period, the Company recorded differences between actual rent payments and straight-line rent expense to a deferred liability account. As of July 31, 2012, this amount was approximately $19,200.

Other

Pursuant to a Clinical Research Service Agreement, the Company is obligated to pay Pharm–Olam International for service fees related to our Phase I clinical trial. As of July 31, 2012, the Company has an outstanding balance of $223,620 on this agreement

8. COMMITMENTS AND CONTINGENCIES :

University of Pennsylvania

During the year ended October 31, 2011, the Company paid approximately $405,000 to Penn under all licensing agreements.

Other

Pursuant to a Clinical Research Service Agreement, the Company is obligated to pay Pharm–Olam International for service fees related to our Phase I clinical trial. As of October 31, 2011, the Company has an outstanding balance of $223,620 on this agreement.

On June 19, 2009 we entered into a Master Agreement and on July 8, 2009 we entered into a Project Agreement with Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda will be responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Per the agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 3,500,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over thelife of the agreement. At October 31, 2011, there was a balance of approximately $1.1 million in deferred expenses related to the Numoda project. From inception of these agreements through October 31, 2011, the Company has paid Numoda approximately $6.3 million.

New Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to a 9,143 square foot leased facility in Princeton, NJ approximately 12 miles south of its former location. The agreement is for a period of approximately twenty months at the rate of approximately $15,600 per month plus utilities. Utility costs are estimated to be $7,200 per month and are capped at approximately $10,700 per month. Under the current lease, the Company expects to spend approximately $72,000 through October 31, 2011 and approximately $288,000 for the fiscal year ended October 31, 2012. The Company made an initial payment of approximately $54,000 prior to entering the new facility. As an inducement to enter into the agreement, the company will receive rent abatement for a specified number of months through July 31, 2011. The agreement has a termination date of November 29, 2012 and the Company is in discussions with building owner for lease terms beyond this date.

As a result of the rent abatement period, the Company recorded differences between actual rent payments and straight-line rent expense to a deferred liability account. As of October 31, 2011, this amount was approximately $62,000.

Moore Employment Agreement and Option Agreements. We are party to an employment agreement with Mr. Moore, dated as of August 21, 2007 (memorializing an oral agreement dated December 15, 2006), that provides that he will serve as our Chairman of the Board and Chief Executive Officer for an initial term of two years. For so long as Mr. Moore is employed by us, Mr. Moore is also entitled to nominate one additional person to serve on our board of directors. Following the initial term of employment, the agreement was renewed for a one year term, and is automatically renewable for additional successive one year terms, subject to our right and Mr. Moore’s right not to renew the agreement upon at least 90 days’ written notice prior to the expiration of any one year term.

Under the terms of the agreement, Mr. Moore was entitled to receive a base salary of $250,000 per year, subject to increase to $350,000 per year, his current salary, upon our successful raise of at least $4.0 million (which condition was satisfied on November 1, 2007) and subject to annual review for increases by our board of directors in its sole discretion. The agreement also provides that Mr. Moore is entitled to receive family health insurance at no cost to him. Mr. Moore’s employment agreement does not provide for the payment of a bonus.

In connection with our hiring of Mr. Moore, we agreed to grant Mr. Moore up to 1,500,000 shares of our common stock, of which 750,000 shares were issuable on November 1, 2007 upon our successful raise of $4.0 million and 750,000 shares are issuable upon our successful raise of an additional $6.0 million (which condition was satisfied in January 2010 and the shares were then issued in June 2010). In addition, on December 15, 2006, we granted Mr. Moore options to purchase 2,400,000 shares of our common stock. Each option is exercisable at $0.143 per share (which was equal to the closing sale price of our common stock on December 15, 2006) and expires on December 15, 2016. The options vest in 24 equal monthly installments. On July 21, 2009, we granted Mr. Moore options to purchase 2,500,000 shares of our common stock. Each option is exercisable at $0.10 per share (which was equal to the closing sale price of our common stock on July 21, 2009) and expires on July 21, 2019. One-third of these options vested on the grant date, and the remaining vest in one third installments on the first and second anniversary of the grant. On October 14, 2010, we granted Mr. Moore options to purchase 2,000,000 shares of our common stock. Each option is exercisable at $0.15 per share. These options vest over a three year period beginning one year from the grant date.

We have also agreed to grant Mr. Moore 1,500,000 shares of our common stock if the price of common stock (adjusted for any splits) is equal to or greater than $0.40 for 40 consecutive business days. Pursuant to the terms of his employment agreement, all options will be awarded and vested upon a merger of the company which is a change of control or a sale of the company while Mr. Moore is employed. In addition, if Mr. Moore’s employment is terminated by us, Mr. Moore is entitled to receive severance payments equal to one year’s salary at the then current compensation level.

Mr. Moore has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 12 months thereafter under certain circumstances. In addition, Mr. Moore is subject to a non-solicitation provision for 12 months after termination of his employment.

Rothman Employment Agreement and Option Agreements. We previously entered into an employment agreement with Dr. Rothman, Ph.D., dated as of March 7, 2005, that provided that he would serve as our Vice President of Clinical Development for an initial term of one year. Dr. Rothman’s current salary is $305,000, consisting of $275,000 in cash and $30,000 in stock, payable in our common stock, issued on a semi-annual basis, based on the average closing stock price for such six month period, with a minimum price of $0.20. While the employment agreement has expired and has not been formally renewed in accordance with the agreement, Dr. Rothman remains employed by us and is currently our Executive V.P. of Clinical and Scientific Operations.

In addition, on March 1, 2005, we granted Dr. Rothman options to purchase 360,000 shares of our common stock. Each option is exercisable at $0.287 per share (which was equal to the closing sale price of our common stock on March 1, 2005) and expires on March 1, 2015. All of these options have vested. On March 29, 2006, we granted Dr. Rothman options to purchase 150,000 shares of our common stock. Each option is exercisable at $0.26 per share (which was equal to the closing sale price of our common stock on March 29, 2006) and expires on March 29, 2016. One-fourth of these options vested on the first anniversary of the grant date, and the remaining vest in 12 equal quarterly installments. On February 15, 2007, we granted Dr. Rothman options to purchase 300,000 shares of our common stock. Each option is exercisable at $0.165 per share (which was equal to the closing sale price of our common stock on February 15, 2007) and expires on February 15, 2017. One-fourth of these options vested on the first anniversary of the grant date, and the remaining vest in 12 equal quarterly installments. Pursuant to the terms of the 2005 plan, at least 75% of Dr. Rothman’s options will be vested upon a merger of the company which is a change of control or a sale of the company while Dr. Rothman is employed, unless the administrator of the plan otherwise allows for all options to become vested. On July 21, 2009, we granted Mr. Rothman options to purchase 1,750,000 shares of our common stock. Each option is exercisable at $0.10 per share (which was equal to the closing sale price of our common stock on July 21, 2009) and expires on July 21, 2019. One-third of these options vested on the grant date, and the remaining vest, in one third installments on the first and second anniversary of the grant. On October 14, 2010, we granted Dr. Rothman options to purchase 2,250,000 shares of our common stock. Each option is exercisable at $0.15 per share. These options vest over a three year period beginning one year from the grant date.

Dr. Rothman has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 18 months thereafter under certain circumstances. In addition, Dr. Rothman is subject to a non-solicitation provision for 18 months after termination of his employment.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SHAREHOLDERS' EQUITY

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

12. SHAREHOLDERS’ EQUITY

Series B Preferred Stock Financing

On April 4, 2011, the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share (the “ Series B Preferred Stock”) at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

During December 2011, the Company unreserved for issuance shares related to the Optimus warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

For the three and nine months ended July 31, 2012, the Company did not issue and sell any shares of non-convertible, redeemable Series B Preferred Stock to Optimus pursuant to the terms of a Preferred Stock Purchase.

As of July 31, 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000 per share in addition to 25,560,000 warrants remaining outstanding. These warrants may vest and become exercisable only if the Company delivers a tranche notice. During December 2011, the Company unreserved common shares related to these warrants. In addition, under the terms of each of the May, October and December 2011 Notes, the Company may issue Optimus securities only to the extent the net proceeds of such issuance are used to repay May, October and December 2011 Noteholders.

Warrants

During the nine months ending July 31, 2012, investors in the Company exercised 2,745,097 warrants at a price of $0.15 per share, resulting in total proceeds to the Company of approximately $412,000.

2011 Warrant Exchange

In addition, in an effort to reduce the number of the warrants outstanding from the October 17, 2007 private placement by the Company, the Company has entered into exchange agreements with certain of the holders of such warrants pursuant to which such holders received shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock”), and/or warrants to purchase shares of Common Stock in amounts that were determined in such negotiations.

For the three months ended January 31, 2012, the Company exchanged October 2007 warrants to purchase 4,791,337 shares of Common Stock for new warrants to purchase 6,388,449 shares of Common Stock. The new warrants issued pursuant to the exchanges are identical to the October 2007 warrants, except that such warrants do not contain any economic anti-dilution adjustment. The Company recorded noncash expense of approximately $25,000 to the changes in fair value account resulting from this exchange for the three months ended January 31, 2012. Subsequently, in the three months ended April 30, 2012, the Company exchanged these new warrants, in the amount of 6,388,449 for shares of our common stock in the amount of 1,597,112. The Company recorded noncash income of approximately $54,000 due to the changes in fair value at the date of exchange and a noncash expense of approximately $89,000 resulting from this exchange of warrants for shares of our common stock during the six month period ended April 30, 2012.

As of July 31, 2012, the Company had approximately 47 million warrants subject to anti-dilution provisions. Therefore, any future financial offering or instrument issuance below $0.15 per share of the Company’s common stock or warrants will cause further anti-dilution and/or repricing provisions in these 47 million warrants.

July 2012 Warrant Exchange

On June 8, 2012, Thomas A. Moore, our Chief Executive Officer, waived our obligation to keep reserved from our authorized and available shares of common stock, such number of shares of our common stock necessary to effect the exercise or conversion, as applicable, in full, of (i) warrants to purchase an aggregate of 11,064,611 shares of our common stock and (ii) promissory notes convertible into 800,000 shares of our common stock. This waiver expired on August 16, 2012, the date that we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock.

On July 5, 2012, in consideration for the waiver described above, we entered into an exchange agreement with Mr. Moore, with an effective date of June 8, 2012, pursuant to which Mr. Moore surrendered warrants to purchase an aggregate of approximately 11,064,611 shares of our common stock to us in exchange for receiving warrants to purchase an aggregate of approximately 11,064,611 shares of our common stock that were not exercisable and for which no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. Mr. Moore also agreed pursuant to the exchange agreement not to convert the promissory notes convertible into 800,000 shares of our common stock until the Company filed on amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to its authorized shares of common stock. In addition, the warrants to be issued in the exchange have an extended expiration date of two years following issuance.

In July 2012, we entered into exchange agreements with certain additional holders of an additional 23,726,545 warrants to purchase shares of our common stock. Similar to Mr. Moore, these holders have surrendered warrants to purchase an aggregate of approximately 23,726,545 shares of our common stock to us in exchange for receiving warrants to purchase the same aggregate amount of our common stock .These warrant shares were not exercisable and no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. In addition, warrants to be issued in the exchange have an extended expiration date of two years following issuance.

The Company recorded noncash income of approximately $408,000 as a result of these exchanges.

The Company has included the above exchanged warrants, aggregating to 34,791,156, in its total warrants of 114,738,770 as of July 31, 2012 . These new warrants are expected to be issued during 2012.

As of July 31, 2012, there were outstanding warrants to purchase 79,947,614 shares of our common stock and exchange warrants - nonexercisable to purchase 34,791,156 shares of our common stock with exercise prices ranging from $0.15 to $0.17 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant (2)	$	0.15		50,660,663	October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2014	May 2011Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15-$0.17		24,712,208	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.15		3,735,430	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
Exchange warrants – nonexercisable				34,791,156		July 2012 Warrant Exchanges
Common Stock Purchase Warrant		TBD (1)		25,560,000	April 2014	Optimus Preferred Stock Agreement (04/04/2011)
		Grand Total		114,738,770

(1)

At July 31, 2012, the Company had approximately 15.1 million of its total 114.7 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the stockholders equity section of the balance sheet. Our equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

11. SHAREHOLDERS’ EQUITY :

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances.

Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 40,500,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $0.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding.

On April 4, 2011,the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share (the “ Series B Preferred Stock”) at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

In order to satisfy certain conditions set forth in the Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “ Additional Warrant”) to purchase up to an additional 25,560,000 shares of the Company’s common stock, at an initial exercise price of $0.15 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “ Warrant Shares”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Purchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “ Promissory Note”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled.

On April 4, 2011, the Company and the Holder also entered into an Amended and Restated Security Agreement to ensure that any Promissory Note issued upon exercise of the Additional Warrant will be entitled to the benefits of the security and collateral provisions of the Security Agreement dated as of July 19, 2010.

From November 1, 2010, through October 31, 2011 the Company issued and sold 177 shares of non-convertible, redeemable Series B Preferred Stock to Optimus pursuant to the terms of a Preferred Stock Purchase. Prior to closing on the Preferred Stock purchase, the company received $300,000 from Optimus in exchange for promissory notes (subsequently repaid at closing). The Company received gross proceeds of $1.47 million (net proceeds of $1.34 million) from this transaction.

In connection with these transactions, Optimus exercised 15,752,903 warrants at exercise prices ranging from $.15 to $.155. In addition, on April 4, 2011, under an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010, the Company issued Optimus a three-year warrant to purchase 25,560,000 shares of the Company’s common stock at an initial exercise price of $0.15. As of October 31, 2011, 25,560,000 warrants remained outstanding.

As of October 31, 2011, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000. Under the terms of the May 2011 Notes, the Company may issue Optimus securities only to the extent the net proceeds of such issuance are used to repay May 2011 Noteholders.

Warrants

Some of our warrants (except the warrants issued to an affiliate of Optimus) contain “full-ratchet” anti-dilution provisions originally set at $0.20 with a term of five years. The Optimus transaction on January 11, 2010 triggered the anti-dilution provisions of the warrant agreements requiring a reset of both the price of these warrants (from $.20 to $.17) and an increase in amount of warrants. Subsequently, the Optimus transaction on September 28, 2010 triggered the anti-dilution provisions of the warrant agreements requiring a reset of both the price of these warrants (from $0.17 to $0.15) and an increase in the amount of warrants. Therefore, any future financial offering or instrument issuance below $0.15 per share of the Company’s common stock or warrants will cause further anti-dilution and/or repricing provisions in approximately 49.4 million of our outstanding warrants.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

· Level 1 — Quoted prices in active markets for identical assets or liabilities

· Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

· Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2012:

July 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from October 2012 through November 2015	$	-	$	$	1,265,985	$	1,265,985
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013	$	-	$	$	2,136	$	2,136
May 2012 Notes				$	472,840	$	472,870

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the three and nine months ended July 31, 2012 and July 31, 2011.

Embedded derivative liability

	July 31, 2012			July 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046		$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568			200,569
Note Conversions and Payoffs		(670,755	)		-
Change in fair value		159,657			(51,972	)
Balance at January 31, 2012 and 2011		741,496			229,625
Issuance of embedded derivatives associated with convertible notes		-			697,736
Note Conversions		(165,693	)		-
Note Payoffs		-			(5,904	)
Change in fair value		(438,054	)		918,870
Balance at April 30, 2012 and 2011	$	137,749		$	1,840,327
Issuance of embedded derivatives associated with convertible notes					2,719,345
Debt for Equity Exchanges: May, October and December 2011 Notes		(115,046	)
Note Conversions and Payoffs		-			(739,787	)
Reclassification of JMJ Note					(516,571	)
Change in fair value		(20,567	)		(2,216,715	)
Balance at July 31, 2012 and 2011		2,136			1,086,599

Common stock warrant liability:

	July 31, 2012			July 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071		$	13,006,194
Issuance of common stock warrants		-			600,407
Exercises and Exchanges of warrants		59,572			(1,295,884	)
Change in fair value		(923,052	)		(3,789,889	)
Balance at January 31, 2012 and 2011	$	5,527,591		$	8,520,828

Issuance of common stock warrants		-			3,111,758
Exercises of warrants		-			(639,960	)
Exchanges of warrants		(134,796	)		-
Change in fair value		(2,302,707	)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088		$	15,908,302
Issuance of common stock warrants		291,400			36,376
Reclassification of liabilities to equity		-			613,003
Debt for Equity Exchange: Bridge Notes		(4,750	)		-
July Warrant Exchanges		(407,501	)		-
Exercises and/or Exchanges of warrants		-			(1,714,266	)
Change in fair value		(1,703,252	)		(6,906,747	)
Balance at July 31, 2012 and 2011		1,265,985			7,936,668

May 2012 Notes	July 31, 2012

Issuance of notes		687,000

Issuance of C/S warrants		(291,400	)

Changes in fair value		77,270

	$	472,870

In fair valuing the embedded derivative liability, at July 31, 2012 and July 31, 2011, the Company used the following inputs:

in its BSM Model:

	7/31/2012	7/31/2011


Exercise Price:	0.15	0.15

Stock Price	0.073	0.1485

Expected term:	92-162 days	92-286 days

Volatility %	79.53%-86%	54.73%-78.46%

Risk Free Rate:	.11%-.15%	.10-.18%

In fair valuing the warrant liability, at July 31, 2012 and July 31, 2011, the Company used the following inputs:

in its BSM Model:

	7/31/2012	7/31/2011


Exercise Price:	0.15	0.15

Stock Price	0.073	0.1485

Expected term:	15-1752 days	185-1825 days

Volatility %	65.59%-91.95%	65.68%-174.18%

Risk Free Rate:	.07%-.27%	.10-.18%

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). As of July 31, 2012, the Company utilized different exercise prices of $0.15 and $0.10, weighting the possibility of warrants being exercised at $0.15 between 50% and 70% and warrants being exercised at $0.10 between 50% and 30%.

In fair valuing the embedded conversion feature related to the May 2012 Notes, at July 31, 2012, the Company used the following inputs in its BSM Model:

Exercise Price:	0.15

Stock Price	0.073

Expected term:	291 days

Volatility %	71.25	%

Risk Free Rate:	0.15	%

12. Fair Value

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction betweenmarket participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

· Level 1 — Quoted prices in active markets for identical assets or liabilities

· Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

In accordance with FASB ASC 820, “Fair Value Measurements and Disclosures”, the following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of October 31, 2011:

	Level 3 — 2011
Fair Value of Embedded Derivative	$	946,046
Common Stock Warrants	$	6,391,071
Total	$	7,337,117

. Accordingly, the derivatives were valued using the Black-Scholes model as described in Note 6

In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial instruments that are required to be measured at fair value as of October 31, 2011 and October 31, 2010:

October 31, 2011	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $.15 - $0.1952 from February 2011 through November 2015	$	-	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012	$	-	$	$	946,046	$	946,046

October 31, 2010	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $.15 - $0.287 from February 2011 through August 2015	$		$	-	$	13,006,194	$	13,006,194
C Embedded derivative liability, convertible at $0.15 from October 2010 through May 2011	$	-	$	-	$	81,028	$	81,028

As of October 31, 2011, the fair values of the Company's Level 3 financial instruments were $7,337,117. As of October 31, 2010, the fair values of these financial instruments, classified as Level 3 financial instruments, were $13,087,222. These financial instruments consist of common stock warrants and embedded derivatives.

As of October 31, 2011 and October 31, 2010, the Company held no Level 2 or Level 1 financial instruments.

As of October 31, 2011, the fair value of the Company's Level 3 financial instruments totaled $7,491,422. The Level 3 financial instruments consist of common stock warrants issued by the Company between October 2005 and May 2011, which include features requiring liability treatment of the warrants. The fair value of warrants issued to purchase 91,415,804 shares of the Company’s common stock was estimated by the Company using the Black-Scholes model (BSM Model). The Company computes valuations, each quarter, using the BSM model for each warrant to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrant at the reporting date.

There were no transfers of assets or liabilities between level 1, level 2 and level 3 during the twelve months ended October 31, 2011 or 2010.

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the twelve months ended October 31, 2011: The following table summarizes the changes in fair value of the Company’s Level 3 financial instruments for the twelve months ended October 31, 2010.

Embedded derivative liability

	October 31, 2011			October 31, 2010
Beginning balance at October 31, 2010 and 2009	$	81,028		$	1,086,514
Issuance of embedded derivatives associated with convertible notes		3,505,605			522,530
Note Conversions and Payoffs		(683,977	)		(825,682	)
Reclassification of embedded derivative liability to equity		(190,449	)		-
Change in fair value		(1,766,161	)		(702,334)
Ending balance	$	946,046		$	81,028

Common stock warrant liability:

	October 31, 2011			October 31, 2010
Beginning balance at October 31, 2010 and 2009	$	13,006,194		$	11,961,734
Issuance of common stock warrants		5,065,326			8,579,900
Exercises and Exchanges of warrants		(3,826,409	)		(7,792,198	)
Reclassification of common stock warrant liability to equity		101,867			-
Change in fair value		(7,955,907	)		256,758
Ending balance	$	6,391,071		$	13,006,194

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUBSEQUENT EVENTS

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Subsequent Events [Abstract]

Subsequent Events [Text Block]

14. SUBSEQUENT EVENTS

Accredited Investor Note

On August 2, 2012, we issued a one year convertible promissory note to an accredited investor in the principal amount of $66,667 . for a purchase price of $50,000. The Note was issued with an original issue discount of 25%. The investor paid $0.75 for each $1.00 of principal amount of the Note purchased. The Note is convertible into shares of our common stock, at a per share conversion price equal to $0.15, with a reset provision on December 1, 2012. We may redeem or exchange the Note under certain circumstances.

August 2012 Note- JMJ Financial

On August 27, 2012, we issued a convertible promissory note in the aggregate principal amount of $100,000 to JMJ Financial, for an aggregate purchase price of $100,000. There are no periodic payments of interest on the August 2012 Note. The August 2012 Note is initially convertible at a per share conversion price equal to $0.15. In addition, if the August 2012 Note is converted after November 30, 2012 and the market price of our common stock is less than $0.16 per share on the date of conversion, then the conversion price shall equal 95% of the average of the three lowest closing prices in the 15 trading days prior to the date of the conversion. The August 2012 Note matures on August 29, 2013. To the extent JMJ Financial does not elect to convert the August 2012 Note as described above, the principal amount of the August 2012 Note not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The August 2012 Note may be converted by JMJ Financial, at its option, in whole or in part. The August 2012 Note includes a limitation on conversion, which provides that at no time will JMJ Financial be entitled to convert any portion of the August 2012 Note, to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

Pursuant to the terms of the August 2012 Note, we agreed to register up to 3,250,000 shares of our common stock which may be issuable upon conversion of the August 2012 Note with the Securities and Exchange Commission.. These shares were registered on August 31, 2012.

JMJ August 2012 Settlement Agreement

On August 27, 2012, we entered into a settlement agreement with JMJ Financial pursuant to which we issued to JMJ Financial 4,076,923 shares of our common stock for the mutual release of any claims held by our company or JMJ Financial relating to our failure to file the registration statement related to the May 2012 issuance of 4,000,000 shares of our common stock to JMJ Financial and have the registration statement declared effective by certain prescribed deadlines. A registration statement filed with the Securities and Exchange Commission on August 31, 2012 included the above mentioned shares.

Additional Convertible Promissory Notes

During September, 2012 we issued two convertible promissory notes in the principal amounts of $100,000 and $132,500 to two accredited investors The notes bear interest at the rate of 8 and 12% respectively and there are re are no periodic payments of interest on the notes. The notes are convertible at a per share conversion price equal to between 69% and 65% respectively of the market price of our shares in a formula prescribed in the notes.. The notes mature in 9.and 8 months respectively .

Amendment to Certificate of Incorporation

On August 16, 2012, we filed a certificate of amendment to our amended and restated certificate of incorporation with the Delaware Secretary of State to increase the total number of authorized shares of capital stock available for issuance from 505,000,000, consisting of 500,000,000 shares of our common stock and 5,000,000 shares of “blank check” preferred stock, to 1,005,000,000, consisting of 1,000,000,000 shares of our common stock and 5,000,000 shares of “blank check” preferred stock. The certificate of amendment became effective upon filing.

13. SUBSEQUENT EVENTS

December 2011 Note Financing

On December 29, 2011, we entered into a Note Purchase Agreement, which we refer to as the December 2011 purchase agreement, with certain accredited investors, whereby the investors acquired approximately $1.2 million of our convertible promissory notes, which we refer to as the Notes, for an aggregate purchase price of approximately $1.0 million in a private placement, which we refer to as the December 2011 offering. The Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the December 2011 offering. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $0.15 per share.

The Notes mature on January 9, 2013. We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before January 9, 2015. The Warrants may be exercised on a cashless basis under certain circumstances.

To the extent an investor does not elect to convert its Notes as described above, the principal amount of the Notes not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided in the Notes, only 85% of the initial principal amount of each Note is convertible prior to maturity. The Notes and Warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the Notes or exercise any of the Warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

In connection with the December 2011 offering, we intend to enter into a Registration Rights Agreement with the investors. Pursuant to such agreement, we agree with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and agree to file a registration statement within 45 days of the closing of the December 2011 offering to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants.

Rodman & Renshaw, LLC, which we refer to as Rodman, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM) acted as the exclusive placement agent in connection with the December 2011 offering and received compensation of a cash placement fee equal to 7% of the aggregate purchase price paid by investors in the December 2011 offering (approximately $73,000) and Warrants to purchase 575,098 shares of our common stock (approximately 7% of the shares of our common stock issuable upon conversion of the Notes), which warrants are exercisable at $0.15 per share and shall expire on January 9, 2015.

Junior Subordinated Convertible Promissory Notes

During November and December 2011, the Company converted approximately $169,000 in principal into 1,126,667 shares of the Company’s common stock at an conversion price of $0.15, in full satisfaction of these junior subordinated convertible promissory notes.

In addition, the Company paid approximately $53,000 in principal on an outstanding junior subordinated convertible promissory note. In exchange for extending the remaining principal on this note, of approximately $300,000, for an additional nine months, the Company agreed to issue this investor approximately 2.3 million additional warrants at an exercise price of $0.15 as well as pay additional interest in the amount of approximately $53,000.

May 2011 Notes

During November and December 2011, the Company converted approximately $1.7m in principal into 11,313,727 shares of the Company’s common stock at an conversion price of $0.15.

October 2011 Notes

During December 2011 and January 2012, the Company converted $1.28 million in principal into 8,183,333 shares of the Company’s common stock at an conversion price of $0.15.

University of Pennsylvania

On December 12, 2011, we entered into a third amendment to the Penn license agreement pursuant to which we acquired an exclusive worldwide license agreement for additional patent applications from the laboratory of Dr. Yvonne Paterson. One application pertains to the antigen ISG15 from Penn for use in our Lm -LLO based immunotherapies for the treatment of cancer and other diseases. This intellectual property resulted from work performed in the laboratory of Dr. Yvonne Paterson that demonstrated ISG15 was an effective immunological target for the treatment of a number of different cancers in animal models, including ovarian, colon, breast and other cancers. SG-15 expression is elevated in “triple negative” breast cancer, a disease in which HER2, estrogen and progesterone receptors are lacking, and thus has no defined therapeutic immune target at the moment. An Lm-LLO vaccine that targets ISG-15 may prove to be an effective agent in an area where there is a significant unmet medical need. As part of this amendment, we exercised our option for the rights to two additional patent dockets at an option exercise fee payable in the form of $20,000 in cash.

PRIOR PERIOD ADJUSTMENT

9 Months Ended

Jul. 31, 2012

Prior Period Adjustment [Abstract]

Prior Period Adjustment [Text Block]

15. Prior Period Adjustment

The Company has restated its July 31, 2012 Balance Sheet and Statement of Operations for the nine months ended July 31, 2012 for the correction of an error made in the first and second fiscal quarters of 2012. These non-cash errors relate to the interpretation and application of accounting standards in calculating its loss on conversions of convertible notes with bifurcated embedded derivative liabilities. The correction of these errors amounting to approximately an additional $819,000 Loss on note retirement, no material effect on Net Loss per share, and no effect on Shareholders’ Deficiency. The Company plans to restate its Form 10-Q for periods ended January 31, 2012 and April 30, 2012.

SHARE-BASED COMPENSATION EXPENSE

12 Months Ended

Oct. 31, 2011

Share-Based Compensation [Abstract]

Share Based Compensation [Text Block]

2. SHARE-BASED COMPENSATION EXPENSE

The Company adopted ASC 718 and uses the modified prospective transition method, which requires the application of the accounting standard as of November 1, 2005, the first day of the Company’s fiscal year 2006. In accordance with the modified prospective transition method, the Company’s Financial Statements for prior periods were not restated to reflect, and do not include the impact of ASC 718. The Company began recognizing expense in an amount equal to the fair value of share-based payments (stock option awards) on their date of grant, over the requisite service period of the awards (usually the vesting period). Under the modified prospective method, compensation expense for the Company is recognized for all share based payments granted and vested on or after November 1, 2005 and all awards granted to employees prior to November 1, 2005 that were unvested on that date but vested in the period over the requisite service periods in the Company’s Statement of Operations. Prior to the adoption of the fair value method, the Company accounted for stock-based compensation to employees under the intrinsic value method of accounting set forth in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees , and related interpretations. Therefore, compensation expense related to employee stock options was not reflected in operating expenses in any period prior to the fiscal year of 2006 and prior period results have not been restated. Since the date of inception to October 31, 2005 had the Company adopted the fair value based method of accounting for stock-based employee compensation under the provisions of ASC 718, Stock Compensation expense would have totaled $328,176 and the effect on the Company’s net loss would have been as follows for the period March 1, 2002 (date of inception) to October 31, 2011:

	March 1, 2002 (date of inception) to October 31, 2011
Net Loss as reported	$	(35,487,856	)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176	)
Adjusted Net Loss	$	(35,726,815	)

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2011 and 2010 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s Common Stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options’ expected lives. The company used their own historical volatility in determining the volatility to be used. Expected lives are based on contractual terms given the early stage of the business and lack of intrinsic value. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

	Year Ended			Year Ended
	October 31, 2011			October 31, 2010
Expected volatility		150.44	%		156.5	%
Expected Life	10.0 years			10.0 years
Dividend yield		0			0
Risk-free interest rate		3.50	%		2.75	%

Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that vested during the period. Stock-based compensation expense for the twelve months ended October 31, 2011 includes compensation expense for share-based payment awards granted prior to, but not yet vested as of October 31, 2005 based on the grant date fair value and compensation expense for the share-based payment awards granted subsequent to October 31, 2005 based on the grant date fair value estimated in accordance with the provisions of ASC 718. Compensation expense for all share-based payment awards to be recognized using the straight line method over the requisite service period. As stock-based compensation expense for the fiscal years 2011 and 2010 is based on awards granted and vested, it has been reduced for estimated forfeitures (4.4%). ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In the Company’s pro forma information required under SFAS 123 for the periods prior to fiscal 2006, the Company accounted for forfeitures as they occurred.

The Company accounts for nonemployee stock-based awards in which goods or services are the consideration received for the equity instruments issued based on the fair value of the equity instruments.

NOTES PAYABLE

12 Months Ended

Oct. 31, 2011

Notes Payable [Abstract]

Notes Payable [Text Block]

5. NOTES PAYABLE:

Moore Notes

On September 22, 2008, Advaxis entered into an agreement (the “Moore Agreement”) with the Company’s Chief Executive Officer, Thomas Moore, pursuant to which the Company agreed to sell senior promissory notes to Mr. Moore, from time to time (“the Moore Notes”). On June 15, 2009, Mr. Moore and the Company amended the Moore Notes to increase the amounts available pursuant to the Moore Agreement from $800,000 to $950,000 and change the maturity date of the Moore Notes from June 15, 2009 to the earlier of January 1, 2010 or the Company’s next equity financing resulting in gross proceeds to the Company of at least $6 million.

On February 15, 2010, we agreed to amend the terms of the Moore Notes such that (i) Mr. Moore may elect, at his option, to receive accumulated interest thereon on or after March 17, 2010, (ii) we would begin to make monthly installment payments of $100,000 on the outstanding principal amount beginning on April 15, 2010; provided, however, that the balance of the principal will be repaid in full on consummation of our next equity financing resulting in gross proceeds to us of at least $6.0 million and (iii) we would retain $200,000 of the repayment amount for investment in our next equity financing.

On March 17, 2011, in connection with a loan made by our Chief Executive Officer, Thomas A. Moore, to us in the amount of $230,000, we agreed to further amend and restate the terms of the amended and restated senior promissory note held by Mr. Moore (the “Moore Notes”) . Under the terms of the amended and restated Moore Notes: (i) the maturity date is the earlier of (x) the date of consummation of an equity financing by us in an amount of $6.0 million or more and (y) the occurrence of any event of default as defined in the Moore Notes, (ii) Mr. Moore may elect, at his option, to receive accumulated interest thereon on or after April 15, 2011, (iii) we will make monthly installment payments of $100,000 on the outstanding principal amount beginning on June 15, 2011, and (iv) we may retain, at the option of Mr. Moore, $200,000 of the repayment amount for investment in our next equity financing.

In addition, Mr. Moore acquired a Note in the October 2011 Offering in exchange for the cancellation of $400,000 of outstanding indebtedness owed by the Company under the Moore Notes. As an investor in the October 2011 Offering, Mr. Moore received 1,568,627 warrants at an exercise price of $0.15. These warrants expire in October 2014.

For the twelve months ending October 31, 2011, the Company paid Mr. Moore $200,000 in principal and approximately $5,500 in interest on the Moore Notes. As of October 31, 2011 and October 31, 2010, respectively, the Company was not in default under the terms of the Moore Agreement. As of October 31, 2011, the Company owed Mr. Moore approximately $273,000 in principal and approximately $135,000 in accrued interest under the Moore Notes. As of October 31, 2010, the Company owed Mr. Moore approximately $573,000 in principal and approximately $57,000 in accrued interest under the Moore Notes.

Senior Convertible Promissory Notes

Effective June 18, 2009, the Company entered into a Note Purchase Agreement with certain accredited investors, pursuant to which such investors acquired senior convertible promissory notes of the Company. At July 31, 2011, the Company had one outstanding senior convertible promissory note with $88,824 in principal value and $26,471 in accrued interest remaining. On August 19, 2011, the Company issued 768,633 shares of common stock to this investor in full satisfaction of this senior convertible promissory note. As of October 31, 2011, the Company had no remaining senior convertible promissory notes outstanding.

Junior Subordinated Convertible Promissory Notes

At October 31, 2010, the Company had approximately $688,000 in outstanding principal related to its Junior Subordinated Convertible Promissory Notes. During the twelve months ended October 31, 2011, the Company entered into Junior Subordinated Convertible Promissory Notes in the aggregate principal value of $1,886,851 for aggregate net purchase prices of $1,670,000. These notes had maturity dates ranging from December 31, 2010 to October 31, 2012.

During the twelve month period ended October 31, 2011, the Company reached agreement with ten investors, whose notes were to mature on dates ranging from December 31, 2010 to April 30, 2011, in the aggregate principal value of approximately $479,000 (included in the above aggregate principal value of $1,886,851) to exchange their original notes for new notes due on dates ranging from March 31, 2011 to August 2, 2011. In return for exchanging their notes, these investors received additional interest of $25,208 plus approximately 816,000 additional warrants, valued using the BSM model, at approximately $87,000.

During the twelve month period ended October 31, 2011,the Company reached agreement with three investors, whose notes were to mature on dates ranging between August 1 and October 31, 2011,in the aggregate principal value of approximately$318,000 (included in the above aggregate principal value of $1,886,851) to make partial repayments on their notes totaling $99,000 and exchanged the remaining principal on the original notes for new notes (with the same amount of principal) due on dates ranging from March 31, 2012 to May 31, 2012. These three investors also received approximately 730,000 additional warrants, valued using the BSM model, totaling approximately $80,000.

The Company accounted for two of these three note exchanges as substantial debt modifications under ASC 470-50: Debt Modifications and Extinguishments. Therefore, the Company recorded the present values of the principal on the new notes along with the fair value of the additional warrants issued and wrote off the remaining principal on the old notes. The Company then recorded a loss on exchange of approximately $22,000 (other income/(expense)) for the difference between (1) the sum of the remaining principal on the old notes and (2) the sum of the present values of the principal on the new notes and the fair value of the additional warrants. For the third investor, the Company recorded approximately $27,000 to equity (included in the above fair value of $80,000), representing the fair value of the additional warrants issued upon exchange of their note.

During the twelve month period ended October 31, 2011, the Company repaid approximately $530,000 in principal and interest. In addition, the Company converted approximately $1.3 million of principal and interest on these outstanding junior subordinated convertible promissory notes into 8,652,737 shares of the Company’s common stock at a conversion price of $0.15 per share.

As of October 31, 2011, the Company had approximately $756,000(in principal to be repaid to investors) in outstanding junior subordinated convertible promissory notes with Original Issue Discount (“OID”) amounts ranging from 10% to 15% and with maturity dates ranging from October 19, 2011 to May 12, 2012.

We refer to all Senior Convertible Promissory Notes and Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at an exercise price contingent on the completion of an equity financing. For every dollar invested in our Bridge Notes, each Investor received warrants to purchase between 1½ and 2 ½ shares of common stock (the “Bridge Warrants”) subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of Warrant. As of October 31, 2011, substantially all of the Bridge Warrants have an exercise price of $.15 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the Maturity Date. The warrants may be exercised on a cashless basis under certain circumstances.

May 2011 Note Financing

On May 9, 2011, we entered into a Note Purchase Agreement with certain accredited investors, whereby the Company issued to investors acquired approximately $7.1 million of our convertible promissory notes, which we refer to as the May 2011 Notes, for an aggregate purchase price of approximately $6.0 million in a private placement. The May 2011 Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of May 2011 Notes purchased at the closing on May 12, 2011. The May 2011 Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2011 Note at an exercise price of $0.15 per share.

The May 2011 Notes mature on May 12, 2012. We may redeem the May 2011 Notes, at the option of the Company only, under certain circumstances. The warrants are exercisable at any time on or before May 12, 2014. The warrants may be exercised on a cashless basis under certain circumstances. To the extent an investor does not elect to convert its May 2011 Notes as described above, the principal amount not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The May 2011Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided, only 85% of the initial principal amount of each May 2011 Note is convertible prior to maturity. The May 2011 Notes and warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the May 2011 Notes or exercise any of the warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

During the twelve months ended October 31, 2011, the Company converted approximately $1,897,000 in principal into 12,647,077 shares of the Company’s common stock at a conversion price of $0.15. At October 31, 2011, the Company had approximately $5.18 million in principal outstanding on the May 2011 Notes.

October 2011 Note Financing

On October 28, 2011, we entered into a Note Purchase Agreement, which we refer to as the October 2011 Notes, with certain accredited investors, including Thomas A. Moore, our Chairman and Chief Executive Officer, and Mark J. Rosenblum, our Chief Financial Officer, (Mr. Rosenblum acquired a note in the principal amount of approximately $59,000 for an aggregate purchase price of $50,000) whereby the investors acquired approximately $2.3 million of our convertible promissory notes, which we refer to as the Notes, for an aggregate purchase price of approximately $2.0 million in a private placement, which we refer to as the October 2011 offering. The Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the October 2011 offering, which took place on October 31, 2011. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $0.15 per share. The Notes purchased in the October 2011 offering were paid for in cash or, with respect to Notes acquired by Mr. Moore, in exchange for the cancellation of $400,000 of outstanding indebtedness owed by us to Mr. Moore.

The Notes mature on October 31, 2012. We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before October 31, 2014. The Warrants may be exercised on a cashless basis under certain circumstances.

In connection with the October 2011 offering, we entered into a Registration Rights Agreement, dated as of October 28, 2011 with the investors. Pursuant to such agreement, we agreed with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and filed a registration statement to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants which became effective on November 23, 2011.

Rodman & Renshaw, LLC, which we refer to as Rodman, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM) acted as the exclusive placement agent in connection with the October 2011 offering and received compensation of a cash placement fee equal to 7% of the aggregate purchase price paid by investors in the October 2011 offering (approximately $110,000) and Warrants to purchase 866,078 shares of our common stock (approximately 7% of the shares of our common stock issuable upon conversion of the Notes, except for the Notes issued to Mr. Moore), which warrants are exercisable at $0.15 per share and shall expire on October 31, 2014.

As of October 31, 2011, all the October 2011 Notes remained outstanding.

We refer to all convertible promissory notes with a maturity date less than one year (the Bridge Notes, May 2011 Notes and October 2011 Notes) collectively as “Short-term Convertible Promissory Notes”

Short-term Convertible Promissory Notes – Principal Value - Issued	$	16,039,350
Principal payments on Bridge Notes		(2,071,910	)
Short-term Convertible Promissory Note Conversions		(5,704,169	)
Bridge Note Exchanges		(26,357)
Original Issue Discount, net of accreted interest		(1,300,347	)
Fair Value of Attached Warrants at issuance		(5,234,373	)
Fair Value of Embedded Derivatives at issuance		(5,727,932	)
Accreted interest on embedded derivative and warrant liabilities		8,170,990

Convertible Notes- as of October 31, 2011	$	4,145,252
Embedded Derivatives Liability at October 31, 2011		946,046
Short-Term Convertible Promissory Notes and fair value of embedded derivative	$	5,091,298

BioAdvance Note

BioAdvance Biotechnology Greenhouse of Southeastern Pennsylvania Notes (“BioAdvance”) received notes from the Company for $10,000 dated November 13, 2003 and $40,000 dated December 17, 2003 that were each due on the fifth anniversary date thereof. At October 31, 2010, the Company owed approximately $40,000 in principal and approximately $12,000 in interest to BioAdvance. During the year ended October 31, 2011, the Company accrued additional interest of approximately $1,600, for total accrued interest of approximately $13,630. In May 2011, the Company repaid BioAdvance $50,000 in full satisfaction of the outstanding note.

Long-term Convertible Promissory Notes

On April 28, 2011, Advaxis, Inc. issued and sold to an accredited investor a convertible promissory note of the Company (“Long-term Convertible Promissory Notes”) in the aggregate principal amount of $500,000 (together with the related ancillary documents, the “ A-Note ”) in return for the payment in cash from the Investor of $500,000. The A-Note bears interest in the form of a one time interest charge of 8% of the principal amount of the A-Note, payable with the A-Note’s aggregate principal amount outstanding on the maturity date, April 28, 2014. The A-Note is convertible, in whole or in part, into shares of the Company’s common stock, $0.001 par value. at a per share conversion price equal to 80% of the average of the two lowest trade prices for the Common Stock in the 20 trading days previous to the effective date of each such conversion, subject to a conversion floor of $0.15. The A-Note may be prepaid by the Company without penalty beginning twelve months after issue date of the A-Note. To the extent the Investor does not elect to convert the A-Note as described above, the principal amount of the A-Note not so converted shall be payable in cash on the maturity date.

On April 28, 2011, the Company also issued and sold to the same accredited investor a convertible promissory note of the Company (“Long-term Convertible Promissory Notes”) in the aggregate principal amount of $800,000 (together with the related ancillary documents, the “ B-Note ” and together with the A-Note, the “ Company Notes ”). The B-Note bears interest in the form of a one time interest charge of 8% of the principal amount of the B-Note, payable with the B-Note’s aggregate principal amount outstanding on the maturity date, April 28, 2014. All or any portion of the aggregate principal and interest outstanding under the B-Note is convertible, at the option of the Investor from time to time (subject to the prior pre-payment of the such principal amount of the C-Note (as defined below) equal to the such principal amount of the B-Note subject to such conversion), into shares of Common Stock, at a per share conversion price equal to 80% of the average of the two lowest trade prices for the Common Stock in the 20 trading days previous to the effective date of each such conversion, subject to a conversion floor of $0.15.

Concurrently with the issuance of the B-Note, the Investor issued and delivered to the Company a secured and collateralized promissory note (together with the related ancillary documents, the “ C-Note ”), which served as the sole consideration paid to the Company for the Company’s issuance of the B-Note to the Investor. The C-Note was issued in the aggregate principal amount of $800,000, bears interest in the form of a one time interest charge of 8% of the principal amount of the C-Note, payable with the C-Note’s aggregate principal amount outstanding on the maturity date, April 28, 2014. The C-Note is to be secured by $800,000 of an unspecified money market fund, or other assets, having a value of at least $800,000.

Immediately after the purchase by the Investor of the B-Note for the C-Note, the Investor delivered to the Company the sum of $80,000 in cash as a pre payment on the principal amount outstanding under the C-Note. In September 2011, the investor delivered another $80,000 under this note. While no further mandatory principal or interest payments are due on the C-Note until its maturity date, the C-Note contemplates (but does not require) further voluntary pre payments by the Investor on the C-Note to the Company at the approximate rate of $250,000 per month, beginning seven months after the issuance of the C-Note, or commencing on or about November 28, 2011, but only provided: (i) all requests by the Investor for conversion of principal and interest on the B-Note are honored and (ii) the Common Stock issued upon such conversions of portions of the principal and interest on the B-Note may be freely resold by the Investor without the requirement of any restrictive legend pursuant to applicable securities laws, rules and regulations.

Additionally, the Investor may purchase up to an additional $2.3 million in aggregate principal amount of notes in the form of the B-Note from the Company (each, an “ Additional B-Note s”). The purchase price for each such Additional B-Note issued to the Investor will be paid by the issuance by the Investor to the Company of an additional note in the form of the C-Note (each, an “ Additional C-Note ”), with such Additional B-Notes and Additional C-Notes containing the same terms and provisions described above.

We refer to all convertible promissory notes, with a maturity date greater than one year collectively as “Long-term Convertible Promissory Notes”

As of October 31, 2011, the Company owed $712,800 in outstanding principal under the Long-term Convertible Promissory Notes. Due to the conversion feature into a variable number of shares these notes are valued at fair value at each report period. As of October 31, 2011, the fair value of the notes was $570,802.

STOCK OPTIONS

12 Months Ended

Oct. 31, 2011

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

7. STOCK OPTIONS:

2004 Stock Option Plan

In November 2004, our board of directors adopted and our stockholders approved the 2004 Stock Option Plan, which we refer to as the 2004 plan. The 2004 plan provides for the grant of options to purchase up to 2,381,525 shares of our common stock to employees, officers, directors and consultants. Options may be either “incentive stock options” or non-qualified options under the Federal tax laws. Incentive stock options may be granted only to our employees, while non-qualified options may be issued, in addition to employees, to non-employee directors and consultants. As of October 31, 2011, all options to purchase shares of our common stock have been granted under the 2004 plan.

The 2004 plan is administered by “disinterested members” of our board of directors or the compensation committee, who determine, among other things, the individuals who will receive options, the time period during which the options may be partially or fully exercised, the number of shares of common stock issuable upon the exercise of each option and the option exercise price.

Subject to a number of exceptions, the exercise price per share of common stock subject to an incentive option may not be less than the fair market value per share of common stock on the date the option is granted. The per share exercise price of our common stock subject to a non-qualified option may be established by our board of directors, but will not, however, be less than 85% of the fair market value per share of common stock on the date the option is granted. The aggregate fair market value of common stock for which any person may be granted incentive stock options which first become exercisable in any calendar year may not exceed $100,000 on the date of grant.

No stock option may be transferred by an optionee other than by will or the laws of descent and distribution, and, during the lifetime of an optionee, the option will be exercisable only by the optionee. In the event of termination of employment or engagement other than by death or disability, the optionee will have no more than three months after such termination during which the optionee will be entitled to exercise the option to the extent vested at termination, unless otherwise determined by our board of directors. Upon termination of employment or engagement of an optionee by reason of death or permanent and total disability, the optionee’s options remain exercisable for one year to the extent the options were exercisable on the date of such termination. No similar limitation applies to non-qualified options.

We must grant options under the 2004 plan within ten years from the effective date of the 2004 plan. The effective date of the 2004 plan was November 12, 2004. Subject to a number of exceptions, holders of incentive stock options granted under the 2004 plan cannot exercise these options more than ten years from the date of grant. Options granted under the 2004 plan generally provide for the payment of the exercise price in cash and may provide for the payment of the exercise price by delivery to us of shares of common stock already owned by the optionee having a fair market value equal to the exercise price of the options being exercised, or by a combination of these methods. Therefore, if it is provided in an optionee’s options, the optionee may be able to tender shares of common stock to purchase additional shares of common stock and may theoretically exercise all of his stock options with no additional investment other than the purchase of his original shares.

Any unexercised options that expire or that terminate upon an employee’s ceasing to be employed by us become available again for issuance under the 2004 plan.

As of September 27, 2011, the date on which the Advaxis, Inc. 2011 Omnibus Incentive Plan was approved by our shareholders, no further awards may be made under the 2004 plan.

2005 Stock Option Plan

In June 2006 our board of directors adopted, and on June 6, 2006 our stockholders approved, the 2005 Stock Option Plan, which we refer to as the 2005 plan.

The 2005 plan provides for the grant of options to purchase up to 5,600,000 shares of our common stock to employees, officers, directors and consultants. Options may be either “incentive stock options” or non-qualified options under the Federal tax laws. Incentive stock options may be granted only to our employees, while non-qualified options may be issued to non-employee directors, consultants and others, as well as to our employees. As of October 31, 2011, all options to purchase shares of our common stock have been granted under the 2005 plan.

The 2005 plan is administered by “disinterested members” of our board of directors or the compensation committee, who determine, among other things, the individuals who will receive options, the time period during which the options may be partially or fully exercised, the number of shares of common stock issuable upon the exercise of each option and the option exercise price.

Except when agreed to by our board of directors or the administrator of the 2005 plan, no stock option may be transferred by an optionee other than by will or the laws of descent and distribution, and, during the lifetime of an optionee, the option will be exercisable only by the optionee. In the event of termination of employment or engagement other than by death or disability, the optionee will have no more than three months after such termination during which the optionee will be entitled to exercise the option, unless otherwise determined by our board of directors. Upon termination of employment or engagement of an optionee by reason of death or permanent and total disability, the optionee’s options remain exercisable for one year to the extent the options were exercisable on the date of such termination. No similar limitation applies to non-qualified options.

We must grant options under the 2005 plan within ten years from the effective date of the 2005 plan. The effective date of the 2005 plan was January 1, 2005. Subject to a number of exceptions, holders of incentive stock options granted under the 2005 plan cannot exercise these options more than ten years from the date of grant. Options granted under the 2005 plan generally provide for the payment of the exercise price in cash and may provide for the payment of the exercise price by delivery to us of shares of common stock already owned by the optionee having a fair market value equal to the exercise price of the options being exercised, or by a combination of these methods. Therefore, if it is provided in an optionee’s options, the optionee may be able to tender shares of common stock to purchase additional shares of common stock and may theoretically exercise all of his stock options with no additional investment other than the purchase of his original shares.

Any unexercised options that expire or that terminate upon an employee’s ceasing to be employed by us become available again for issuance under the 2005 plan.

As of September 27, 2011, the date on which the Advaxis, Inc. 2011 Omnibus Incentive Plan was approved by our shareholders, no further awards may be made under the 2005 plan.

2009 Stock Option Plan

Our board of directors adopted the 2009 Stock Option Plan effective July 21, 2009, and recommended that it be submitted to our shareholders for their approval at the next annual meeting. On April 23, 2010, our board of directors approved and adopted, and on June 1, 2010 our stockholders approved, the amended and restated 2009 Stock Option Plan, which we refer to as the 2009 plan. An aggregate of 20,000,000 shares of our common stock (subject to adjustment by the compensation committee) are reserved for issuance upon the exercise of options granted under the 2009 plan. As of October 31, 2011, options to purchase 358,101 shares of our common stock are available for grant under the 2009 plan. However, due to the approval of the Advaxis, Inc. 2011 Omnibus Incentive Plan by our shareholders, on September 27, 2011, no further awards may be made under the 2009 plan (see Note #7 for details on the Advaxis Inc. 2011 Omnibus Incentive Plan).

The 2009 plan is to be administered by the compensation committee of our board of directors; provided, however, that except as otherwise expressly provided in the 2009 plan, our board of directors may exercise any power or authority granted to the compensation committee under the 2009 plan. Subject to the terms of the 2009 plan, the compensation committee is authorized to select eligible persons to receive options, determine the type, number and other terms and conditions of, and all other matters relating to, options, prescribe option agreements (which need not be identical for each participant), and the rules and regulations for the administration of the 2009 plan, construe and interpret the 2009 plan and option agreements, correct defects, supply omissions or reconcile inconsistencies therein, and make all other decisions and determinations as the compensation committee may deem necessary or advisable for the administration of the 2009 plan.

The maximum number of shares of common stock to which options may be granted to any one individual under the 2009 plan is 6,000,000 (subject to adjustment by the compensation committee). The shares acquired upon exercise of options granted under the 2009 plan will be authorized and issued shares of our common stock. Our shareholders will not have any preemptive rights to purchase or subscribe for any common stock by reason of the reservation and issuance of common stock under the 2009 plan. If any option granted under the 2009 plan should expire or terminate for any reason other than having been exercised in full, the unpurchased shares subject to that option will again be available for purposes of the 2009 plan.

The persons eligible to receive awards under the 2009 plan are the officers, directors, employees, consultants and other persons who provide services to us or any related entity. An employee on leave of absence may be considered as still in our or a related entity’s employ for purposes of eligibility for participation in the 2009 plan. All options granted under the 2009 plan must be evidenced by a written agreement. The agreement will contain such terms and conditions as the compensation committee shall prescribe, consistent with the 2009 plan, including, without limitation, the exercise price, term and any restrictions on the exercisability of the options granted. For any option granted under the 2009 plan, the exercise price per share of common stock may be any price determined by the compensation committee; however, the exercise price per share of any incentive stock option may not be less than the fair market value of the common stock on the date such incentive stock option is granted.

The compensation committee may permit the exercise price of an option to be paid for in cash, by certified or official bank check or personal check, by money order, with already owned shares of common stock that have been held by the optionee for at least six (6) months (or such other shares as we determine will not cause us to recognize for financial accounting purposes a charge for compensation expense), the withholding of shares of common stock issuable upon exercise of the option, by delivery of a properly executed exercise notice together with such documentation as shall be required by the compensation committee (or, if applicable, the broker) to effect a cashless exercise, or a combination of the above. If paid in whole or in part with shares of already owned common stock, the value of the shares surrendered is deemed to be their fair market value on the date the option is exercised.

No incentive stock option, and unless the prior written consent of our compensation committee is obtained (which consent may be withheld for any reason) and the transaction does not violate the requirements of Rule 16b-3 of the Exchange Act, no non-qualified stock option granted under the 2009 plan is assignable or transferable, other than by will or by the laws of descent and distribution. During the lifetime of an optionee, an option is exercisable only by him or her, or in the case of a non-qualified stock option, by his or her permitted assignee.

The expiration date of an option under the 2009 plan will be determined by our compensation committee at the time of grant, but in no event may such an option be exercisable after 10 years from the date of grant. An option may be exercised at any time or from time to time or only after a period of time in installments, as determined by our compensation committee. Our compensation committee may in its sole discretion accelerate the date on which any option may be exercised. Each outstanding option granted under the 2009 plan may become immediately fully exercisable in the event of certain transactions, including certain changes in control of us, certain mergers and reorganizations, and certain dispositions of substantially all our assets.

Unless otherwise provided in the option agreement, the unexercised portion of any option granted under the 2009 plan shall automatically be terminated (a) three months after the date on which the optionee’s employment is terminated for any reason other than (i) cause (as defined in the 2009 plan), (ii) mental or physical disability, or (iii) death; (b) immediately upon the termination of the optionee’s employment for cause; (c) one year after the date on which the optionee’s employment is terminated by reason of mental or physical disability; or (d) one year after the date on which the optionee’s employment is terminated by reason of optionee’s death, or if later, three months after the date of optionee’s death if death occurs during the one year period following the termination of the optionee’s employment by reason of mental or physical disability.

Unless earlier terminated by our board, the 2009 plan will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the 2009 plan, (b) termination of the 2009 plan by our board, or (c) the tenth anniversary of the effective date of the 2009 plan. Options outstanding upon expiration of the 2009 plan shall remain in effect until they have been exercised or terminated, or have expired.

As of September 27, 2011, the date on which the Advaxis, Inc. 2011 Omnibus Incentive Plan was approved by our shareholders, no further awards may be made under the 2009 plan.

2011 Omnibus Incentive Plan

Our board of directors adopted the 2011 Omnibus Incentive Plan on August 22, 2011, and recommended that it be submitted to our shareholders for their approval at the next annual meeting. On September 27, 2011, our stockholders approved the 2011 Omnibus Incentive Plan, which we refer to as the 2011 plan. An aggregate of 20,000,000 shares of our common stock (subject to adjustment by the compensation committee) are reserved and available for delivery under the 2011 plan. As of October 31, 2011, no grants had been made under the 2011 Omnibus Incentive Plan.

Upon receiving stockholder approval of the 2011 plan on September 27, 2011, no further awards were permitted to be made under the 2004 plan, the 2005 plan or the 2011 plan.

During any 12-month period, no participant in the 2011 plan may be granted (i) stock options or stock appreciation rights with respect to more than 4,000,000 shares of our common stock, or (ii) shares of restricted stock, restricted stock units, performance shares and other stock based-awards with respect to more than 4,000,000 shares of our common stock. The maximum amount that may be paid out as performance units with respect to any 12-month performance period is $2,500,000 (pro-rated for any 12-month performance period that is less than 12 months), and with respect to any performance period that is more than 12 months, $2,000,000 multiplied by the number of full 12 month periods that are in the performance period.

The Committee, as defined below, is authorized to adjust the limitations described above and is authorized to adjust outstanding awards (including adjustments to exercise prices of options and other affected terms of awards) in the event that a dividend or other distribution, recapitalization, forward or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange or other similar corporate transaction or event affects our common stock so that an adjustment is appropriate. The Committee is also authorized to adjust performance conditions and other terms of awards in response to these kinds of events or in response to changes in applicable laws, regulations or accounting principles.

The persons eligible to receive awards under the 2011 plan are the officers, directors, employees, consultants and other persons who provide services to us on a full-time basis. The foregoing notwithstanding, only our full-time employees, or any of our parent corporations or subsidiary corporations, shall be eligible for purposes of receiving any incentive stock options.

The 2011 plan is to be administered by a committee designated by our board of directors consisting of not less than two directors (the “Committee”), provided, however, that except as otherwise expressly provided in the 2011 plan, our board of directors may exercise any power or authority granted to the Committee under the 2011 plan. Subject to the terms of the 2011 plan, the Committee is authorized to select eligible persons to receive awards, determine the type, number and other terms and conditions of, and all other matters relating to, awards, prescribe award agreements, and the rules and regulations for the administration of the 2011 plan, construe and interpret the 2011 plan and award agreements, correct defects, supply omissions or reconcile inconsistencies therein, and make all other decisions and determinations as the Committee may deem necessary or advisable for the administration of the 2011 plan.

The Committee is authorized to grant stock options, including both incentive stock options and non-qualified stock options, and stock appreciation rights entitling the participant to receive the amount by which the fair market value of a share of our common stock on the date of exercise exceeds the grant price of the stock appreciation right. The maximum term of each option or stock appreciation right, the times at which each option or stock appreciation right will be exercisable, and provisions requiring forfeiture of unexercised options or stock appreciation rights at or following termination of employment generally are fixed by the Committee, except that no option or stock appreciation right may have a term exceeding ten years. Methods of exercise and settlement and other terms of the options and stock appreciation right are determined by the Committee. The Committee, thus, may permit the exercise price of options awarded under the 2011 plan to be paid in cash, shares, other awards or other property (including loans to participants).

The Committee is authorized to grant restricted stock and restricted stock units. Restricted stock is a grant of shares of our common stock which may not be sold or disposed of, and which shall be subject to such risks of forfeiture and other restrictions as the Committee may impose. An award of restricted stock units confers upon a participant the right to receive shares of our common stock or cash equal to the fair market value of the specified number of shares of our common stock covered by the restricted stock units at the end of a specified deferral period, subject to such risks of forfeiture and other restrictions as the Committee may impose. Prior to settlement, an award of restricted stock units carries no voting or dividend rights or other rights associated with share ownership, although dividend equivalents may be granted, as discussed below.

The Committee is authorized to grant dividend equivalents conferring on participants the right to receive, currently or on a deferred basis, cash, shares of our common stock, other awards or other property equal in value to dividends paid on a specific number of shares of our common stock or other periodic payments. Dividend equivalents may be granted alone or in connection with another award, may be paid currently or on a deferred basis and, if deferred, may be deemed to have been reinvested in additional shares of our common stock, awards or otherwise as specified by the Committee.

The Committee is authorized to grant shares of our common stock as a bonus free of restrictions, or to grant shares of our common stock or other awards in lieu of our obligations to pay cash under the 2011 plan or other plans or compensatory arrangements, subject to such terms as the Committee may specify.

The Committee or our board of directors is authorized to grant awards that are denominated or payable in, valued by reference to, or otherwise based on or related to shares of our common stock. The Committee determines the terms and conditions of such awards.

The Committee is authorized to grant performance awards to participants on terms and conditions established by the Committee. The performance criteria to be achieved during any performance period and the length of the performance period are determined by the Committee upon the grant of the performance award. Performance awards may be settled by delivery of cash, shares or other property, or any combination thereof, as determined by the Committee. The Committee may, in its discretion, determine that the amount payable as a performance award will be reduced from the amount of any potential award.

Awards may be settled in the form of cash, shares of our common stock, other awards or other property, in the discretion of the Committee. The Committee may require or permit participants to defer the settlement of all or part of an award in accordance with such terms and conditions as the Committee may establish, including payment or crediting of interest or dividend equivalents on deferred amounts, and the crediting of earnings, gains and losses based on deemed investment of deferred amounts in specified investment vehicles. The Committee may condition any payment relating to an award on the withholding of taxes and may provide that a portion of any shares of our common stock or other property to be distributed will be withheld (or previously acquired shares of our common stock or other property be surrendered by the participant) to satisfy withholding and other tax obligations.

The Committee may, in its discretion, accelerate the exercisability, the lapsing of restrictions or the expiration of deferral or vesting periods of any award, and such accelerated exercisability, lapse, expiration and if so provided in the award agreement or otherwise determined by the Committee, vesting shall occur automatically in the case of a “change in control” of the Company, as defined in the 2011 plan (including the cash settlement of stock appreciation rights which may be exercisable in the event of a change in control).

Our board of directors may amend, alter, suspend, discontinue or terminate the 2011 plan or the Committee’s authority to grant awards without further stockholder approval, except that stockholder approval must be obtained for any amendment or alteration if such approval is required by law or regulation or under the rules of any stock exchange or quotation system on which shares of our common stock are then listed or quoted. Thus, stockholder approval may not necessarily be required for every amendment to the 2011 plan which might increase the cost of the 2011 plan or alter the eligibility of persons to receive awards. Stockholder approval will not be deemed to be required under laws or regulations, such as those relating to incentive stock options, that condition favorable treatment of participants on such approval, although our board of directors may, in its discretion, seek stockholder approval in any circumstance in which it deems such approval advisable. Unless earlier terminated by our board of directors, the 2011 plan will terminate at the earliest of (a) such time as no shares of our common stock remain available for issuance under the 2011 plan, (b) termination of the 2011 plan by our board of directors, or (c) the tenth anniversary of the effective date of the 2011 plan. Awards outstanding upon expiration of the 2011 plan shall remain in effect until they have been exercised or terminated, or have expired.

A summary of the grants, cancellations and expirations (none were exercised) of the Company’s outstanding options for the periods starting with October 31, 2009 through October 31, 2011 is as follows:

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2009	18,331,591			0.16		6.0	$	306,500
Granted	11,075,000			0.16		9.8		42,500
Exercised	(306,000	)		0.09		8.1		(16,860	)
Cancelled or Expired	(2,633,167	)		0.12		8.6		(104,912	)
Outstanding as of October 31, 2010	26,467,424			0.16		7.4		415,967
Granted	850,000			0.12		9.2		15,200
Cancelled or Expired	-			-		-		-
Outstanding as of October 31, 2011	27,317,424			0.16		8.1		367,417

Vested & Exercisable at October 31, 2011	20,451,266		$	0.16		6.75	$	337,082

The fair value of options granted for the year ended October 31, 2011 amounted to $103,125

As of October 31, 2011, there was approximately $759,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 2.3 years.

A summary of the status of the Company’s nonvested shares as of October 31, 2009, and changes during the years ended October 31, 2010 and 2011 are presented below:	Number of Shares		Weighted Average Exercise Price at Grant Date		Weighted Average Remaining Contractual Term (in years)
Non-vested shares at October 31, 2009	6,720,417		$	0.10	8.7
Options Granted	10,108,333		$	0.14	2.8
Options Vested	(4,518,333	)	$	0.10	1.0
Non-vested shares at October 31, 2010	12,310,417		$	0.13	2.3
Options Granted	850,000		$	0.12	9.5
Options Vested	(6,294,259)			0.13	8.45
Non-Vested shares at October 31, 2011	6,866,158			.15	9.0

INCOME TAXES

12 Months Ended

Oct. 31, 2011

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

9. INCOME TAXES:

The Company has a net operating loss carry forward of approximately $32,485,000 and $20,095,000 at October 31, 2011 and 2010, respectively, available to offset taxable income through 2030. Due to change in control provisions, the Company’s utilization of these losses may be limited. The tax effects of loss carry forwards give rise to a deferred tax asset and a related valuation allowance at October 31, as follows:

		2011			2010
Net operating loss carryforwards-federal	$	12,994,244		$	8,038,146
Stock based compensation		1,474,016			1,202,168
Valuation on warrants		(3,241,085	)		-
Others		(613,170	)		-
Less valuation allowance		(10,614,005	)		(9,240,314	)
	$	-		$	-

The difference between income taxes computed at the statutory federal rate of 34% and the provision for income taxes relates to the following:

	Year ended October 31, 2011			Year ended October 31, 2010


Pre-Tax Book Income (Loss)		34.00	%		34.00	%
Perm Item		-19.61	%		-
Change in Valuation Allowance		-16.93	%		(34	)
Other		2.54	%		-
Total		-	%		-	%

In a letter dated November 13, 2008 from the New Jersey Economic Development Authority we were notified that our application for the New Jersey Technology Tax Certificate Transfer Program was preliminarily approved. Under the State of New Jersey NOL Transfer Program for small business we received a net cash amount of $922,020 on December 12, 2008 from the sale of our State Net Operating Losses (“NOL”) through December 31, 2007 of $1,084,729. In January 2010, the company received a net cash amount of $278,978 from the sale of some of our State Net Operating Losses (“NOL”) through December 31, 2008. In February 2011, the Company received a net cash amount of $379,742 from the sale of our State Net Operating Losses (“NOL”) through the year ending October 31, 2009. We have received notification from the State of New Jersey that the Company is eligible to sell approximately $408,000 in Net Operating Losses related to our 2010 fiscal year.

We adopted ASC 740, Income Taxes, formerly Financial Interpretation Number 48, “Accounting for Uncertain Tax Positions” (“FIN 48”) on November 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with FASB Statement No. 109,” Accounting for Income Taxes.” ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. We did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were no adjustments for uncertain tax positions in the current year.

We will account for interest and penalties related to uncertain tax positions, if any, as part of our provision for federal and state income taxes.

We do not expect that the amounts of unrecognized benefits will change significantly within the next 12 months.

We are no longer subject to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions through 2006.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

CAPITALIZATION

12 Months Ended

Oct. 31, 2011

Capitalization, Long-Term Debt and Equity [Abstract]

Schedule of Capitalization [Table Text Block]

9. INCOME TAXES:

		2011			2010
Net operating loss carryforwards-federal	$	12,994,244		$	8,038,146
Stock based compensation		1,474,016			1,202,168
Valuation on warrants		(3,241,085	)		-
Others		(613,170	)		-
Less valuation allowance		(10,614,005	)		(9,240,314	)
	$	-		$	-

The difference between income taxes computed at the statutory federal rate of 34% and the provision for income taxes relates to the following:

	Year ended October 31, 2011			Year ended October 31, 2010


Pre-Tax Book Income (Loss)		34.00	%		34.00	%
Perm Item		-19.61	%		-
Change in Valuation Allowance		-16.93	%		(34	)
Other		2.54	%		-
Total		-	%		-	%

We will account for interest and penalties related to uncertain tax positions, if any, as part of our provision for federal and state income taxes.

We do not expect that the amounts of unrecognized benefits will change significantly within the next 12 months.

We are no longer subject to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions through 2006.

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Polices)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Accounting Policies [Abstract]

Comparability of Prior Year Financial Data, Policy [Policy Text Block]

Prior Period Restatements

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (money market) that at times exceed federally insured limits.

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Intangible assets, which consist primarily of legal and filing costs in obtaining patents and licenses and are being amortized on a straight-line basis over 20 years.

We review our long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, we would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued we would record an impairment of its estimated book value.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Accounting for Stock-Based Compensation

Stock-based compensation is estimated at the grant date based on the award’s fair value as calculated by the Black-Scholes-Merton option-pricing model (hereinafter referred to as the “BSM model”) and is recognized as expense over the requisite service period. The BSM model requires various assumptions including volatility, forfeiture rates and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense may differ materially in the future from that recorded in the current period. See Note #2 for information on stock-based compensation expense incurred (in addition to the various assumptions utilized in the BSM Model) in the years ending October 31, 2011 and 2010.

Derivatives, Embedded Derivatives [Policy Text Block]

Warrants/Embedded Derivatives

Warrant Liability/Embedded Derivative Liability

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Basis of Presentation and Significant Accounting Policies [Text Block]

Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Results of operations for the interim periods presented are not necessarily indicative of results to be expected for the year.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Fixed Assets [Policy Text Block]

Fixed Assets

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

	As of October 31,
	2011		2010
Warrants		137,841,857		103,139,628
Stock Options		27,317,424		26,467,424
Convertible Debt (using the if-converted method)		61,660,382		4,358,176
Total		226,819,663		133,965,228

Income Tax, Policy [Policy Text Block]

Income Taxes

Accounts Payable [Policy Text Block]

Accounts Payable

Accounts payable consists entirely of trade accounts payable

NET LOSS PER SHARE (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

	As of July 31 ,
	2012		2011
Warrants (includes Optimus warrant of 25,560,000 at July 31, 2012 and 2011 and exchange warrants(see Note 12) of 34,791,156 at July 31, 2012)		114,738,770		96,994
Stock Options		44,807,424		27,317,424
Convertible Debt (using as-if converted method)		11,594,873		-
Total		171,141,067		27,414,418

	As of October 31,
	2011		2010
Warrants		137,841,857		103,139,628
Stock Options		27,317,424		26,467,424
Convertible Debt (using the if-converted method)		61,660,382		4,358,176
Total		226,819,663		133,965,228

INTANGIBLE ASSETS (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The following is a summary of intangible assets as of the end of the following fiscal periods:

	(Unaudited)
	July 31, 2012			October 31, 2011
License	$	651,992		$	651,992
Patents		2,376,445			2,117,505
Total intangibles		3,028,437			2,769,497
Accumulated Amortization		(622,503	)		(512,645	)
Intangible Assets	$	2,405,934		$	2,256,852

The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31, 2011			October 31, 2010
License	$	651,992		$	651,992
Patents		2,117,505			1,854,355
Total intangibles		2,769,497			2,506,347
Accumulated Amortization		(512,645	)		(380,356	)
Intangible Assets	$	2,256,852		$	2,125,991

Schedule of Expected Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2012	$	140,000
2013		140,000
2014		140,000
2015		140,000
2016		140,000

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

The following table represents the major components of accounts payable and accrued expenses:

	(Unaudited)
	July 31, 2012		October 31, 2011
Accounts Payable	$	4,947,357	$	4,778,508
Salaries and other compensation		696,645		531,040
Clinical Trial		56,468		-
Vendors		77,512		-
Consultants		32,200		32,200
Financing Costs		140,492		-
Legal		81,231		46,346
Other		21,768		8,500
	$	6,053,853	$	5,396,594

The following table represents the major components of accrued expenses:

	October 31, 2011		October 31, 2010
Salaries and other compensation	$	531,041	$	500,927
Sponsored Research Agreement		-		119,698
Clinical Research Organization (CRO)		2,358,247		-
Consultants		32,200		18,000
Legal		46,346
Other		8,500		8,500
	$	2,976,334	$	647,125

NOTES PAYABLE - CONVERTIBLE PROMISSORY NOTES (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Debt Disclosure [Abstract]

Schedule of Short-term Debt [Table Text Block]

We refer to all convertible promissory notes with a maturity date less than one year collectively as “Short-term Convertible Promissory Notes.”

Short-term Convertible Promissory Notes – Principal Value – Issued	$	18,225,036
Principal payments on Bridge Notes		(2,124,851	)
Short-term Convertible Promissory Note Conversions		(9,890,228	)
May, October and December 2011 Debt for Equity Exchanges		(4,114,176	)
Bridge Note Exchanges		4,712
Original Issue Discount, net of accreted interest		(26,525	)
Fair Value of Attached Warrants at issuance		(5,805,580	)
Fair Value of Embedded Derivatives at issuance		(6,034,500	)
Accreted interest on embedded derivative and warrant liabilities		11,097,689
Adjustments to fair value – May 2012 Notes		(248,142	)

Convertible Notes- as of July 31, 2012	$	1,083,435
Embedded Derivatives Liability at July 31, 2012		2,136
Notes Payable – convertible promissory notes and fair value of embedded derivative	$	1,085,571

Short-term Convertible Promissory Notes – Principal Value - Issued	$	16,039,350
Principal payments on Bridge Notes		(2,071,910	)
Short-term Convertible Promissory Note Conversions		(5,704,169	)
Bridge Note Exchanges		(26,357)
Original Issue Discount, net of accreted interest		(1,300,347	)
Fair Value of Attached Warrants at issuance		(5,234,373	)
Fair Value of Embedded Derivatives at issuance		(5,727,932	)
Accreted interest on embedded derivative and warrant liabilities		8,170,990

Convertible Notes- as of October 31, 2011	$	4,145,252
Embedded Derivatives Liability at October 31, 2011		946,046
Short-Term Convertible Promissory Notes and fair value of embedded derivative	$	5,091,298

DERIVATIVE INSTRUMENTS (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments [Table Text Block]

The table below lists the Company’s derivative instruments as of July 31, 2012:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Total Valuation at October 31, 2011	$	8,976,071		$	1,300,347		$	6,391,071		$	946,046
Issuance of December 2011 Notes		1,232,353			258,178			-			306,568
Conversion of Bridge Notes		(169,000	)								-
Conversion of May 2011 Notes		(1,924,060	)								(341,342	)
Conversion of October 2011 Notes		(1,227,500	)								(329,433	)
Partial Note Repayments		(52,941	)
Conversion of Long-term Convertible Promissory Notes		(540,000	)
Exchange of Warrants								59,572
Accreted Interest					(532,559	)
Change in FV								(923,052	)		159,657
Total Valuation at January 31, 2012	$	6,294,923		$	1,025,966		$	5,527,591		$	741,496
Exchange of Bridge Notes		52,941						-
Conversion of May 2011 Notes		(38,000	)								(5,016	)
Conversion of December 2011 Notes		(827,500	)								(160,677	)
Exchange of Warrants								(134,796	)
Accreted Interest					(569,419	)
Change in FV								(2,302,707	)		(438,054	)
Total Valuation at April 30, 2012	$	5,482,364		$	456,547		$	3,090,088		$	137,749

Issuance of May 2012 Notes		953,333						291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673	)		(200,632	)					(115,046	)
Debt for Equity Exchange: Bridge Notes		(50,000	)					(4,750	)
July 2012Exchange of Warrants								(407,501	)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800	)
Accreted Interest					(229,392	)
Change in FV								(1,703,252	)		(20,567	)
Total Valuation at July 31, 2012	$	1,739,224			26,523			1,265,985			2,136

The table below lists the Company’s derivative instruments as of October 31, 2011:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Bridge Note 1-June 18, 2009	$	1,131,353		$	169,703		$	250,392		$	711,258
Bridge Note II & III-October 26 & 30, 2009		2,147,059			322,059			690,119			868,388
Optimus September 24, 2009		-			-			3,587,625			-
Other outstanding warrants		-			-			12,785,695			-
Total Valuation at Origination		3,278,412			491,762			17,313,831			1,579,646
Change in fair value		-			-			(5,352,697	)		(493,132	)
Accreted interest		-			(123,846	)		-			-
Total Valuation as of October 31, 2009	$	3,278,412		$	367,916		$	11,961,734		$	1,086,514
Bridge Notes IV-December 1, 2009 through January 31. 2010		555,882			83,382			207,617			164,400
Bridge Note I- Extension of Maturity Date		-			-			202,500			103,400
Change in fair value		-			-			1,995,372			(905,259	)
Accreted interest		-			(225,321	)		-			-
Exercise of Common Stock Warrants		-			-			(1,702,073	)		-
Total Valuation as of January 31, 2010	$	3,834,294		$	225,977		$	12,665,150		$	449,055
Bridge Note V		640,307			97,807			229,619			271,554
Change in fair value		-			-			5,363,854			421,404
Accreted interest		-			(251,188	)		-			-
Exercise of common stock warrants		-			-			(1,790,823	)		-
Note Payoffs		(1,040,177	)		(4,222	)		-			(64,354	)
Total Valuation as of April 30, 2010		3,434,424			68,374			16,467,800			1,077,659
Issuance of Optimus Warrants		-			-			6,856,946			-
Bridge Note Conversions		(2,420,373	)		-			-			(701,718	)
Change in fair value		-			-			(3,866,801	)		(260,843	)
Accreted interest		-			(50,842	)		-			-
Exercise of common stock warrants		-			-			(1,475,758	)		-
Note Payoffs		(88,236	)								(12,665	)
Total Valuation as of July 31, 2010	$	925,815		$	17,532		$	17,982,187		$	102,433
Bridge Note VI		265,457			25,457			72,300			39,416
Note Payoff		(414,118	)		-			-			(46,945	)
Issuance of Warrants		-			-			1,042,559			-
Accreted Interest		-			(21,052	)		-			-
Exercise of Warrants		-			-			(4,156,797	)		-
Change in FV		-			-			(1,934,055	)		(13,876	)
Total Valuation at October 31, 2010	$	777,154		$	21,937		$	13,006,194		$	81,028
Issuance of November 2010 Bridge Notes		931,579			96,579			391,076			150,156
Exchange of November 2010 Bridge Notes		17,175			17,175			86,963			9,389
Issuance of January 2011 Bridge Notes		452,941			57,941			173,808			41,024
Note Payoffs		(187,582	)
Issuance of Warrants								35,523
Accreted Interest					(73,363	)
Exercise of Warrants								(1,382,847	)
Change in FV								(3,789,889	)		(51,972	)
Total Valuation at January 31, 2011		1,991,267			120,269			8,520,828			229,625

Issuance of Q2 2011 Bridge Notes		473,392			43,392			121,238			71,336
Issuance of Long-term Convertible Promissory Notes		626,400									-
Note Payoffs		(159,675	)								(5,904	)
Issuance of Warrants								2,990,520
Accreted Interest					(74,422	)
Exercise of Warrants								(639,960	)
Change in FV								4,915,676			763,523
Total Valuation at April 30, 2011	$	2,931,384		$	89,239		$	15,908,302		$	1,058,580

Issuance of Q3 2011 Bridge Notes		11,765			1,765			4,968			5,051
Issuance of May 2011 Notes		7,077,936			1,553,254			-			2,719,345
Note Payoffs		(26,316	)								(8,860	)
Additional warrants issued to Bridge Note holder								36,376
Exchange of Bridge Notes		8,033			8,033						2,656
Conversion of Bridge Notes		(1,164,947	)								(381,209	)
Conversion of May 2011 Notes		(671,500	)								(166,980	)
Exchanges/Exercises of October 2007 Warrants								(1,186,959	)
Accreted Interest					(340,050	)
Change in FV								(6,826,019	)		(2,141,984	)
Total Valuation at July 31, 2011	$	8,166,355			1,312,241			7,936,668			1,086,599
Issuance of October 2011 Notes		2,326,471			459,396			-			396,818
Note Payoffs		(155,806	)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788)									(10,530	)
Conversion of May 2011 Notes		(1,225,561)									(110,494	)
Reclassification of Warrant liability to Equity								(186,908)
Exchange of Warrants								816,259
Accreted Interest					(471,290	)
Change in FV								(2,174,948 )			(416,347	)
Total Valuation at October 31, 2011	$	8,976,071			1,300,347			6,391,071			946,046

Schedule Of Derivative Instruments Warrants [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	0.15		47,090,487	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		287,001	August 2012	August 2007 Notes
Common Stock Purchase Warrant	$	0.15		23,593,122	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		7,754,902	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15 - $0.17		22,630,101	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		7,674,512	August 2014	Executive Officer
Common Stock Purchase Warrant	$	0.15-$0.1952		446,956	February 2012	Vendor & Other
Common Stock Purchase Warrant	$	0.15		2,804,776	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
	Subtotal			112,281,857

Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Optimus Preferred Stock Agreement (4/04/2011)
	Grand Total			137,841,857

(1) For purposes of this warrant, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41678-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

+ Details

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The table below summarizes compensation expenses from share-based payment awards:

	Three Months Ended				Nine months Ended
	July 31,				July 31,
	2012		2011		2012		2011

Research & Development	$	128,011	$	95,263	$	397,231	$	265,768
General & Administrative		161,678		104,005		480,020		353,531
Total stock compensation recognized	$	289,689	$	199,268	$	877,251	$	619,299

	March 1, 2002 (date of inception) to October 31, 2011
Net Loss as reported	$	(35,487,856	)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176	)
Adjusted Net Loss	$	(35,726,815	)

Schedule Of Share Based Compensation Activity [Table Text Block]

The Company utilized the following assumptions in the Black-Scholes valuation model to arrive at a fair value of $0.1448 per option granted during the three and nine months ended July 31, 2012:

Exercise Price:	$	0.148
Stock Price:	$	0.148
Days to Maturity:		3,650 days (10-year life for all options granted	)
Risk-free Rate:		2.10	%
Volatility:		143	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of changes in the stock option plan for nine months ended July 31, 2012 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2011:		27,317,424	$	0.16
Granted		17,740,000	$	0.15
Exercised		-		—
Expired		-
Outstanding at January 31, 2012		45,057,424	$	0.16
Cancelled		250,000		0.15
Outstanding at April 30, 2012		44,807,424		0.16
Outstanding at July 31, 2012		44,807,424		0.16
Exercisable at July 31, 2012		27,560,653	$	0.16
Not Exercisable at July 31, 2012		17,246,771	$	0.15

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Oct. 31, 2011

Stockholders' Equity Note [Abstract]

Schedule Of Derivative Instruments Warrants [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	0.15		47,090,487	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		287,001	August 2012	August 2007 Notes
Common Stock Purchase Warrant	$	0.15		23,593,122	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		7,754,902	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15 - $0.17		22,630,101	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		7,674,512	August 2014	Executive Officer
Common Stock Purchase Warrant	$	0.15-$0.1952		446,956	February 2012	Vendor & Other
Common Stock Purchase Warrant	$	0.15		2,804,776	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
	Subtotal			112,281,857

Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Optimus Preferred Stock Agreement (4/04/2011)
	Grand Total			137,841,857

(1) For purposes of this warrant, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

FAIR VALUE (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]

	Level 3 — 2011
Fair Value of Embedded Derivative	$	946,046
Common Stock Warrants	$	6,391,071
Total	$	7,337,117

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2012:

July 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from October 2012 through November 2015	$	-	$	$	1,265,985	$	1,265,985
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013	$	-	$	$	2,136	$	2,136
May 2012 Notes				$	472,840	$	472,870

October 31, 2011	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $.15 - $0.1952 from February 2011 through November 2015	$	-	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012	$	-	$	$	946,046	$	946,046

October 31, 2010	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $.15 - $0.287 from February 2011 through August 2015	$		$	-	$	13,006,194	$	13,006,194
C Embedded derivative liability, convertible at $0.15 from October 2010 through May 2011	$	-	$	-	$	81,028	$	81,028

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the three and nine months ended July 31, 2012 and July 31, 2011.

Embedded derivative liability

	July 31, 2012			July 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046		$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568			200,569
Note Conversions and Payoffs		(670,755	)		-
Change in fair value		159,657			(51,972	)
Balance at January 31, 2012 and 2011		741,496			229,625
Issuance of embedded derivatives associated with convertible notes		-			697,736
Note Conversions		(165,693	)		-
Note Payoffs		-			(5,904	)
Change in fair value		(438,054	)		918,870
Balance at April 30, 2012 and 2011	$	137,749		$	1,840,327
Issuance of embedded derivatives associated with convertible notes					2,719,345
Debt for Equity Exchanges: May, October and December 2011 Notes		(115,046	)
Note Conversions and Payoffs		-			(739,787	)
Reclassification of JMJ Note					(516,571	)
Change in fair value		(20,567	)		(2,216,715	)
Balance at July 31, 2012 and 2011		2,136			1,086,599

Common stock warrant liability:

	July 31, 2012			July 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071		$	13,006,194
Issuance of common stock warrants		-			600,407
Exercises and Exchanges of warrants		59,572			(1,295,884	)
Change in fair value		(923,052	)		(3,789,889	)
Balance at January 31, 2012 and 2011	$	5,527,591		$	8,520,828

Issuance of common stock warrants		-			3,111,758
Exercises of warrants		-			(639,960	)
Exchanges of warrants		(134,796	)		-
Change in fair value		(2,302,707	)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088		$	15,908,302
Issuance of common stock warrants		291,400			36,376
Reclassification of liabilities to equity		-			613,003
Debt for Equity Exchange: Bridge Notes		(4,750	)		-
July Warrant Exchanges		(407,501	)		-
Exercises and/or Exchanges of warrants		-			(1,714,266	)
Change in fair value		(1,703,252	)		(6,906,747	)
Balance at July 31, 2012 and 2011		1,265,985			7,936,668

May 2012 Notes	July 31, 2012

Issuance of notes		687,000

Issuance of C/S warrants		(291,400	)

Changes in fair value		77,270

	$	472,870

Embedded derivative liability

	October 31, 2011			October 31, 2010
Beginning balance at October 31, 2010 and 2009	$	81,028		$	1,086,514
Issuance of embedded derivatives associated with convertible notes		3,505,605			522,530
Note Conversions and Payoffs		(683,977	)		(825,682	)
Reclassification of embedded derivative liability to equity		(190,449	)		-
Change in fair value		(1,766,161	)		(702,334)
Ending balance	$	946,046		$	81,028

Common stock warrant liability:

	October 31, 2011			October 31, 2010
Beginning balance at October 31, 2010 and 2009	$	13,006,194		$	11,961,734
Issuance of common stock warrants		5,065,326			8,579,900
Exercises and Exchanges of warrants		(3,826,409	)		(7,792,198	)
Reclassification of common stock warrant liability to equity		101,867			-
Change in fair value		(7,955,907	)		256,758
Ending balance	$	6,391,071		$	13,006,194

Embedded Derivative Liability [Member]

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

In fair valuing the embedded derivative liability, at July 31, 2012 and July 31, 2011, the Company used the following inputs:

in its BSM Model:

	7/31/2012	7/31/2011


Exercise Price:	0.15	0.15

Stock Price	0.073	0.1485

Expected term:	92-162 days	92-286 days

Volatility %	79.53%-86%	54.73%-78.46%

Risk Free Rate:	.11%-.15%	.10-.18%

Common Stock Warrant Liability [Member]

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

In fair valuing the warrant liability, at July 31, 2012 and July 31, 2011, the Company used the following inputs:

in its BSM Model:

	7/31/2012	7/31/2011


Exercise Price:	0.15	0.15

Stock Price	0.073	0.1485

Expected term:	15-1752 days	185-1825 days

Volatility %	65.59%-91.95%	65.68%-174.18%

Risk Free Rate:	.07%-.27%	.10-.18%

May Two Thousand and Twelve Notes [Member]

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

In fair valuing the embedded conversion feature related to the May 2012 Notes, at July 31, 2012, the Company used the following inputs in its BSM Model:

Exercise Price:	0.15

Stock Price	0.073

Expected term:	291 days

Volatility %	71.25	%

Risk Free Rate:	0.15	%

- Definition

Tabular disclosure related to assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a recurring and/or nonrecurring basis in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a,b,bb)
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=7578670&loc=SL7498348-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 33
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 6
-Footnote 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

SHARE-BASED COMPENSATION EXPENSE (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2012

Oct. 31, 2011

Share-Based Compensation [Abstract]

Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table Text Block]

The table below summarizes compensation expenses from share-based payment awards:

	Three Months Ended				Nine months Ended
	July 31,				July 31,
	2012		2011		2012		2011

Research & Development	$	128,011	$	95,263	$	397,231	$	265,768
General & Administrative		161,678		104,005		480,020		353,531
Total stock compensation recognized	$	289,689	$	199,268	$	877,251	$	619,299

	March 1, 2002 (date of inception) to October 31, 2011
Net Loss as reported	$	(35,487,856	)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176	)
Adjusted Net Loss	$	(35,726,815	)

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended			Year Ended
	October 31, 2011			October 31, 2010
Expected volatility		150.44	%		156.5	%
Expected Life	10.0 years			10.0 years
Dividend yield		0			0
Risk-free interest rate		3.50	%		2.75	%

- Definition

+ References + Details

STOCK OPTIONS (Tables)

12 Months Ended

Oct. 31, 2011

Equity [Abstract]

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2009	18,331,591			0.16		6.0	$	306,500
Granted	11,075,000			0.16		9.8		42,500
Exercised	(306,000	)		0.09		8.1		(16,860	)
Cancelled or Expired	(2,633,167	)		0.12		8.6		(104,912	)
Outstanding as of October 31, 2010	26,467,424			0.16		7.4		415,967
Granted	850,000			0.12		9.2		15,200
Cancelled or Expired	-			-		-		-
Outstanding as of October 31, 2011	27,317,424			0.16		8.1		367,417

Vested & Exercisable at October 31, 2011	20,451,266		$	0.16		6.75	$	337,082

Schedule Of Nonvested Share Activity [Table Text Block]

A summary of the status of the Company’s nonvested shares as of October 31, 2009, and changes during the years ended October 31, 2010 and 2011 are presented below:	Number of Shares		Weighted Average Exercise Price at Grant Date		Weighted Average Remaining Contractual Term (in years)
Non-vested shares at October 31, 2009	6,720,417		$	0.10	8.7
Options Granted	10,108,333		$	0.14	2.8
Options Vested	(4,518,333	)	$	0.10	1.0
Non-vested shares at October 31, 2010	12,310,417		$	0.13	2.3
Options Granted	850,000		$	0.12	9.5
Options Vested	(6,294,259)			0.13	8.45
Non-Vested shares at October 31, 2011	6,866,158			.15	9.0

INCOME TAXES (Tables)

12 Months Ended

Oct. 31, 2011

Income Tax Disclosure [Abstract]

Summary of Operating Loss Carryforwards [Table Text Block]

The tax effects of loss carry forwards give rise to a deferred tax asset and a related valuation allowance at October 31, as follows:

		2011			2010
Net operating loss carryforwards-federal	$	12,994,244		$	8,038,146
Stock based compensation		1,474,016			1,202,168
Valuation on warrants		(3,241,085	)		-
Others		(613,170	)		-
Less valuation allowance		(10,614,005	)		(9,240,314	)
	$	-		$

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The difference between income taxes computed at the statutory federal rate of 34% and the provision for income taxes relates to the following:

	Year ended October 31, 2011			Year ended October 31, 2010


Pre-Tax Book Income (Loss)		34.00	%		34.00	%
Perm Item		-19.61	%		-
Change in Valuation Allowance		-16.93	%		(34	)
Other		2.54	%		-
Total		-	%		-	%

NET LOSS PER SHARE (Details) - shares	9 Months Ended		12 Months Ended
NET LOSS PER SHARE (Details) - shares	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010
Total	171,141,067	27,414,418	226,819,663	133,965,228
Warrant [Member]
Total	114,738,770	96,994	137,841,857	103,139,628
Stock Options [Member]
Total	44,807,424	27,317,424	27,317,424	26,467,424
Convertible Debt Securities [Member]
Total	11,594,873	0	61,660,382	4,358,176

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

NET LOSS PER SHARE (Details Textual) - shares	Jul. 31, 2012	Oct. 31, 2011	Jul. 31, 2011
Class of Warrant or Right, Outstanding	114,738,770	137,841,857
Optimus warrant [Member]
Class of Warrant or Right, Outstanding	25,560,000		25,560,000
Exchange Warrants [Member]
Class of Warrant or Right, Outstanding	34,791,156

INTANGIBLE ASSETS (Details) - USD ($)	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
License	$ 651,992	$ 651,992	$ 651,992
Patents	2,376,445	2,117,505	1,854,355
Total intangibles	3,028,437	2,769,497	2,506,347
Accumulated Amortization	(622,503)	(512,645)	(380,356)
Accumulated Amortization	$ 2,405,934	$ 2,256,852	$ 2,125,991

INTANGIBLE ASSETS (Details 1)	Oct. 31, 2011 USD ($)
2012	$ 140,000
2013	140,000
2014	140,000
2015	140,000
2016	$ 140,000

INTANGIBLE ASSETS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		116 Months Ended	125 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2011	Jul. 31, 2012
Amortization expense of intangibles	$ 37,435	$ 34,018	$ 109,859	$ 99,274	$ 132,288	$ 100,420	$ 594,640	$ 704,499
Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs					33,000		33,000
Capitalized Costs Related With Licenses and Patents					$ 2,769,497		$ 2,769,497
Minimum [Member]
Finite Lived Patents Expirations			2014
Maximum [Member]
Finite Lived Patents Expirations			2023

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Accounts Payable	$ 4,947,357	$ 4,778,508
Salaries and other compensation	696,645	531,040	$ 500,927
Clinical Trial	56,468	0
Vendors	77,512	0
Consultants	32,200	32,200	18,000
Financing Costs	140,492
Legal	81,231	46,346
Other	21,768	8,500	8,500
Accrued Liabilities		2,976,334	647,125
Total accounts payable & accured expenses	$ 6,053,853	5,396,594
Sponsored Research Agreement [Member]
Total accounts payable & accured expenses		0	119,698
Clinical Research Organization (Cro) [Member]
Total accounts payable & accured expenses		$ 2,358,247	$ 0

DEFERRED INVESTMENT FUNDS (Details Textual)	9 Months Ended
DEFERRED INVESTMENT FUNDS (Details Textual)	Jul. 31, 2012 USD ($)
Deferred Investment Funds	$ 240,000
Chief Executive Officer [Member]
Deferred Investment Funds	50,000
Accredited Investors [Member]
Proceeds from Sale of Equity Method Investments	290,000
Mr. Moore'S [Member]
Proceeds from Sale of Equity Method Investments	$ 50,000

NOTES PAYABLE - CONVERTIBLE PROMISSORY NOTES (Details) - USD ($)	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2010	Jul. 31, 2010	Apr. 30, 2010	Jan. 31, 2010	Oct. 31, 2009
Short-term Convertible Promissory Notes - Principal Value - Issued	$ 18,225,036			$ 16,039,350
Principal payments on Bridge Notes	(2,124,851)			(2,071,910)
Short-term Convertible Promissory Note Conversions	(9,890,228)			(5,704,169)
May, October and December 2011 Debt for Equity Exchanges	(4,114,176)
Bridge Note Exchanges	4,712			(26,357)
Original Issue Discount, net of accreted interest	(26,525)			(1,300,347)
Fair Value of Attached Warrants at issuance	(5,805,580)			(5,234,373)
Fair Value of Embedded Derivatives at issuance	2,136			946,046				$ 81,028
Accreted interest on embedded derivative and warrant liabilities	11,097,689			8,170,990
Adjustments to fair value ? May 2012 Notes	(248,142)
Convertible Notes- as of July 31, 2012	1,083,435			4,145,252
Embedded Derivative Liability	2,136	$ 137,749	$ 741,496	946,046	$ 1,086,599	$ 1,058,580	$ 229,625	81,028	$ 102,433	$ 1,077,659	$ 449,055	$ 1,086,514
Notes Payable - convertible promissory notes and fair value of embedded derivative	$ 1,085,571			$ 5,091,298				$ 751,456

NOTES PAYABLE - CONVERTIBLE PROMISSORY NOTES (Details Textual)	1 Months Ended												2 Months Ended	3 Months Ended				9 Months Ended			12 Months Ended					116 Months Ended	125 Months Ended
	Aug. 31, 2012 shares	Jul. 30, 2012 USD ($) shares	Jul. 21, 2012 USD ($)	Dec. 29, 2011 USD ($) $ / shares shares	Oct. 28, 2011 USD ($)	Aug. 31, 2011 shares	Apr. 28, 2011 USD ($) $ / shares	Oct. 31, 2007 shares	Aug. 31, 2007 USD ($)	Mar. 31, 2006 USD ($)	Feb. 28, 2006 USD ($)	Nov. 30, 2004 USD ($)	Dec. 31, 2011 USD ($) shares	Jul. 31, 2012 USD ($) $ / shares shares	Apr. 30, 2012 USD ($) shares	Jan. 31, 2012 USD ($)	Jul. 31, 2011 USD ($)	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 30, 2012 shares	Jul. 31, 2011 USD ($)	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares shares	Oct. 31, 2007 USD ($)	Oct. 31, 2006 USD ($)	Oct. 31, 2005 USD ($)	Oct. 31, 2011 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Sep. 30, 2012 USD ($) $ / shares	Aug. 27, 2012 USD ($) shares	Aug. 02, 2012 $ / shares	Jul. 08, 2012 shares	Jul. 05, 2012 shares	May 31, 2012 shares	May 14, 2012 USD ($)	May 08, 2012 USD ($)	May 31, 2011 USD ($)	May 09, 2011 USD ($) $ / shares	Sep. 28, 2010	Jul. 19, 2010	Aug. 24, 2007 shares	Nov. 12, 2004 shares
Class of Warrant or Right, Exercise Price of Warrants or Rights				0.15										0.15				0.15			0.15	0.15				0.15	0.15		0.15									0.17	0.25		0.40
Long-term Debt, Gross				$ 540,000	$ 59,000		$ 800,000							$ 300,000				$ 300,000			$ 1,886,851	$ 688,000				$ 1,886,851	$ 300,000
Other Noncash Expense																		$ 89,000
Stock Issued During Period, Shares, New Issues \| shares																		25,560,000			40,500,000
Short-term Convertible Promissory Note Conversions										$ 1,500,000	$ 1,500,000							$ 53,000			$ 1,300,000
Debt Instrument, Maturity Date				Jan. 09, 2013			Apr. 28, 2014														May 12, 2014
Debt Issuance Cost														247,000		$ 25,000		27,000
Debt Conversion, Converted Instrument, Amount												$ 618,000		$ 38,000				$ 169,000			$ 1,897,000		$ 1,000,010	$ 300,000	$ 613,158
Debt Conversion, Converted Instrument, Shares Issued \| shares	0	800,000		3,600,000		768,633								253,333				1,126,667			8,652,737
Debt Instrument, Discount Percentage				15.00%										10.00%				10.00%			10.00%					10.00%	10.00%			25.00%							15.00%
Debt Instrument, Maturity Date Range, Start																		Oct. 19, 2011
Debt Instrument, Convertible, Conversion Price \| $ / shares				$ 0.15			$ 0.15							$ 0.15				$ 0.15			$ 0.15					$ 0.15	$ 0.15	$ 65		$ 0.15							$ 0.15
Convertible Notes Payable				$ 1,200,000	2,300,000									$ 2,300,000				$ 2,300,000									$ 2,300,000										$ 7,100,000
Debt Instrument, Maturity Date Range, End																		Jun. 30, 2012
Debt Instrument Purchase Price				1,000,000	50,000		$ 500,000							$ 50,000				$ 50,000									$ 50,000										$ 6,000,000
Common stock, par value (in dollars per share) \| $ / shares							$ 0.001							$ 0.001				$ 0.001			$ 0.001	$ 0.001				$ 0.001	$ 0.001
Debt Instrument, Interest Rate, Stated Percentage							8.00%																					12.00%												12.00%
Repayments of Debt																		$ 172,800			$ 712,800
Fair Value, Option, Changes in Fair Value, Gain (Loss)														$ 9,000				85,000
Debt Instrument, Fair Value Disclosure														99,602				99,602			$ 570,802					$ 570,802	$ 99,602
Debt Instrument, Face Amount							$ 80,000							$ 587,000				$ 587,000									$ 587,000	$ 132,500	$ 100,000
Notes Issued									$ 600,000
Issuance of common stock warrants																$ 279,807
Class of Warrant or Right, Outstanding \| shares														114,738,770				114,738,770			137,841,857					137,841,857	114,738,770
Common stock, shares issued \| shares	4,000,000													375,135,008				375,135,008			250,173,570	198,100,817				250,173,570	375,135,008		4,076,923				4,000,000
Warrant Liability														$ 99,600,000				$ 99,600,000			$ 25,600,000	$ 15,800,000				$ 25,600,000	$ 99,600,000
Non Cash Income On Conversion Of Notes Payable														250,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares																															11,064,611	79,947,614								150,000	87,108
(Loss) on note retirement														$ (932,421)			$ (115,396)	(2,173,491)		$ (109,492)	$ (461,595)	$ 123,963				$ 1,194,845	$ (978,646)
Other Noncash Income		$ 408,000																$ 54,000
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Class of Warrant or Right, Outstanding \| shares														64,800,000				64,800,000									64,800,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues \| shares								49,228,334
Long Term Convertible Promissory Notes [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Long-term Debt, Gross				$ 540,000										$ 300,000				$ 300,000									$ 300,000
Stock Issued During Period, Shares, New Issues \| shares														4,725,927
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares														660,000
Short-term Convertible Promissory Note Conversions																		$ 352,941
Debt Instrument, Maturity Date																		Jun. 30, 2012
Warrants Purchased During Period \| shares																		2,352,940
Debt Issuance Cost																		$ 247,000
Debt Conversion, Converted Instrument, Shares Issued \| shares				3,600,000
Repayments of Debt																		172,800
Debt Instrument, Fair Value Disclosure														$ 99,602				99,602									$ 99,602
Notes Issued																		$ 247,000
Other Noncash Income														250,000
Long Term Convertible Promissory Notes [Member] \| A Notes Payable [Member]
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Convertible, Conversion Price \| $ / shares							$ 0.15
Long Term Convertible Promissory Notes [Member] \| B Notes Payable [Member]
Long-term Debt, Gross							$ 800,000
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Convertible, Conversion Price \| $ / shares							$ 0.15
Debt Instrument, Face Amount							$ 3,000,000
Long Term Convertible Promissory Notes [Member] \| C Notes Payable [Member]
Long-term Debt, Gross							$ 800,000
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Face Amount							$ 80,000
July Two Thousand and Twelve Note [Member]
Long-term Debt, Gross			$ 250,000
Debt Instrument, Maturity Date			Dec. 31, 2012
Debt Instrument, Interest Rate, Stated Percentage			33.00%
Jmj Financial [Member]
Other Noncash Expense															$ 805,000
Debt Conversion, Converted Instrument, Shares Issued \| shares															4,000,000
Debt Instrument, Fair Value Disclosure															$ 324,000
Unrealized Gain (Loss) on Securities														$ 75,000
Other Borrowings																																			$ 500,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15			0.15	0.15				0.15	0.15
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.17				0.17			0.1952	0.287				0.1952	0.17
Bridge Notes [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Long-term Debt, Gross														$ 300,000				$ 300,000			$ 1,886,851	$ 688,000				$ 1,886,851	$ 300,000
Stock Issued During Period, Shares, New Issues \| shares														583,000
Short-term Convertible Promissory Note Conversions																		$ 53,000			$ 1,300,000
Debt Instrument, Maturity Date																		Jun. 30, 2012
Debt Conversion, Converted Instrument, Amount																		$ 169,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																		1,126,667			8,652,737
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15				$ 0.15			$ 0.15					$ 0.15	$ 0.15
Debt Instrument, Face Amount														$ 587,000				$ 587,000									$ 587,000
Bridge Notes [Member] \| Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Debt Instrument, Maturity Date														Oct. 31, 2015				Feb. 29, 2012
Bridge Notes [Member] \| Original Issue Discount (O D I) [Member]
Debt Instrument, Maturity Date Range, Start																		Oct. 19, 2011
Debt Instrument, Maturity Date Range, End																		Jun. 30, 2012
Debt Instrument, Face Amount														$ 587,000				$ 587,000									$ 587,000
Bridge Notes [Member] \| Minimum [Member]
Warrant Coverage Percentage														23.00%				23.00%									23.00%
Debt Instrument, Discount Percentage														10.00%				10.00%			10.00%					10.00%	10.00%
Bridge Notes [Member] \| Minimum [Member] \| Original Issue Discount (O D I) [Member]
Debt Instrument, Discount Percentage														10.00%				10.00%									10.00%
Bridge Notes [Member] \| Maximum [Member]
Warrant Coverage Percentage														75.00%				75.00%									75.00%
Debt Instrument, Discount Percentage														15.00%				15.00%			15.00%					15.00%	15.00%
Bridge Notes [Member] \| Maximum [Member] \| Original Issue Discount (O D I) [Member]
Debt Instrument, Discount Percentage														15.00%				15.00%									15.00%
May 2011 Note Financing [Member]
Debt Instrument, Maturity Date																					May 12, 2014
Debt Conversion, Converted Instrument, Amount														$ 38,000							$ 1,897,000
Debt Conversion, Converted Instrument, Shares Issued \| shares														253,333							12,647,077
Debt Instrument, Discount Percentage																																					15.00%
Debt Instrument, Convertible, Conversion Price \| $ / shares																					$ 0.15					$ 0.15											$ 0.15
October 2011 Note Financing [Member]
Long-term Debt, Gross					59,000									$ 1,100,000				$ 1,100,000									$ 1,100,000
Debt Conversion, Converted Instrument, Amount																		$ 1,227,500
Debt Conversion, Converted Instrument, Shares Issued \| shares																		8,183,333
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15				$ 0.15			$ 0.15					$ 0.15	$ 0.15
Debt Instrument, Face Amount														$ 400,000				$ 400,000									$ 400,000
December 2011 Note Financing [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				0.15
Long-term Debt, Gross														$ 405,000				405,000									$ 405,000
Debt Instrument, Maturity Date				Jan. 09, 2013
Debt Conversion, Converted Instrument, Amount																		$ 827,500
Debt Conversion, Converted Instrument, Shares Issued \| shares																		5,516,666
Debt Instrument, Discount Percentage				15.00%
Debt Instrument, Convertible, Conversion Price \| $ / shares				$ 0.15										$ 0.15				$ 0.15									$ 0.15
Convertible Notes Payable				$ 1,200,000										$ 1,200,000				$ 1,200,000									$ 1,200,000
Debt Instrument Purchase Price				$ 1,000,000										1,000,000				$ 1,000,000									$ 1,000,000
Rodman 2011 Financings [Member]
Other Noncash Expense														1,500,000
Debt Conversion, Converted Instrument, Amount														$ 4,500,000
Debt Conversion, Converted Instrument, Shares Issued \| shares														52,200,000
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15				$ 0.15									$ 0.15
Warrants and Rights Outstanding														$ 52,200,000				$ 52,200,000									$ 52,200,000
Class of Warrant or Right, Outstanding \| shares														38,784,491				38,784,491									38,784,491
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares														5,800,000				5,800,000									5,800,000
Loss On Note Retirement														$ 1,500,000
Stock Repurchased During Period, Shares \| shares																			31,300,000
Rodman 2011 Financings [Member] \| Waiver Agreements [Member]
Debt Instrument, Face Amount														$ 249,000				$ 249,000									$ 249,000
Rodman 2011 Financings [Member] \| Accredited Investors [Member]
Long-term Debt, Gross													$ 59,000								$ 59,000					$ 59,000										$ 59,000
Debt Instrument, Face Amount													50,000								50,000					50,000										50,000
Rodman 2011 Financings [Member] \| Mr. Moore'S [Member]
Debt Instrument, Face Amount													400,000								$ 400,000					$ 400,000										$ 400,000
Rodman 2011 Financings [Member] \| Warrant [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15				$ 0.15									$ 0.15
Issuance of common stock warrants																		$ 38,784,491
Rodman 2011 Financings [Member] \| Private Placement [Member]
Debt Instrument Purchase Price														$ 9,000,000				9,000,000									$ 9,000,000
Notes Issued					$ 9,000,000
Rodman 2011 Financings [Member] \| Long Term Convertible Promissory Notes [Member]
Debt Instrument Purchase Price														$ 10,600,000				$ 10,600,000									$ 10,600,000
Rodman 2012 Financings [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Other Noncash Expense																		$ 69,000
Debt Instrument, Maturity Date																		May 18, 2013
Debt Conversion, Converted Instrument, Amount																		$ 4,017,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																		26,780,392
Debt Instrument, Discount Percentage														50.00%				50.00%									50.00%
Debt Instrument, Conversion Percentage														7.00%				7.00%									7.00%
Debt Instrument, Fair Value Disclosure																																		$ 291,400
Warrant Liability														$ 222,467				$ 222,467									$ 222,467
Warrant Liability Non Cash Income																		$ 69,000
Rodman 2012 Financings [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Debt Instrument, Discount Percentage														25.00%				25.00%									25.00%
Debt Instrument Purchase Price														$ 715,000				$ 715,000									$ 715,000
Rodman 2012 Financings [Member] \| May Two Thousand and Twelve Notes [Member]
Debt Instrument, Fair Value Disclosure														$ 454,680				$ 454,680									$ 454,680
Rodman 2012 Financings [Member] \| Rodman Renshaw, Llc [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights														0.15				0.15									0.15
Long-term Debt, Gross														$ 28,000				$ 28,000									$ 28,000
Warrants Purchased During Period \| shares																		355,556
Debt Instrument Purchase Price														$ 400,000				$ 400,000									$ 400,000
Convertible Notes Payable [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares														0.15				0.15									0.15
Stock Issued During Period, Shares, New Issues \| shares														583,000
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares														50,000
Debt Conversion, Converted Instrument, Amount														$ 660,000
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15				$ 0.15									$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares														20,834				20,834									20,834
(Loss) on note retirement														$ 24,000
Convertible Notes Payable [Member] \| July Two Thousand and Twelve Note [Member]
Debt Conversion, Converted Instrument, Amount													$ 500,000
Debt Conversion, Converted Instrument, Shares Issued \| shares													3,600,000
Debt Instrument, Fair Value Disclosure														820,000				$ 820,000									$ 820,000
Unrealized Gain (Loss) on Securities														17,000				186,000
Other Noncash Income													$ 36,000
Holders Not Participated In Exchange Agreement [Member]
Debt Instrument, Face Amount														$ 249,000				$ 249,000									$ 249,000

NOTES PAYABLE - OFFICER (Details Textual)	1 Months Ended				9 Months Ended		12 Months Ended		116 Months Ended	125 Months Ended
NOTES PAYABLE - OFFICER (Details Textual)	Jun. 30, 2011 USD ($)	Apr. 30, 2010 USD ($)	Feb. 28, 2010 USD ($)	Sep. 22, 2008 USD ($)	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2011 USD ($)	Oct. 31, 2011 USD ($) shares	Oct. 31, 2010 USD ($)	Oct. 31, 2011 USD ($) shares	Jul. 31, 2012 USD ($) $ / shares shares	Aug. 27, 2012	Dec. 29, 2011 USD ($)	Oct. 28, 2011 USD ($)	Apr. 28, 2011 USD ($)	Mar. 17, 2011 USD ($)	Sep. 28, 2010	Jul. 19, 2010	Feb. 15, 2010 USD ($)	Nov. 12, 2004
Notes Payable, Current				$ 6,000,000											$ 6,000,000			$ 6,000,000
Debt Instrument, Periodic Payment, Principal	$ 100,000	$ 100,000	$ 100,000	100,000
Principal payments on notes payable				$ 200,000	$ 87,941	$ 613,573	$ 769,379	$ 1,798,119	$ 2,691,089	$ 2,779,030
Long-term Debt, Gross					$ 300,000		$ 1,886,851	$ 688,000	$ 1,886,851	$ 300,000		$ 540,000	$ 59,000	$ 800,000
Class of Warrant or Right, Outstanding \| shares					114,738,770		137,841,857		137,841,857	114,738,770
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.15		0.15	0.15	0.15	0.15	0.15	0.15				0.17	0.25		0.40
Accrued Liabilities							$ 2,976,334	$ 647,125	$ 2,976,334
Debt Instrument, Increase, Accrued Interest							13,630
Moore Notes [Member]
Notes Payable, Current					$ 158,000					$ 158,000
Debt Instrument, Periodic Payment, Principal					35,000		200,000
Long-term Debt, Gross							$ 273,000		$ 273,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							0.15		0.15
Accrued Liabilities					396,000					$ 396,000
Debt Instrument, Increase, Accrued Interest					$ 150,000

DERIVATIVE INSTRUMENTS (Details) - USD ($)	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2010	Jul. 31, 2010	Apr. 30, 2010	Jan. 31, 2010	Oct. 31, 2009
Principal	$ 1,739,224	$ 5,482,364	$ 6,294,923	$ 8,976,071	$ 8,166,355	$ 2,931,384	$ 1,991,267	$ 777,154	$ 925,815	$ 3,434,424	$ 3,834,294	$ 3,278,412
Original Issue Discount	26,523	456,547	1,025,966	1,300,347	1,312,241	89,239	120,269	21,937	17,532	68,374	225,977	367,916
Warrant Liability	1,265,985	3,090,088	5,527,591	6,391,071	7,936,668	15,908,302	8,520,828	13,006,194	17,982,187	16,467,800	12,665,150	1,086,514
Embedded Derivative Liability	2,136	137,749	741,496	946,046	1,086,599	1,058,580	229,625	81,028	102,433	1,077,659	449,055	1,086,514
Bridge Note 1-June 18, 2009 [Member]
Principal												1,131,353
Original Issue Discount												169,703
Warrant Liability												250,392
Embedded Derivative Liability												711,258
Bridge Note II & III-October 26 & 30, 2009 Member]
Principal												2,147,059
Original Issue Discount												322,059
Warrant Liability												690,119
Embedded Derivative Liability												868,388
Optimus September 24, 2009 [Member]
Principal												0
Original Issue Discount												0
Warrant Liability												3,587,625
Embedded Derivative Liability												0
Other outstanding warrants [Member]
Principal												0
Original Issue Discount												0
Warrant Liability												12,785,695
Embedded Derivative Liability												0
Total Valuation at Origination [Member]
Principal												3,278,412
Original Issue Discount												491,762
Warrant Liability												17,313,831
Embedded Derivative Liability												1,579,646
Change in fair value [Member]
Principal				0	0	0	0	0	0	0	0	0
Original Issue Discount				0	0	0	0	0	0	0	0	0
Warrant Liability	(1,703,252)	(2,302,707)	(923,052)	(2,174,948)	(6,826,019)	(4,915,676)	(3,789,889)	(1,934,055)	(3,866,801)	5,363,854	1,995,372	(5,352,697)
Embedded Derivative Liability	(20,567)	(438,054)	159,657	(416,347)	(2,141,984)	(763,523)	(51,972)	(13,876)	(260,843)	421,404	905,259	(493,132)
Accreted Interest [Member]
Principal	0	0	0	0	0	0	0	0	0	0	0	0
Original Issue Discount	(229,392)	(569,419)	(532,559)	(471,290)	(340,050)	(74,422)	(73,363)	(21,052)	(50,842)	251,188	225,321	(123,846)
Warrant Liability	0	0	0	0	0	0	0	0	0	0	0	0
Embedded Derivative Liability	0	0	0	0	0	0	0	0	0	0	0	$ 0
Bridge Notes IV-December 1, 2009 through January 31. 2010 [Member]
Principal											555,882
Original Issue Discount											83,382
Warrant Liability											207,617
Embedded Derivative Liability											164,400
Bridge Note I- Extension of Maturity Date [Member]
Principal											0
Original Issue Discount											0
Warrant Liability											202,500
Embedded Derivative Liability											103,400
Exercise of Common Stock Warrants [Member]
Principal									0	0	0
Original Issue Discount									0	0	0
Warrant Liability									(1,475,758)	(1,790,823)	1,702,073
Embedded Derivative Liability									0	0	$ 0
Bridge Note V [Member]
Principal										640,307
Original Issue Discount										97,807
Warrant Liability										229,619
Embedded Derivative Liability										271,554
Note Payoffs [Member]
Principal				(155,806)	(26,316)	(159,675)	(187,582)	(414,118)	(88,236)	(1,040,177)
Original Issue Discount				0	0	0	0	0	0	(4,222)
Warrant Liability				0	0	0	0	0	0	0
Embedded Derivative Liability				0	(8,860)	(5,904)	0	(46,945)	(12,665)	$ (64,354)
Issuance of Optimus Warrants
Principal									0
Original Issue Discount									0
Warrant Liability									(6,856,946)
Embedded Derivative Liability									0
Bridge Note Conversions [Member]
Principal			(169,000)	(221,788)	(1,164,947)				(2,420,373)
Original Issue Discount			0	0	0				0
Warrant Liability			0	0	0				0
Embedded Derivative Liability			0	(10,530)	(381,209)				$ (701,718)
Exercise Of Warrants [Member]
Principal						0	0	0
Original Issue Discount						0	0	0
Warrant Liability						(639,960)	(1,382,847)	(4,156,797)
Embedded Derivative Liability						0	0	0
Issuance Of Warrants [Member]
Principal						0	0	0
Original Issue Discount						0	0	0
Warrant Liability						2,990,520	35,523	1,042,559
Embedded Derivative Liability						0	0	0
Bridge Note VI [Member]
Principal								265,457
Original Issue Discount								25,457
Warrant Liability								72,300
Embedded Derivative Liability								$ 39,416
Issuance of November 2010 Bridge Notes [Member]
Principal							931,579
Original Issue Discount							96,579
Warrant Liability							391,076
Embedded Derivative Liability							150,156
Exchange of November 2010 Bridge Notes [Member]
Principal							17,175
Original Issue Discount							17,175
Warrant Liability							86,963
Embedded Derivative Liability							9,389
Issuance of January 2011 Bridge Notes [Memebr]
Principal							452,941
Original Issue Discount							57,941
Warrant Liability							173,808
Embedded Derivative Liability							$ 41,024
Issuance of Q2 2011 Bridge Notes [Member]
Principal						473,392
Original Issue Discount						43,392
Warrant Liability						121,238
Embedded Derivative Liability						71,336
Issuance of Q3 2011 Bridge Notes [Member]
Principal					11,765	626,400
Original Issue Discount					1,765	0
Warrant Liability					4,968	0
Embedded Derivative Liability					5,051	$ 0
Issuance of May 2011 Notes [Member]
Principal					7,077,936
Original Issue Discount					1,553,254
Warrant Liability					0
Embedded Derivative Liability					2,719,345
Additional warrants issued to Bridge Note holder [Member]
Principal					0
Original Issue Discount					0
Warrant Liability					36,376
Embedded Derivative Liability					0
Exchange Of Bridge Notes [Member]
Principal	52,941	52,941			8,033
Original Issue Discount					8,033
Warrant Liability	0	0			0
Embedded Derivative Liability					2,656
Conversion of May 2011 Notes [Member]
Principal	(38,000)	(38,000)	(1,924,060)	(1,225,561)	(671,500)
Original Issue Discount	0	0	0	0	0
Warrant Liability	0	0	0	0	0
Embedded Derivative Liability	(5,016)	(5,016)	(341,342)	(110,494)	(166,980)
Exchanges/Exercises of October 2007 Warrants [Member]
Principal					0
Original Issue Discount					0
Warrant Liability					(1,186,959)
Embedded Derivative Liability					$ 0
Issuance of October 2011 Notes [Member]
Principal				2,326,471
Original Issue Discount				459,396
Warrant Liability				0
Embedded Derivative Liability				396,818
Reclassification Of Warrant Liability To Equity [Member]
Principal				0
Original Issue Discount				0
Warrant Liability				(186,908)
Embedded Derivative Liability				0
Issuance Of Long Term Convertible Promissory Notes [Member]
Principal			(540,000)	86,400
Original Issue Discount				0
Warrant Liability				0
Embedded Derivative Liability				0
Exchange Of Warrants [Member]
Principal				0
Original Issue Discount				0
Warrant Liability	(134,796)	(134,796)	59,572	816,259
Embedded Derivative Liability				$ 0
Issuance Of December Two Thousand and Eleven Notes [Member]
Principal	(827,500)		1,232,353
Original Issue Discount			258,178
Warrant Liability			0
Embedded Derivative Liability	(160,677)		306,568
Conversion Of October Two Thousand and Eleven Notes [Member]
Principal			(1,227,500)
Original Issue Discount			0
Warrant Liability			0
Embedded Derivative Liability			(329,433)
Partial Note Repayments [Member]
Principal			$ (52,941)
Conversion Of December 2011 Notes [Member]
Principal	(827,500)	(827,500)
Original Issue Discount	0	0
Warrant Liability	0	0
Embedded Derivative Liability	(160,677)	$ (160,677)
Issuance of May 2012 Notes [Member]
Principal	953,333
Original Issue Discount	(200,632)
Warrant Liability	291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes [Member]
Principal	(4,473,673)
Original Issue Discount	0
Embedded Derivative Liability	(115,046)
Debt for Equity Exchange: Bridge Notes [Member]
Principal	(50,000)
Original Issue Discount	0
Warrant Liability	(4,750)
Embedded Derivative Liability	0
July 2012Exchange of Warrants [Member]
Warrant Liability	(407,501)
JMJ Settlement Agreement [Member]
Principal	540,000
JMJ Note Conversions [Member]
Principal	$ (712,800)

DERIVATIVE INSTRUMENTS (Details 1)	9 Months Ended	12 Months Ended
DERIVATIVE INSTRUMENTS (Details 1)	Jul. 31, 2012 $ / shares shares	Oct. 31, 2011 shares	Aug. 27, 2012	Dec. 29, 2011	Jul. 31, 2011 shares	Oct. 31, 2010	Sep. 28, 2010	Jul. 19, 2010	Nov. 12, 2004
Exercise Price	0.15	0.15	0.15	0.15		0.15	0.17	0.25	0.40
Amount	114,738,770	137,841,857
Minimum [Member]
Exercise Price	0.15	0.15				0.15
Maximum [Member]
Exercise Price	0.17	0.1952				0.287
Vendor & Other [Member] \| Minimum [Member]
Exercise Price		0.15
Vendor & Other [Member] \| Maximum [Member]
Exercise Price		0.1952
Placement Agent Convertible Debt Financing [Member]
Amount	25,560,000				25,560,000
Common Stock Purchase Warrant [Member] \| 2007 Securities Purchase Agreement [Member]
Exercise Price	0.15	0.15
Amount	50,660,663	47,090,487
Expiration Date	Oct-12	August October 2012
Common Stock Purchase Warrant [Member] \| August 2007 Notes [Member]
Exercise Price	0.15	0.15
Amount	287,001	287,001
Expiration Date	August 2012	August 2012
Common Stock Purchase Warrant [Member] \| May 2011 Convertible Debt Financing [Member]
Exercise Price	0.15	0.15
Amount	3,578,949	23,593,122
Expiration Date	May-14	May 2014
Common Stock Purchase Warrant [Member] \| October 2011 Convertible Debt Financing [Member]
Exercise Price	0.15	0.15
Amount	1,453,553	7,754,902
Expiration Date	Oct-14	October 2014
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member]
Exercise Price	0.15
Amount	2,213,234
Expiration Date	January 2015
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member]
Amount	24,712,208	22,630,101
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Minimum [Member]
Exercise Price	0.15	0.15
Expiration Date	January 2013
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Maximum [Member]
Exercise Price	0.17	0.17
Expiration Date	April 2015
Common Stock Purchase Warrant [Member] \| Executive Officer [Member]
Exercise Price	0.15	0.15
Amount	7,674,512	7,674,512
Expiration Date	August 2014	August 2014
Common Stock Purchase Warrant [Member] \| Vendor & Other [Member]
Exercise Price	0.15
Amount	46,956	446,956
Expiration Date	N/A	February 2012
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member]
Exercise Price	0.15	0.15
Amount	3,735,430	2,804,776
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Minimum [Member]
Expiration Date	May 2014
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Maximum [Member]
Expiration Date	November 2015
Common Stock Purchase Warrant [Member] \| Subtotal [Member]
Amount	111,381,303	112,281,857
Common Stock Purchase Warrant [Member] \| Optimus Preferred Stock Agreement (04/04/2011) [Member]
Amount	25,560,000	25,560,000
Expiration Date	April 2014	April 2014

DERIVATIVE INSTRUMENTS (Details Textual)	3 Months Ended			9 Months Ended		12 Months Ended
DERIVATIVE INSTRUMENTS (Details Textual)	Jul. 31, 2012 USD ($) $ / shares shares	Jan. 31, 2012 shares	Jul. 31, 2011 USD ($)	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2011 USD ($) shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares shares	Oct. 31, 2007 shares	Aug. 27, 2012	Dec. 29, 2011	Apr. 28, 2011 $ / shares	Sep. 28, 2010	Jul. 19, 2010	Nov. 12, 2004
Warrant [Member]
Class Of Warrant Or Right Owned By Entity	$ 99,600,000			$ 99,600,000
Class of Warrant or Right, Outstanding \| shares	64,800,000			64,800,000
Total \| shares				137,000,000
Derivative Liability, Fair Value, Net						$ 6,400,000	$ 13,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.15			0.15
Proceeds from Stock Options Exercised						$ 1,085,000
Class of Warrant or Right, Outstanding \| shares	114,738,770			114,738,770		137,841,857
Total \| shares				171,141,067	27,414,418	226,819,663	133,965,228
Derivative Liability, Fair Value, Net						$ 6,400,000	$ 13,000,000
Fair Value, Option, Changes In Fair Value, Gain					$ 5,800,000
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013	$ 2,136			$ 2,136		$ 946,046	81,028
Embedded Derivative, Gain on Embedded Derivative				$ 307,000	1,300,000
Embedded Derivative, Loss on Embedded Derivative	$ 28,000		$ 2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used						BSM model
Increased Income For Net Change In Fair Value Of Warrant and Embedded Derivative Liability						$ 9,800,000	$ 446,000
Exercised Number of Options \| shares		0				7,233,341	(306,000)
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.15			0.15		0.15	0.15		0.15	0.15		0.17	0.25	0.40
Proceeds from Stock Options Exercised						$ 1,085,000
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001			$ 0.001		$ 0.001	$ 0.001				$ 0.001
Number Of Common Stock Exercisable For Warrant Received \| shares						7,674,512
Number Of Common Stock Exercisable For Settlement Of Warrant \| shares								2,666,667
Number Of Common Stock Exercisable For Warrant Received Amended \| shares						4,118,956
Reduction In Warrant Outstanding Subject To Anti Dilution Provisions						$ 49,400,000
Gain (Loss) on Sale of Derivatives						458,000
Noncash Warrant Expenses						72,000
Warrant Liability	$ 99,600,000			$ 99,600,000		25,600,000	$ 15,800,000
Bridge Loan [Member] \| Private Placement [Member]
Noncash Warrant Expenses						$ 72,000
Warrant Exchange Agreement [Member]
Common stock, par value (in dollars per share) \| $ / shares						$ 0.001
Number Of Common Stock Exercisable For Warrant Received \| shares						7,674,512
Gain (Loss) on Sale of Derivatives						$ 458,000
Noncash Warrant Expenses						$ 486,000
Amended Note Purchase Agreement [Member]
Number Of Common Stock Exercisable For Warrant Received Amended \| shares						4,118,956
Warrant Liability [Member]
Class of Warrant or Right, Outstanding \| shares	114,700,000			114,700,000		101,000,000
Total \| shares				47,000,000		49,400,000
Derivative Liability, Fair Value, Net	$ 1,266,000			$ 1,266,000
Fair Value, Option, Changes In Fair Value, Gain				4,900,000	$ 5,800,000
Fair Value Option Changes In Fair Value Loss	1,700,000		$ 6,900,000
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013	$ 2,140			$ 2,140

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
Total stock compensation recognized	$ 289,689	$ 199,268	$ 877,251	$ 619,299
Research and Development Expense [Member]
Total stock compensation recognized	128,011	95,263	397,231	265,768
General and Administrative Expense [Member]
Total stock compensation recognized	$ 161,678	$ 104,005	$ 480,020	$ 353,531

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS (Details 1) - $ / shares	9 Months Ended
	Jul. 31, 2012	Jun. 13, 2012
Exercise Price:	$ 0.148
Stock Price:	$ 0.148	$ 0.15
Days to Maturity:	10 years
Risk-free Rate:	2.10%
Volatility:	143.00%

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS (Details 2) - $ / shares	3 Months Ended		12 Months Ended
	Jul. 31, 2012	Jan. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Outstanding Number of Options	45,057,424	27,317,424	26,467,424	18,331,591
Granted Number of Options		17,740,000	850,000	11,075,000
Exercised Number of Options		0	7,233,341	(306,000)
Expired Number of Options		0
Outstanding Number of Options	44,807,424	45,057,424	27,317,424	26,467,424
Not Exercisable Number of Options	17,246,771
Cancelled Number of Options		250,000
Exercisable Number of Options	27,560,653		20,451,266
Outstanding Weighted-Average Exercise Price	$ 0.16	$ 0.16	$ 0.16	$ 0.16
Granted Weighted-Average Exercise Price		0.15	0.12	0.16
Exercised Weighted-Average Exercise Price		0		0.09
Cancelled Weighted-Average Exercise Price		0.15
Exercisable Weighted-Average Exercise Price	0.16		0.16
Not Exercisable Weighted-Average Exercise Price	0.15
Outstanding Weighted-Average Exercise Price	$ 0.16	$ 0.16	$ 0.16	$ 0.16

ACCOUNTING FOR STOCK BASED COMPENSATION PLANS (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Jul. 31, 2012	Jul. 31, 2012	Aug. 31, 2012	May 31, 2012	Feb. 29, 2012	Oct. 31, 2011
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 2,250,000	$ 2,250,000				$ 759,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		2 years
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		17,740,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.1448
Employee Stock Ownership Plan E S O P Discount Rate		85.00%
Employee Stock Ownership Plan (ESOP), Number of Allocated Shares	5,000,000	5,000,000
Employee Stock Ownership Plan (Esop), Tax Withheld From Employee		$ 18,300
Employee Stock Ownership Plan (ESOP), Shares in ESOP			122,819	68,397	15,862
Amount Withheld From Employee	$ 8,535
Shares Authorised Under Incentive Plan	45,000,000

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)				1 Months Ended						3 Months Ended			9 Months Ended		10 Months Ended	12 Months Ended					116 Months Ended	125 Months Ended
	Apr. 04, 2011	May 10, 2010	Dec. 15, 2006	Jan. 31, 2010	Jul. 21, 2009	Nov. 30, 2007	Feb. 15, 2007	Mar. 29, 2006	Mar. 31, 2005	Jul. 31, 2012	Jan. 31, 2012	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011	Dec. 31, 2002	Oct. 31, 2011	Oct. 31, 2010	Oct. 14, 2010	Oct. 31, 2007	Oct. 31, 2005	Oct. 31, 2011	Jul. 31, 2012	Aug. 31, 2012	Aug. 27, 2012	Jul. 24, 2012	Jun. 13, 2012	May 31, 2012	Dec. 12, 2011
Option Exercise Fee Payable																												$ 20,000.00
Stock Issued During Period, Value, New Issues															$ 235,000	$ 1,676,554			$ 9,380,902
Stock Issued During Period, Shares, New Issues													25,560,000			40,500,000
Stock Price:										$ 0.148			$ 0.148									$ 0.148				$ 0.15
Research & Development Expenses										$ 1,331,415		$ 1,958,518	$ 5,760,158	$ 6,392,919		$ 8,078,901	$ 4,904,298				$ 23,156,740	$ 28,916,898
Issuance of common stock to consultants																				$ 166,777
Payments for Leasing Costs	$ 15,600
Cost of Utilities	$ 7,200
Cost Of Utilities Per R E	$ 10,700
Expected Lease Operating Expenses	$ 288,000
Operating Leases, Rent Expense													$ 34,000			$ 62,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period													17,740,000
Granted Number of Options											17,740,000					850,000	11,075,000
Granted Weighted-Average Exercise Price											$ 0.15					$ 0.12	$ 0.16
Common stock, shares issued										375,135,008			375,135,008			250,173,570	198,100,817				250,173,570	375,135,008	4,000,000	4,076,923			4,000,000
Accounts Payable										$ 4,947,357			$ 4,947,357			$ 4,778,508					$ 4,778,508	$ 4,947,357
Non Cash Income																										$ 869,000
Deferred Rent Credit										19,200			19,200									19,200
Mr.Moore [Member]
Base Officers Compensation																250,000
Increase Decrease In Officer Compensation																$ 350,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				750,000		750,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased			$ 0.143		$ 2,500,000													$ 2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					1 month 6 days											24 months		1 month 24 days
Granted Number of Options																1,500,000
Granted Weighted-Average Exercise Price																$ 0.4
Officers' Compensation																$ 4,000,000
Dr.Rothman [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased					$ 1,750,000		$ 300,000	$ 150,000	$ 360,000							$ 0.20		$ 2,250,000			$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					1 month 1 day		1 month 29 days	3 months 4 days	3 months 13 days									0 months
Officers' Compensation																$ 305,000
Officer Compensation Payable In Cash																275,000
Officer Compensation Payable In Stock																30,000
Pennsylvania [Member]
Option Exercise Fee Payable		$ 35,000
Stock Issued During Period, Value, New Issues		$ 70,000
Stock Issued During Period, Shares, New Issues		388,889
Stock Price:		$ 0.18
Licenses Revenue													507,000			249,000
Pharm Olam International [Member]
Option Exercise Fee Payable																223,620					$ 223,620
Research & Development Expenses													12,200,000			12,200,000
Accounts Payable										223,620			223,620									223,620
Numoda [Member]
Issuance of common stock to consultants		$ 350,000
Issuance of common stock to consultants (in shares)		3,500,000
Payments of Distributions to Affiliates													7,400,000			1,100,000
Due from Affiliates																$ 6,300,000					$ 6,300,000
Common stock, shares issued																									11,111,000	15,000,000
Accounts Payable																										$ 1,700,000
Claims Payable										1,800,000			1,800,000									1,800,000
Accounts Receivable, Net																										$ 2,250,000
Socius [Member]
Non Cash Income										444,000			444,000									444,000
Claims Payable										$ 1,800,000			1,800,000									$ 1,800,000			$ 2,888,860
Related Party Transaction, Amounts of Transaction													$ 444,000

SHAREHOLDERS' EQUITY (Details)	1 Months Ended	9 Months Ended	12 Months Ended
SHAREHOLDERS' EQUITY (Details)	Jul. 30, 2012	Jul. 31, 2012 $ / shares shares	Oct. 31, 2011 shares	Aug. 27, 2012	Dec. 29, 2011	Jul. 31, 2011 shares	Oct. 31, 2010	Sep. 28, 2010	Jul. 19, 2010	Nov. 12, 2004
Common Stock To Be Purchased In Exchange Of Unissued Warrants	34,791,156
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15	0.15	0.15		0.15	0.17	0.25	0.40
Class of Warrant or Right, Outstanding		114,738,770	137,841,857
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15				0.15
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.17	0.1952				0.287
Vendor & Other [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15
Vendor & Other [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.1952
Placement Agent Convertible Debt Financing [Member]
Class of Warrant or Right, Outstanding		25,560,000				25,560,000
Common Stock Purchase Warrant [Member] \| 2007 Securities Purchase Agreement [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant (2)
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15
Class of Warrant or Right, Outstanding		50,660,663	47,090,487
Expiration Date		Oct-12	August October 2012
Common Stock Purchase Warrant [Member] \| May 2011 Convertible Debt Financing [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15
Class of Warrant or Right, Outstanding		3,578,949	23,593,122
Expiration Date		May-14	May 2014
Common Stock Purchase Warrant [Member] \| October 2011 Convertible Debt Financing [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15
Class of Warrant or Right, Outstanding		1,453,553	7,754,902
Expiration Date		Oct-14	October 2014
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15
Class of Warrant or Right, Outstanding		2,213,234
Expiration Date		January 2015
Common Stock Purchase Warrant [Member] \| May 2012 Convertible Debt Financing [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15
Class of Warrant or Right, Outstanding		2,777,777
Expiration Date		May-17
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Outstanding		24,712,208	22,630,101
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15
Expiration Date		January 2013
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.17	0.17
Expiration Date		April 2015
Common Stock Purchase Warrant [Member] \| Vendor & Other [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15
Class of Warrant or Right, Outstanding		46,956	446,956
Expiration Date		N/A	February 2012
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.15	0.15
Class of Warrant or Right, Outstanding		3,735,430	2,804,776
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Minimum [Member]
Expiration Date		May 2014
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Maximum [Member]
Expiration Date		November 2015
Common Stock Purchase Warrant [Member] \| ?July 2012 Warrant Exchanges [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Exchange warrants nonexercisable
Class of Warrant or Right, Outstanding		34,791,156
Common Stock Purchase Warrant [Member] \| Optimus Preferred Stock Agreement (04/04/2011) [Member]
Common Stock To Be Purchased In Exchange Of Unissued Warrants		Common Stock Purchase Warrant
Class of Warrant or Right, Outstanding		25,560,000	25,560,000
Expiration Date		April 2014	April 2014

SHAREHOLDERS' EQUITY (Details Textual)	1 Months Ended				3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended					116 Months Ended	125 Months Ended
SHAREHOLDERS' EQUITY (Details Textual)	Aug. 31, 2012 shares	Jul. 30, 2012 USD ($) shares	Dec. 29, 2011 shares	Aug. 31, 2011 shares	Jul. 31, 2012 USD ($) $ / shares shares	Jan. 31, 2012 USD ($) shares	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2011 USD ($) shares	Dec. 31, 2002 shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares shares	Oct. 31, 2007 shares	Oct. 31, 2006 shares	Oct. 31, 2005 shares	Oct. 31, 2011 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Aug. 27, 2012	Jul. 08, 2012 shares	Jul. 05, 2012 shares	Apr. 28, 2011 $ / shares	Apr. 04, 2011	Sep. 28, 2010	Jul. 19, 2010 $ / shares	Aug. 24, 2007 shares	Nov. 12, 2004 shares
Preferred stock, shares issued					740		740			740	789				740	740
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.001		$ 0.001			$ 10,000	$ 0.001				$ 10,000	$ 0.001
Sale of Stock, Price Per Share \| $ / shares					$ 10,000		$ 10,000									$ 10,000							$ 10,000
Stock Issued During Period, Shares, New Issues							25,560,000			40,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15		0.15		0.15			0.15	0.15				0.15	0.15	0.15					0.17	0.25		0.40
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																					2.00%		2.00%
Proceeds from exercise of warrants \| $							$ 411,765	$ 1,085,001		$ 1,085,001	$ 170,000				$ 1,255,001	$ 1,666,766
Common stock, par value (in dollars per share) \| $ / shares					$ 0.001		$ 0.001			$ 0.001	$ 0.001				$ 0.001	$ 0.001				$ 0.001
Debt Issuance Cost \| $					$ 247,000	$ 25,000	$ 27,000
Fair Value, Option, Changes in Fair Value, Gain (Loss) \| $					$ 9,000		$ 85,000
Incremental Common Shares Attributable to Written Put Options							47,000,000			49,400,000
Total							171,141,067	27,414,418		226,819,663	133,965,228
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																		11,064,611	79,947,614					150,000	87,108
Debt Conversion, Converted Instrument, Shares Issued	0	800,000	3,600,000	768,633	253,333		1,126,667			8,652,737
Class of Warrant or Right, Outstanding					114,738,770		114,738,770			137,841,857					137,841,857	114,738,770
Purchase Of Common Stock In Exchange Of Warrants Surrendered		23,726,545
Common Stock To Be Purchased In Exchange Of Unissued Warrants		34,791,156
Other Noncash Income \| $		$ 408,000					$ 54,000
Warrant Excercised During Period							2,745,097
Warrants Issued In Exchange For Shares							4,791,337
Shares Repurchased In Exchange Of Warrants Issued							6,388,449
Shares Repurchased In Exchange Of Warrants Issued Value \| $							$ 1,597,112
Other Noncash Expense \| $							$ 89,000
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.15		0.15									0.15
Total							137,000,000
Class of Warrant or Right, Outstanding					64,800,000		64,800,000									64,800,000
Equity Warrants [Member]
Total							41,000,000
Class of Warrant or Right, Outstanding					25,560,000		25,560,000									25,560,000
Common Stock [Member]
Preferred stock, shares issued											789
Stock Issued During Period, Shares, New Issues							4,000,000		40,000		789	59,228,334
Stock Issued During Period Shares Warrant Exercised						2,745
Warrants Purchased During Period							292,000
Debt Conversion, Converted Instrument, Shares Issued												6,974,202	1,766,902	2,136,441
Series B Preferred Stock [Member]
Preferred stock, shares issued					740		740			740	789				740	740
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.001		$ 0.001			$ 10,000					$ 10,000	$ 0.001
Sale of Stock, Price Per Share \| $ / shares					$ 10,000		$ 10,000									$ 10,000							$ 10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																							0.25
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																							2.00%
Preferred Stock Shares Available For Sale					284		284									284
Series B Preferred Stock [Member] \| Warrant [Member]
Stock Issued During Period, Shares, New Issues										40,500,000

FAIR VALUE (Details) - USD ($)	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Fair Value of Embedded Derivatives at issuance	$ 2,136	$ 946,046	$ 81,028
Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from August 2012 through November 2015	1,265,985	6,391,071	13,006,194
Total		7,491,422	13,087,222
May 2012 Notes	472,840
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value of Embedded Derivatives at issuance	0	0	0
Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from August 2012 through November 2015	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value of Embedded Derivatives at issuance			0
Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from August 2012 through November 2015			0
Fair Value, Inputs, Level 3 [Member]
Fair Value of Embedded Derivatives at issuance		946,046
Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from August 2012 through November 2015		6,391,071
Total		7,337,117
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value of Embedded Derivatives at issuance	2,136	946,046	81,028
Common stock warrant liability, warrants exercisable at $0.15 - $0.17 from August 2012 through November 2015	1,265,985	$ 6,391,071	$ 13,006,194
May 2012 Notes	$ 472,840

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 4, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 7
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FIN39-1
-Paragraph 10A, 10B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 12-16, 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 12-16, 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

FAIR VALUE (Details 1) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended	12 Months Ended
FAIR VALUE (Details 1) - USD ($)	Aug. 31, 2007	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Jul. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Notes Issued	$ 600,000
Embedded Derivative Liability [Member]
Beginning balance		$ 137,749	$ 741,496	$ 946,046	$ 1,840,327	$ 229,625	$ 81,028	$ 946,046	$ 81,028	$ 1,086,514
Issuances			0	306,568	2,719,345	697,736	200,569	0	3,505,605	522,530
Note Conversions and Payoffs				(670,755)	739,787		0		(683,977)	(825,682)
Change in fair value		(20,567)	(438,054)	159,657	(2,216,715)	(2,216,715)	(51,972)	(438,054)	(1,766,161)	(702,334)
Note Conversions			(165,693)			0		(165,693)	(190,449)	0
Note Payoffs		0	0			(5,904)		0
Reclassification Of Warrants To Equity					(516,571)
Debt For Equity Exchange		(115,046)
Closing Balance		2,136	137,749	741,496	1,086,599	1,840,327	229,625	2,136	946,046	81,028
Common Stock Warrant Liability [Member]
Beginning balance		3,090,088	5,527,591	6,391,071	8,520,828	8,520,828	13,006,194	6,391,071	13,006,194	11,961,734
Issuances		291,400	0	0	36,376	3,111,758	600,407		5,065,326	8,579,900
Note Conversions and Payoffs				59,572			(1,295,884)		(3,826,409)	(7,792,198)
Change in fair value		1,703,252	(2,302,707)	(923,052)	(6,906,747)	4,915,676	(3,789,889)		(7,955,907)	256,758
Note Conversions		0			(639,960)				101,867	0
Note Payoffs		(134,796)
Reclassification Of Warrants To Equity		0			613,003
Debt For Equity Exchange		(4,750)			0
Warrant Exchanges		(407,501)	(134,796)		0	0
Warrant Excercises		0	0		(1,714,266)	(639,960)
Closing Balance		1,265,985	$ 3,090,088	$ 5,527,591	$ 7,936,668	$ 8,520,828	$ 8,520,828	1,265,985	$ 6,391,071	$ 13,006,194
May Two Thousand and Twelve Notes [Member]
Issuances								(291,400)
Change in fair value								77,270
Notes Issued								687,000
Closing Balance		$ 472,870						$ 472,870

FAIR VALUE (Details 2) - $ / shares	9 Months Ended
FAIR VALUE (Details 2) - $ / shares	Jul. 31, 2012	Jul. 31, 2011	Jun. 13, 2012
Stock Price:	$ 0.148		$ 0.15
Embedded Derivative Liability [Member]
Fair Value Assumptions, Exercise Price	0.15	$ 0.15
Stock Price:	$ 0.073	$ 0.1485
Embedded Derivative Liability [Member] \| Minimum [Member]
Fair Value Assumptions, Expected Term	92 days	92 days
Fair Value Assumptions, Expected Volatility Rate	79.53%	54.73%
Fair Value Assumptions, Risk Free Interest Rate	0.11%	0.10%
Embedded Derivative Liability [Member] \| Maximum [Member]
Fair Value Assumptions, Expected Term	162 days	286 days
Fair Value Assumptions, Expected Volatility Rate	86.00%	78.46%
Fair Value Assumptions, Risk Free Interest Rate	0.15%	0.18%
Common Stock Warrant Liability [Member]
Fair Value Assumptions, Exercise Price	$ 0.15	$ 0.15
Stock Price:	$ 0.073	$ 0.1485
Common Stock Warrant Liability [Member] \| Minimum [Member]
Fair Value Assumptions, Expected Term	15 days	185 days
Fair Value Assumptions, Expected Volatility Rate	65.59%	65.68%
Fair Value Assumptions, Risk Free Interest Rate	0.07%	0.10%
Common Stock Warrant Liability [Member] \| Maximum [Member]
Fair Value Assumptions, Expected Term	1752 days	1825 days
Fair Value Assumptions, Expected Volatility Rate	91.95%	174.18%
Fair Value Assumptions, Risk Free Interest Rate	0.27%	0.18%
May Two Thousand and Twelve Notes [Member]
Fair Value Assumptions, Exercise Price	$ 0.15
Stock Price:	$ 0.073
Fair Value Assumptions, Expected Term	291 days
Fair Value Assumptions, Expected Volatility Rate	71.25%
Fair Value Assumptions, Risk Free Interest Rate	0.15%

FAIR VALUE (Details Textual)	9 Months Ended	12 Months Ended
FAIR VALUE (Details Textual)	Jul. 31, 2012 $ / shares	Oct. 31, 2011 USD ($) shares	Aug. 27, 2012	Dec. 29, 2011	Oct. 31, 2010 USD ($)	Sep. 28, 2010	Jul. 19, 2010	Nov. 12, 2004
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.15	0.15	0.15	0.15	0.15	0.17	0.25	0.40
Total \| $		$ 7,491,422			$ 13,087,222
Fair Value Of Warrants Issued \| shares		91,415,804
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.15	0.15			0.15
Warrant Minimum Exercise Price Probablity	30.00%
Warrant Maximum Exercise Price Probablity	50.00%
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.17	0.1952			0.287
Warrant Minimum Exercise Price Probablity	50.00%
Warrant Maximum Exercise Price Probablity	70.00%

- Definition

Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 12-16, 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUBSEQUENT EVENTS (Details Textual)	1 Months Ended							2 Months Ended		3 Months Ended		9 Months Ended	10 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Textual)	Aug. 31, 2012 USD ($) $ / shares shares	Jul. 30, 2012 shares	Dec. 29, 2011 USD ($) $ / shares shares	Aug. 31, 2011 shares	Apr. 28, 2011 USD ($) $ / shares	Aug. 31, 2007 USD ($)	Nov. 30, 2004 USD ($)	Jan. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Jan. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2002 shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) shares	Oct. 31, 2007 USD ($) shares	Oct. 31, 2006 USD ($) shares	Oct. 31, 2005 USD ($) shares	Oct. 31, 2004 USD ($)	Sep. 30, 2012 USD ($) $ / shares	Aug. 27, 2012 USD ($) shares	Aug. 16, 2012 shares	Aug. 02, 2012 USD ($) $ / shares	Jun. 13, 2012 $ / shares	May 31, 2012 shares	Dec. 12, 2011 USD ($)	Oct. 28, 2011 USD ($)	May 09, 2011 USD ($) $ / shares	Sep. 28, 2010	Jul. 19, 2010	Aug. 24, 2007	Nov. 12, 2004
Stock Issued During Period, Shares, New Issues \| shares												25,560,000		40,500,000
Stock Price: \| $ / shares										$ 0.148		$ 0.148												$ 0.15
Long-term Debt, Gross			$ 540,000		$ 800,000					$ 300,000		$ 300,000		$ 1,886,851	$ 688,000												$ 59,000
Notes Issued						$ 600,000
Convertible Notes Payable			1,200,000							2,300,000		2,300,000															2,300,000	$ 7,100,000
Debt Instrument Purchase Price			$ 1,000,000		$ 500,000					50,000		50,000															$ 50,000	$ 6,000,000
Deferred Investment Funds										$ 240,000		$ 240,000
Debt Instrument, Discount Percentage			15.00%							10.00%		10.00%		10.00%									25.00%					15.00%
Debt Instrument, Description	The investor paid $0.75 for each $1.00 of principal amount of the Note purchased.
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 0.15		$ 0.15					$ 0.15		$ 0.15		$ 0.15						$ 65			$ 0.15					$ 0.15
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15							0.15		0.15		0.15	0.15						0.15								0.17	0.25		0.40
Debt Instrument, Maturity Date			Jan. 09, 2013		Apr. 28, 2014									May 12, 2014
Common Stock Outstanding Shares In Percentage																														9.99%
Debt Instrument, Face Amount					$ 80,000					$ 587,000		$ 587,000								$ 132,500	$ 100,000
Debt Conversion, Converted Instrument, Amount							$ 618,000			$ 38,000		$ 169,000		$ 1,897,000		$ 1,000,010	$ 300,000	$ 613,158
Option Exercise Fee Payable																										$ 20,000.00
Debt Instrument, Payment Terms	In addition, if the August 2012 Note is converted after November 30, 2012 and the market price of our common stock is less than $0.16 per share on the date of conversion, then the conversion price shall equal 95% of the average of the three lowest closing prices in the 15 trading days prior to the date of the conversion.
Debt Conversion, Converted Instrument, Shares Issued \| shares	0	800,000	3,600,000	768,633						253,333		1,126,667		8,652,737
Common stock, shares issued \| shares	4,000,000									375,135,008		375,135,008		250,173,570	198,100,817						4,076,923				4,000,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%															12.00%											12.00%
Shares Authorised \| shares																					505,000,000	1,005,000,000
Common stock, shares authorized \| shares										500,000,000		500,000,000		500,000,000	500,000,000						500,000,000	1,000,000,000
Preferred stock, shares authorized \| shares										5,000,000		5,000,000		5,000,000	5,000,000						5,000,000	5,000,000
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										0.15		0.15
Common Stock [Member]
Stock Issued During Period, Shares, New Issues \| shares												4,000,000	40,000		789	59,228,334
Warrants Purchased During Period \| shares												292,000
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares											3,600,000
Debt Conversion, Converted Instrument, Amount																$ 6,974	$ 1,767	$ 2,136,000	$ 2,136
Debt Conversion, Converted Instrument, Shares Issued \| shares																6,974,202	1,766,902	2,136,441
Accredited Investor Note [Member]
Convertible Notes Payable																							$ 66,667
Debt Instrument Purchase Price																							$ 50,000
Debt Instrument, Discount Percentage																							25.00%
Debt Instrument, Description	The investor paid $0.75 for each $1.00 of principal amount of the Note purchased.
Debt Instrument, Convertible, Conversion Price \| $ / shares																							$ 0.15
Convertible Note One Issued On Sep 2012 [Member]
Convertible Notes Payable	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Convertible Notes Conversion Price Percentage												69.00%
Debt Instrument Maturity Period												9 months
Convertible Note Two Issued On Sep 2012 [Member]
Convertible Notes Payable	$ 132,500
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Convertible Notes Conversion Price Percentage												65.00%
Debt Instrument Maturity Period												8 months
Convertible Notes Payable [Member]
Stock Issued During Period, Shares, New Issues \| shares										583,000
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares										50,000
Debt Instrument, Convertible, Conversion Price \| $ / shares										$ 0.15		$ 0.15
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										0.15		0.15
Debt Conversion, Converted Instrument, Amount										$ 660,000
December 2011 Note Financing [Member]
Long-term Debt, Gross										405,000		$ 405,000
Convertible Notes Payable			$ 1,200,000							1,200,000		1,200,000
Debt Instrument Purchase Price			$ 1,000,000							$ 1,000,000		$ 1,000,000
Debt Instrument, Discount Percentage			15.00%
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 0.15							$ 0.15		$ 0.15
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15
Notes Purchased \| shares			0.85
Notes Purchased Per Unit \| $ / shares			$ 1.00
Purchase Of Common Stock In Percentage			50.00%
Debt Instrument, Maturity Date			Jan. 09, 2013
Initial Principal Debt Amount In Percentage			85.00%
Common Stock Outstanding Shares In Percentage			4.99%
Debt Conversion, Converted Instrument, Amount												$ 827,500
Debt Conversion, Converted Instrument, Shares Issued \| shares												5,516,666
December 2011 Note Financing [Member] \| Rodman Renshaw, Llc [Member]
Long-term Debt, Gross			$ 73,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15
Debt Instrument, Maturity Date			Jan. 09, 2015
Received Compensation Of Cash Placement Fee In Percentage			$ 7,000
Debt Instrument, Face Amount			$ 575,098
May 2011 Notes [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares									$ 0.15
Debt Instrument, Face Amount									$ 1,700,000
May 2011 Notes [Member] \| Common Stock [Member]
Stock Issued During Period, Shares, New Issues \| shares									11,313,727
October 2011 Notes [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares								$ 0.15			$ 0.15
Debt Instrument, Face Amount								$ 1,280,000			$ 1,280,000
October 2011 Notes [Member] \| Common Stock [Member]
Stock Issued During Period, Shares, New Issues \| shares								8,183,333
Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues \| shares												52,200,000
Warrants Purchased During Period \| shares												5,800,000
Notes Issued												$ 247,000
Exchange Agreement [Member] \| Warrant [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares												31,300,000
Exchange Agreement [Member] \| Convertible Notes Payable [Member]
Long-term Debt, Gross										$ 4,500,000		$ 4,500,000
Note Purchase Agreement [Member]
Warrants Purchased During Period \| shares												355,556
Convertible Notes Payable										953,333		$ 953,333
Debt Instrument Purchase Price										715,000		715,000
Deferred Investment Funds										$ 240,000		$ 240,000
Debt Instrument, Discount Percentage										25.00%		25.00%
Debt Instrument, Convertible, Conversion Price \| $ / shares										$ 0.15		$ 0.15
Class of Warrant or Right, Exercise Price of Warrants or Rights										0.15		0.15
Note Purchase Agreement [Member] \| Rodman Renshaw, Llc [Member]
Related Party Transaction, Amounts of Transaction												$ 28,000
Jmj Financial [Member]
Long-term Debt, Gross										$ 500,000		$ 500,000
Debt Instrument, Convertible, Conversion Price \| $ / shares	$ 0.15
Debt Instrument, Face Amount																					$ 100,000
Debt Instrument, Payment Terms	the market price of our common stock is less than $0.16 per share on the date of conversion, then the conversion price shall equal 95% of the average of the three lowest closing prices in the 15 trading days prior to the date of the conversion
Noncontrolling Interest, Description												JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date
Debt Conversion, Converted Instrument, Shares Issued \| shares												3,250,000
Junior Unsecured Subordinated Convertible Promissory Notes [Member]
Stock Issued During Period, Shares, New Issues \| shares												583,000
Long-term Debt, Gross									$ 300,000	$ 50,000		$ 50,000
Debt Instrument, Convertible, Conversion Price \| $ / shares									$ 0.15
Class of Warrant or Right, Exercise Price of Warrants or Rights									0.15
Debt Instrument, Face Amount									$ 53,000
Debt Conversion, Converted Instrument, Amount									169,000
Interest Expense, Debt									$ 53,000
Class Of Warrant Or Right Issued \| shares									2,300,000
Junior Unsecured Subordinated Convertible Promissory Notes [Member] \| Warrant [Member]
Stock Issued During Period, Shares, New Issues \| shares									1,126,667
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares												21,000
Numoda Stock Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues \| shares												15,000,000
Stock Price: \| $ / shares										$ 0.15		$ 0.15
Accounts Receivable, Net										$ 2,250,000		$ 2,250,000

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	9 Months Ended		12 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010
Total	171,141,067	27,414,418	226,819,663	133,965,228
Warrant [Member]
Total	114,738,770	96,994	137,841,857	103,139,628
Stock Options [Member]
Total	44,807,424	27,317,424	27,317,424	26,467,424
Convertible Debt Securities [Member]
Total	11,594,873	0	61,660,382	4,358,176

- Definition

+ References

+ Details

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - shares	9 Months Ended		12 Months Ended
	Jul. 31, 2012	Jul. 31, 2011	Oct. 31, 2011	Oct. 31, 2010
Class of Warrant or Right, Outstanding	114,738,770		137,841,857
Total	171,141,067	27,414,418	226,819,663	133,965,228
Finite-Lived Intangible Asset, Useful Life			20 years
Warrant Liability [Member]
Class of Warrant or Right, Outstanding	114,700,000		101,000,000
Total	47,000,000		49,400,000
Equity Warrants [Member]
Class of Warrant or Right, Outstanding			36,800,000
Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years

- Definition

+ References

+ Details

NOTES PAYABLE (Details Textual)	1 Months Ended																3 Months Ended	9 Months Ended	12 Months Ended
NOTES PAYABLE (Details Textual)	Aug. 31, 2012 shares	Jul. 30, 2012 shares	Dec. 29, 2011 USD ($) $ / shares shares	Aug. 31, 2011 shares	Jun. 30, 2011 USD ($)	May 31, 2011	Apr. 28, 2011 USD ($) $ / shares	Apr. 30, 2010 USD ($)	Feb. 28, 2010 USD ($)	Jun. 30, 2009	Sep. 22, 2008 USD ($)	Aug. 31, 2007 USD ($)	Mar. 31, 2006 USD ($) shares	Feb. 28, 2006 USD ($)	Nov. 30, 2004 USD ($)	Nov. 30, 2003 USD ($)	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 30, 2011 USD ($) shares	Oct. 31, 2007 USD ($)	Oct. 31, 2006 USD ($)	Oct. 31, 2005 USD ($)	Dec. 31, 2003 USD ($)	Sep. 30, 2012 USD ($) $ / shares	Aug. 27, 2012 USD ($)	Aug. 02, 2012 $ / shares	Jul. 08, 2012 shares	Jul. 05, 2012 shares	Oct. 28, 2011 USD ($)	Jul. 31, 2011 USD ($)	May 09, 2011 $ / shares	Mar. 17, 2011 USD ($)	Oct. 31, 2010 USD ($)	Sep. 28, 2010	Jul. 19, 2010	Feb. 15, 2010 USD ($)	Jun. 15, 2009 USD ($)	Aug. 24, 2007 shares	Nov. 12, 2004 shares
Debt Instrument, Maturity Date			Jan. 09, 2013				Apr. 28, 2014												May 12, 2014
Debt Instrument, Maturity Date, Description										the Company''''s next equity financing resulting in gross proceeds to the Company of at least $6 million.
Debt Instrument, Periodic Payment, Principal					$ 100,000			$ 100,000	$ 100,000		$ 100,000
Notes Payable, Current											$ 6,000,000																						$ 6,000,000				$ 6,000,000
Debt Instrument Retention Amount																																					$ 200,000
Debt Instrument, Face Amount							$ 80,000										$ 587,000	$ 587,000							$ 132,500	$ 100,000
Debt Instrument, Increase, Accrued Interest																			$ 13,630
Long-term Debt, Gross			$ 540,000				$ 800,000										$ 300,000	$ 300,000	$ 1,886,851											$ 59,000				$ 688,000
Interest Payable																																		$ 57,000
Debt Conversion, Converted Instrument, Shares Issued \| shares	0	800,000	3,600,000	768,633													253,333	1,126,667	8,652,737
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares													3,000,000
Short-term Convertible Promissory Note Conversions													$ 1,500,000	$ 1,500,000				$ 53,000	$ 1,300,000
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 0.15				$ 0.15										$ 0.15	$ 0.15	$ 0.15						$ 65		$ 0.15					$ 0.15
Debt Instrument, Discount Percentage			15.00%														10.00%	10.00%	10.00%								25.00%					15.00%
Debt Instrument, Payment Terms	In addition, if the August 2012 Note is converted after November 30, 2012 and the market price of our common stock is less than $0.16 per share on the date of conversion, then the conversion price shall equal 95% of the average of the three lowest closing prices in the 15 trading days prior to the date of the conversion.
Debt Conversion, Converted Instrument, Amount															$ 618,000		$ 38,000	$ 169,000	$ 1,897,000		$ 1,000,010	$ 300,000	$ 613,158
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares																												11,064,611	79,947,614										150,000	87,108
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15														0.15	0.15	0.15							0.15								0.15	0.17	0.25				0.40
Notes Issued												$ 600,000
Repayments of Debt																		$ 172,800	$ 712,800
Debt Instrument, Fair Value Disclosure																	$ 99,602	$ 99,602	570,802
Bio Advance Biotechnology Greenhouse [Member]
Notes Payable																			40,000															$ 40,000
Debt Instrument, Increase, Accrued Interest																			1,600
Interest Payable																			12,000															$ 12,000
Debt Instrument, Decrease, Repayments																			50,000
Notes Issued																$ 10,000								$ 40,000
Long Term Convertible Promissory Notes [Member]
Debt Instrument, Maturity Date																		Jun. 30, 2012
Long-term Debt, Gross			$ 540,000														$ 300,000	$ 300,000
Debt Conversion, Converted Instrument, Shares Issued \| shares			3,600,000
Short-term Convertible Promissory Note Conversions																		$ 352,941
Class of Warrant or Right, Exercise Price of Warrants or Rights																	0.15	0.15
Notes Issued																		$ 247,000
Repayments of Debt																		172,800
Debt Instrument, Fair Value Disclosure																	$ 99,602	$ 99,602
Long Term Convertible Promissory Notes [Member] \| A Notes Payable [Member]
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Convertible, Conversion Price \| $ / shares							$ 0.15
Long Term Convertible Promissory Notes [Member] \| B Notes Payable [Member]
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Face Amount							$ 3,000,000
Long-term Debt, Gross							$ 800,000
Debt Instrument, Convertible, Conversion Price \| $ / shares							$ 0.15
Debt Instrument, Increase, Additional Borrowings																			2,300,000
Long Term Convertible Promissory Notes [Member] \| C Notes Payable [Member]
Debt Instrument, Maturity Date							Apr. 28, 2014
Debt Instrument, Face Amount							$ 80,000
Long-term Debt, Gross							$ 800,000
Debt Instrument, Periodic Payment																			$ 250,000
Senior Convertible Promissory Note [Member]
Long-term Debt, Gross																															$ 88,824
Interest Payable																															$ 26,471
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																	0.15	0.15	0.15															0.15
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																	0.17	0.17	0.1952															0.287
Junior Subordinated Convertible Promissory Notes [Member]
Notes Payable																			$ 1,670,000
Debt Instrument, Maturity Date																		Jun. 30, 2012
Debt Instrument, Face Amount																	$ 587,000	$ 587,000
Long-term Debt, Gross																	$ 300,000	$ 300,000	$ 1,886,851															$ 688,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																		1,126,667	8,652,737
Debt Instrument, Decrease, Repayments																			$ 530,000
Short-term Convertible Promissory Note Conversions																		$ 53,000	$ 1,300,000
Debt Instrument, Convertible, Conversion Price \| $ / shares																	$ 0.15	$ 0.15	$ 0.15
Debt Conversion, Converted Instrument, Amount																		$ 169,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																	0.15	0.15
Junior Subordinated Convertible Promissory Notes [Member] \| Ten Investors [Member]
Long-term Debt, Gross																			$ 479,000
Interest Payable																			25,208
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares																				816,000
Debt Conversion Converted Instrument Warrants Or Options Issued Value																				$ 87,000
Junior Subordinated Convertible Promissory Notes [Member] \| Three Investors [Member]
Long-term Debt, Gross																			318,000
Debt Instrument, Decrease, Repayments																			$ 99,000
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares																			730,000
Debt Conversion Converted Instrument Warrants Or Options Issued Value																			$ 80,000
Gain (Loss) on Repurchase of Debt Instrument																			$ 22,000
Junior Subordinated Convertible Promissory Notes [Member] \| Third Investor [Member]
Debt Conversion Converted Instrument Warrants Or Options Issued Value																				$ 27,000
Junior Subordinated Convertible Promissory Notes [Member] \| Minimum [Member]
Debt Instrument, Discount Percentage																	10.00%	10.00%	10.00%
Junior Subordinated Convertible Promissory Notes [Member] \| Maximum [Member]
Debt Instrument, Discount Percentage																	15.00%	15.00%	15.00%
May 2011 Note Financing [Member]
Debt Instrument, Maturity Date																			May 12, 2014
Debt Conversion, Converted Instrument, Shares Issued \| shares																	253,333		12,647,077
Debt Instrument, Convertible, Conversion Price \| $ / shares																			$ 0.15													$ 0.15
Debt Instrument, Discount Percentage																																15.00%
Debt Instrument Issue Price Description						$0.85 for each $1.00 of principal amount
Debt Instrument, Payment Terms																			85% of the initial principal amount of each May 2011 Note is convertible prior to maturity.
Debt Conversion, Converted Instrument, Amount																	$ 38,000		$ 1,897,000
October 2011 Note Financing [Member]
Debt Instrument, Face Amount																	400,000	$ 400,000
Long-term Debt, Gross																	$ 1,100,000	$ 1,100,000												$ 59,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																		8,183,333
Debt Instrument, Convertible, Conversion Price \| $ / shares																	$ 0.15	$ 0.15	$ 0.15
Debt Instrument Issue Price Description																			$0.85 for each $1.00
Debt Conversion, Converted Instrument, Amount																		$ 1,227,500
October 2011 Note Financing [Member] \| Placement Agent [Member]
Debt Instrument, Maturity Date																			Oct. 31, 2014
Debt Instrument, Payment Terms																			85% of the initial principal amount of each Note is convertible prior to maturity
Placement Agent Fee Percentage																			7.00%
Placement Agent Fees																			$ 110,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares																			866,078
Class of Warrant or Right, Exercise Price of Warrants or Rights																			0.15
December 2011 Note Financing [Member]
Debt Instrument, Maturity Date			Jan. 09, 2013
Long-term Debt, Gross																	$ 405,000	$ 405,000
Debt Conversion, Converted Instrument, Shares Issued \| shares																		5,516,666
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 0.15														$ 0.15	$ 0.15
Debt Instrument, Discount Percentage			15.00%
Debt Conversion, Converted Instrument, Amount																		$ 827,500
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15
Moore Notes [Member]
Debt Instrument, Periodic Payment, Principal																		35,000	$ 200,000
Notes Payable, Current																	$ 158,000	158,000
Debt Instrument, Face Amount																			5,500														$ 230,000
Debt Instrument, Increase, Accrued Interest																		$ 150,000
Long-term Debt, Gross																			273,000
Interest Payable																			$ 135,000
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares																			1,568,627
Class of Warrant or Right, Exercise Price of Warrants or Rights																			0.15
Moore Notes [Member] \| Before Amendment [Member]
Notes Payable																																						$ 800,000
Debt Instrument, Maturity Date										Jun. 15, 2009
Moore Notes [Member] \| After Amendment [Member]
Notes Payable																																						$ 950,000
Debt Instrument, Maturity Date										Jan. 01, 2010

STOCK OPTIONS (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
STOCK OPTIONS (Details) - USD ($)	Jul. 21, 2009	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Jul. 31, 2012
Outstanding Number of Options		45,057,424	27,317,424	26,467,424	18,331,591
Granted Number of Options			17,740,000	850,000	11,075,000
Exercised Number of Options			0	7,233,341	(306,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period		250,000		0	(2,633,167)
Outstanding Number of Options		45,057,424	45,057,424	27,317,424	26,467,424
Exercisable Number of Options				20,451,266		27,560,653
Outstanding Weighted-Average Exercise Price		$ 0.16	$ 0.16	$ 0.16	$ 0.16
Granted Weighted-Average Exercise Price			0.15	0.12	0.16
Exercised Weighted-Average Exercise Price			0		0.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price				0	0.12
Outstanding Weighted-Average Exercise Price		$ 0.16	$ 0.16	0.16	$ 0.16
Exercisable Weighted-Average Exercise Price				$ 0.16		$ 0.16
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms			8 years 2 months	7 years 5 months	6 years
Share Based Compensation Arrangement By Share Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term				9 years 3 months	9 years 9 months
Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term					8 years 2 months
Share Based Compensation Arrangement By Share Based Payment Award, Options, Cancelled Or Expired, Weighted Average Remaining Contractual Term				0 years	8 years 7 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 months			6 years 9 months
Outstanding Weighted Average Remaining Contractual Terms				8 years 2 months	7 years 5 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 367,417	$ 415,967	$ 306,500
Share Based Compensation Arrangement By Share Based Payment Award, Options, Granted, Intrinsic Value				15,200	42,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value					(16,860)
Share Based Compensation Arrangement By Share Based Payment Award, Options, Cancelled Or Expired, Intrinsic Value				0	(104,912)
Outstanding Aggregate Intrinsic Value				367,417	$ 415,967
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value				$ 337,082

STOCK OPTIONS (Details 1) - $ / shares	12 Months Ended
STOCK OPTIONS (Details 1) - $ / shares	Oct. 31, 2011	Oct. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	12,310,417	6,720,417
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	850,000	10,108,333
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(6,294,259)	(4,518,333)
Non-vested Number of Shares	6,866,158	12,310,417
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 0.13	$ 0.10
Options Granted Weighted Average Exercise Price at Grant Date	0.12	0.14
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	0.13	0.10
Non-vested shares Weighted Average Exercise Price at Grant Date	$ 0.15	$ 0.13
Share Based Compensations Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term	2 years 4 months	8 years 8 months
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms	9 years 6 months	2 years 9 months
Share Based Compensations Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Remaining Contractual Term	8 years 6 months	1 year
Non-vested shares Weighted Average Remaining Contractual Term (in years)	9 years	2 years 4 months

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References + Details

STOCK OPTIONS (Details Textual) - USD ($)		1 Months Ended			3 Months Ended	12 Months Ended
STOCK OPTIONS (Details Textual) - USD ($)	Jun. 06, 2006	Sep. 27, 2011	Jul. 21, 2009	Nov. 30, 2004	Jan. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Jul. 31, 2012	Oct. 31, 2007
Granted Number of Options					17,740,000	850,000	11,075,000
Common Stock, Capital Shares Reserved for Future Issuance						250,173,570	198,100,817	287,038,332
Share Based Compensation Stock Options Shares Eligible For Individual						500,000,000	500,000,000	500,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term			6 months			6 years 9 months
Fair Value Of Options Granted						$ 103,125
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options						$ 759,000		$ 2,250,000
Common Stock [Member]
Common Stock, Capital Shares Reserved for Future Issuance									59,228,334
Two Thousand and Four Stock Option Plan [Member]
Granted Number of Options				100,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				85.00%
Two Thousand and Four Stock Option Plan [Member] \| Common Stock [Member]
Granted Number of Options				2,381,525
Two Thousand and Five Stock Option Plan [Member]
Granted Number of Options	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Two Thousand and Five Stock Option Plan [Member] \| Common Stock [Member]
Granted Number of Options	5,600,000
Two Thousand and Nine Stock Option Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance			20,000,000
Share Based Compensation Stock Options Shares Eligible For Individual			6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term			10 years
Two Thousand and Nine Stock Option Plan [Member] \| Common Stock [Member]
Granted Number of Options			358,101
Two Thousand and Eleven Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance		20,000,000
Two Thousand and Eleven Omnibus Incentive Plan [Member] \| Common Stock [Member]
Granted Number of Options		4,000,000
Two Thousand and Eleven Omnibus Incentive Plan [Member] \| Common Stock [Member] \| Less Than Twelve Months [Member]
Incentive Fee, Amount Paid		$ 2,500,000
Two Thousand and Eleven Omnibus Incentive Plan [Member] \| Common Stock [Member] \| More Than Twelve Months [Member]
Incentive Fee, Amount Paid		$ 2,000,000

INCOME TAXES (Details) - USD ($)	Oct. 31, 2011	Oct. 31, 2010
Net operating loss carryforwards-federal	$ 12,994,244	$ 8,038,146
Stock based compensation	1,474,016	1,202,168
Valuation on warrants	(3,241,085)	0
Others	(613,170)	0
Less valuation allowance	(10,614,005)	(9,240,314)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

INCOME TAXES (Details 1)	12 Months Ended
INCOME TAXES (Details 1)	Oct. 31, 2011	Oct. 31, 2010
Pre-Tax Book Income -Loss)	34.00%	34.00%
Perm Item	(19.61%)	0.00%
Change in Valuation Allowance	(16.93%)	(34.00%)
Other	2.54%	0.00%
Total	0.00%	0.00%

INCOME TAXES (Details Textual) - USD ($)	2 Months Ended	12 Months Ended
INCOME TAXES (Details Textual) - USD ($)	Dec. 31, 2007	Oct. 31, 2010	Oct. 31, 2011	Oct. 31, 2009	Dec. 31, 2008	Dec. 12, 2008
Deferred Tax Assets, Operating Loss Carryforwards		$ 20,095,000	$ 32,485,000
Net Cash Received Amount On Net Operating Losses				$ 379,742	$ 278,978	$ 922,020
Sale Of Net Operating Losses	$ 1,084,729	$ 408,000

CAPITALIZATION (Details Textual)	1 Months Ended											3 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended						116 Months Ended	125 Months Ended
CAPITALIZATION (Details Textual)	Aug. 31, 2012 shares	Jul. 30, 2012 shares	Dec. 29, 2011 shares	Aug. 31, 2011 shares	Oct. 31, 2007 USD ($) $ / shares shares	Aug. 31, 2007 USD ($) $ / shares shares	Mar. 31, 2006 USD ($) $ / shares shares	Feb. 28, 2006 USD ($)	Jan. 31, 2005 USD ($) $ / shares shares	Dec. 31, 2004 USD ($)	Nov. 30, 2004 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Jul. 31, 2011 USD ($)	Dec. 31, 2002 USD ($)	Oct. 31, 2011 USD ($) shares	Oct. 31, 2010 USD ($) shares	Oct. 31, 2008 USD ($)	Oct. 31, 2007 USD ($)	Oct. 31, 2006 USD ($)	Oct. 31, 2005 USD ($)	Oct. 31, 2011 USD ($) shares	Jul. 31, 2012 USD ($) $ / shares shares	Sep. 30, 2012	Aug. 27, 2012	Jul. 08, 2012 shares	Jul. 05, 2012 shares	Apr. 28, 2011	Sep. 28, 2010	Jul. 19, 2010	Oct. 17, 2007 shares	Aug. 24, 2007 USD ($) shares	Jan. 12, 2005 shares	Nov. 12, 2004 shares	Mar. 19, 2004 shares
Common stock, shares outstanding												375,135,008	375,135,008			250,173,570	198,100,817					250,173,570	375,135,008
Stock Issued During Period, Value, New Issues \| $															$ 235,000	$ 1,676,554			$ 9,380,902
Stock Issued During Period, Shares, New Issues													25,560,000			40,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										11,064,611	79,947,614					150,000		87,108
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.15									0.15	0.15			0.15	0.15					0.15	0.15		0.15				0.17	0.25				0.40
Debt Conversion, Converted Instrument, Amount \| $											$ 618,000	$ 38,000	$ 169,000			$ 1,897,000			1,000,010	$ 300,000	$ 613,158
Offering Costs \| $																		$ (78,013)	$ (2,243,535)
Short-term Convertible Promissory Note Conversions \| $							$ 1,500,000	$ 1,500,000					$ 53,000			$ 1,300,000
Debt Conversion, Converted Instrument, Warrants or Options Issued							3,000,000
Debt Conversion, Description							The Debentures were convertible at a price equal to the lesser of (i) $0.287 per share ("Fixed Conversion Price"), or (ii) 95% of the lowest volume weighted average price of the Common Stock on the market on which the shares are listed or traded during the 30 trading days immediately preceding the date of conversion ("Market Conversion Price").
Debt Conversion, Converted Instrument, Rate							6.00%
Notes Issued \| $						$ 600,000
Debt Instrument, Interest Rate, Stated Percentage																								12.00%				8.00%				12.00%
Debt Conversion, Converted Instrument, Shares Issued	0	800,000	3,600,000	768,633								253,333	1,126,667			8,652,737
Cash paid for Interest \| $													$ 53,027	$ 70,372		$ 148,392	$ 311,784					$ 681,992	$ 788,017
Center Court [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																															0.2
Financial Advisory Fees \| $					$ 328,000
Adjustment of Warrants Granted for Services \| $					2,483,333
Sunrise Securities, Corp [Member]
Stock Issued During Period, Value, New Issues \| $										$ 2,283,445
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																			2,666,900
Placement Agent Fees \| $																$ 50,530
Private Placement [Member]
Stock Issued During Period, Value, New Issues \| $					$ 7,384,235.1				$ 4,353,000
Stock Issued During Period Unit Price Per Share \| $ / shares					$ 0.15
Stock Issued During Period, Shares, New Issues					49,228,334
Offering Costs \| $									329,673
Shares Issued Value Net Of Offering Cost \| $									4,023,327
Debt Conversion, Description						The promissory note and accrued but unpaid interest thereon are convertible at the option of the holder into shares of our common stock upon the closing by the Company of a sale of its equity securities aggregating $3,000,000
Private Placement [Member] \| First Issue [Member]
Stock Issued During Period, Value, New Issues \| $											$ 2,925,000
Stock Issued During Period Unit Price Per Share \| $ / shares											$ 25,000
Stock Issued During Period, Shares, New Issues											87,108
Private Placement [Member] \| Second Issue [Member]
Stock Issued During Period, Value, New Issues \| $										$ 200,000
Private Placement [Member] \| Third Issue [Member]
Stock Issued During Period, Value, New Issues \| $									$ 128,000
Private Placement [Member] \| Fourth Issue [Member]
Stock Issued During Period, Shares, New Issues									3,832,753
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	3,832,753
Private Placement [Member] \| Fourth Issue [Member] \| Single Investor [Member]
Stock Issued During Period, Value, New Issues \| $									$ 1,100,000
Stock Issued During Period Unit Price Per Share \| $ / shares									$ 25,000
Stock Issued During Period, Shares, New Issues									87,108
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	87,108
Class of Warrant or Right, Exercise Price of Warrants or Rights																																	0.40
Class A Warrant [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued							4,200,000
Debt Conversion Converted Instrument Warrants Or Options Issued1 Exercise Price \| $ / shares							$ 0.287
Class B Warrant [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued							300,000
Debt Conversion Converted Instrument Warrants Or Options Issued1 Exercise Price \| $ / shares							$ 0.3444
Great Expectations and Associates,Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											15,597,723
Stockholders' Equity, Reverse Stock Split											200-for-1
Issuance of common stock to consultants (in shares)											752,600
Great Expectations and Associates,Inc [Member] \| Before Stock Split [Member]
Common stock, shares outstanding																																		150,520,000
Great Expectations and Associates,Inc [Member] \| After Stock Split [Member]
Common stock, shares outstanding																																		752,600
Cornell [Member]
Debt Conversion, Description							Cornell agreed that (i) it would not convert the Debenture or exercise the Warrants if the effect of such conversion or exercise would result in its and its affiliates'''' holdings of more than 4.9% of the outstanding shares of Common Stock, (ii) neither it nor its affiliates will maintain a short position or effect short sales of the Common Stock while the Debentures are outstanding, and (iii) no more than $300,000 principal amount of the Debenture could be converted at the Market Conversion Price during a calendar month.
Debt Instrument, Decrease, Repayments \| $						$ 1,700,000
Purchased Warrants Securities Called By Warrants						4,500,000
Debt Instrument Redemption Description						We paid an aggregate of (i) $2,289,999 to redeem the debentures at the principal amount plus a 20% premium and accrued and unpaid interest, and (ii) $600,000 to repurchase the warrants.
Moore [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																100,000
Short-term Convertible Promissory Note Conversions \| $						$ 4,000,000
Capital Contribution \| $																																$ 400,000
Debt Conversion, Converted Instrument, Shares Issued						2,666,667
Debt Conversion Converted Instrument Warrants Or Options Issued1 Exercise Price \| $ / shares						$ 0.2
Cash paid for Interest \| $						$ 7,101
CAMOFI Master LDC [Member] \| CAMHZN Master LDC [Member]
Stock Issued During Period, Value, New Issues \| $					$ 1,996,700
Stock Issued During Period, Shares, New Issues					10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																															0.2
Warrants Issued During Period					10,000,000
CAMOFI Master LDC [Member] \| Five Year Warrant [Member] \| CAMHZN Master LDC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																															3,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights																															0.001

Prior Period Adjustment (Details Textual)	9 Months Ended
Prior Period Adjustment (Details Textual)	Jul. 31, 2012 USD ($)
Quantifying Misstatement in Current Year Financial Statements, Amount	$ 819,000

Label	Element	Value
Adjustments To Additional Paid In Capital, Share Based Compensation, Stock Options, Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	$ 10,493
Stock Issued During Period Warrants	adxs_StockIssuedDuringPeriodWarrants	$ (1,228,838)
Common Stock [Member]
Retroactive Restatement To Reflect Shares, Re Capitalization	adxs_RetroactiveRestatementToReflectSharesReCapitalization	15,557,723
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 40
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	$ 15,558
Preferred Stock [Member]
Retroactive Restatement To Reflect Shares, Re Capitalization	adxs_RetroactiveRestatementToReflectSharesReCapitalization	(3,481)
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 235,000
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	$ (235,000)
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,418
Additional Paid-In Capital [Member]
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ (40)
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	219,442
Adjustments To Additional Paid In Capital, Share Based Compensation, Stock Options, Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	10,493
Retained Earnings [Member]
Net Income (Loss) Attributable To Parent	us-gaap_NetIncomeLoss	$ (166,936)